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I. Summary 
The tumour suppressor protein p53 is well known for its role in maintaining genetic 
stability by preventing the propagation of damage onto successive generations of cells. 
Depending on the extent of damage experienced by a cell, p53 promotes cell cycle arrest 
to allow for DNA repair or induces apoptosis in cases of severe damage. The canonical 
functions of p53, commonly referred to as the “guardian of the genome”, imply action only 
after the damage has occurred within a cell. Our work challenges this view by providing 
evidence pointing to a more direct and pro-active role for p53 in protecting a cellular 
genome from damage. 
p53 activation enhances the processivity of DNA replication and reduces replicative 
stress, whereas the removal of p53 reduces fork progression. This was observed in 
tumour-derived cells as well as non-transformed murine embryonic fibroblasts with 
heterozygous or homozygous p53 deletion, and in freshly isolated thymocytes from mice 
with differential p53 status. These results expand the tumour-suppressive functions of p53 
with an ex-ante activity that prevents DNA damage during replication. 
MDM2, target gene and main negative regulator of p53, acts to support DNA replication 
downstream of p53. In particular, its RING finger domain with intrinsic E3 ubiquitin ligase 
activity is required for this non-canonical role of MDM2. We demonstrated  a mechanism 
by which MDM2 and its interaction partners of the Polycomb repressor complexes which 
mediate changes in chromatin compaction, prevent the formation of R-loops on the DNA 
template that impair replication progression.  
The p53-MDM2 axis helps to protect the genome during S phase, by preventing R-loops 
and hence enhancing replication. Clinically, our study highlights the importance of small 
molecule inhibitors against MDM2 that inhibit its RING domain on top of inhibitors 
targeting its interaction with p53 currently evaluated in clinical trials. We propose that the 
dual inhibition of both these domains of MDM2 using combination treatments would 
present a more promising chemotherapeutic strategy.  
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II. Introduction 
 
II.1 The p53-MDM2 network 
 
II.1.1 The guardian of the genome – p53 
 
The tumour suppressor protein p53 is encoded by the TP53 gene on chromosome 
17p13.1. It is not only subject to the most common mutations in cancers but also 
functionally attenuated in most tumour entities. p53 was first discovered by co-
precipitation of the SV40 T-large antigen in 1979 and has been a major research focus 
since (Lane and Crawford, 1979; Linzer and Levine, 1979). As a tumour suppressor, p53 
acts to protect a cell population from propagating DNA damage onto successive 
generations of cells and the resulting genomic instability. It is this activity that gave rise to 
the description of p53 as a “guardian of the genome” by Sir David Lane in 1992 (Lane, 
1992). p53 is activated in response to stress signals in the cell and mediates a cellular 
response in form of gene expression. Depending on the type and extent of stress signals, 
p53 activation results in cell cycle arrest, DNA repair, changes in metabolism as well as 
apoptosis.  
 
 
 
 
 
Fig.II.1.1 Domain structure of p53.   
The amino terminal portion of p53 protein consists of two transactivation domains (TADs). The most critical 
residues for its activity are highlighted above. A proline-rich domain (Pro) as well as the DNA binding domain 
that interacts with response elements (p53RE) on template DNA are located at the core of the protein. The 
carboxyl terminus consists of an oligomerisation domain (OD) harbouring a nuclear localisation signal (NLS) 
and a C-terminal domain (CTD) with a nuclear export signal (NES). 
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The TP53 gene locus encodes for a multi-domain protein with a molecular weight of about 
53 kDa. It is heavily post-translationally modified for both its activation and degradation 
resulting in a fast turnover and short half-life.  In its activated form, p53 tetramerises and 
acts as a transcription factor to induce target gene expression. Several features of its 
domain structure reflect its function as a transcription factor (Fig.II.1.1). 
 
The most amino terminal region of the protein is highly acidic and contains interspersed 
hydrophobic residues. This region ranging from aa 1 to 83 can be further subdivided into 
two distinct transactivation domains (TADs) that act synergistically to bind to 
transcriptional co-regulators (Candau et al., 1997; Chang et al., 1995). Most critical are 
not the acidic but specific hydrophobic residues within these domains that allow binding to 
factors involved in histone modifications, chromatin remodelling as well as transcription 
initiation and elongation (Lemon and Tjian, 2000). Studies using knock-in mutants for both 
TADs have identified distinct TAD-dependent target gene induction. A co-disruption of 
active residues in both TADs led to loss of transactivation and tumour suppression 
capacities (Raj and Attardi, 2017). For transactivation, p53 directly interacts with TATA-
binding protein (TBP) and associated factors involved in pre-initiation complex (PIC) 
formation at the gene promotor but also with histone-acetyl-transferases p300 and CREB-
binding protein (CBP) that mediate chromatin opening. Kinases involved in the cellular 
stress response phosphorylate p53 at seven residues within the TADs (Jenkins et al., 
2012). These modifications stabilise p53 by preventing the interaction with its negative 
regulator MDM2 but also by enhancing its affinity for transcriptional co-factors such as 
TFIIH, CBP and p300 (Teufel et al., 2009).  
 
A proline-rich domain (amino acids 60-90) can also be found in the N-terminus of p53. It 
consists of five repeats of the PXXP motif and was found to play a role in p53-mediated 
apoptosis (Baptiste et al., 2002).  
 
A DNA binding domain spanning from aa residues 102 to 292 forms the central core of 
p53. This domain specifically binds to p53 response elements (p53RE) in a sequence 
specific manner. The motif is composed of two palindromic “half-sites” that are separated 
by spacer sequences of up to 13 nucleotides (Kawamura et al., 2009; Smeenk et al., 
2008). A recent study has identified that p53 tetramers can bind to one half site of the 
motif on the DNA template, allowing two tetramers to bind to one response element at a 
time. The resulting DNA loops facilitate transcriptional activation (Kearns et al., 2016). 
The majority of p53 mutations found in cancer cells are located within the DNA binding 
domain. Only about 10% of all are nonsense mutations or deletions with no protein being 
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produced. The remaining 90% consist of various missense mutations of which some are 
more prominent, independent of the tumour entity (so called “hotspot mutations”; Baugh 
et al. 2017). Missense mutations alter the amino acid sequence and influence either DNA 
binding affinity or conformation of the protein. On the other hand, many missense 
mutations also lead to a novel function (“gain-of-function”) that presents a selective 
advantage in terms of cell proliferation, migration or other cancer cell specific 
characteristics (Dittmer et al., 1993; Oren and Rotter, 2010). Mutant p53 molecules exert 
a dominant negative effect on their wildtype counterparts so that tetramers that contain 
only one mutant subunit are non-functional in terms of transactivating p53-target genes 
(Willis et al., 2004). 
 
The carboxyl terminus of p53 harbours an oligomerisation domain from aa 325 to 356. A 
monomer of the oligomerisation (or tetramerisation) domain forms a β-sheet and an α-
helix linked by a single glycine residue (Chène, 2001). Structural data suggests that 
tetramers form as dimer of dimers by the interaction of two β-sheets to form an 
antiparallel double-sheet and subsequently interacts with a double-helical bundle (Lee et 
al., 1994; Mateu and Fersht, 1999; Mateu et al., 1999). 
 
In addition, p53 contains an unstructured and basic C-terminal domain (CTD) at aa 363 to 
393 as well as both a nuclear localisation and export signal. The CTD of p53 has 
regulatory function and is an intrinsically disordered domain (IDD) that can adopt several 
conformations upon binding to different interaction partners. So far, it has been found to 
form α-helices, β-strands, β-turns and U-shapes, providing a mechanism for regulatory 
diversity (Sullivan et al., 2017). The CTD inhibits the DNA binding domain in its 
unmodified state and is post-translationally modified for its activation (Friedler et al., 
2005).  
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II.1.2 The antagonist – MDM2 
 
The oncogenic murine double minute 2 (mdm2) gene was first identified in a screen for 
amplified DNA sequences in a spontaneously transformed murine BALB/c cell line in 
1987 and is now mainly known for its regulatory role towards the tumour suppressor p53 
(Cahilly-Snyder et al., 1987). Double minutes are small extrachromosomal chromatin 
particles that divide in the absence of centromeres (Barker, 1982). Genes for mdm1-3 
were found expressed at 50-fold level in the 3T3DM cell line it was identified in, however, 
only overexpression of MDM2 was sufficient to transform two non-tumorigenic cell lines 
(Fakharzadeh et al., 1991).  
 
Both the murine mdm2 and the human MDM2 gene contain 12 exons and encode for two 
different forms of the MDM2 protein from two promotors. The first promotor (P1) 
expresses a long version of the protein (p90MDM2) and is involved in negatively regulating 
p53, whereas the shorter version expressed from P2 (p76MDM2) lacks the p53 binding 
domain and cannot cause p53 degradation. On the other hand, P2 is a p53-responsive 
promotor and its shorter product acts as a dominant negative inhibitor on p90MDM2 
resulting in an accumulation of p53 (Perry et al., 2000). Alternative splicing adds to the 
variety of isoforms of MDM2 in tissues and tumours (Iwakuma and Lozano, 2003). In both 
murine and human cell lines, most transcripts are expressed from P1 to produce full 
length MDM2 protein (Barak et al., 1994; Mendrysa and Perry, 2000).  
 
Human MDM2 is a protein of 491 amino acids in length and shows a distinct domain 
structure (Fig. II.1.2). Its amino terminal domain forms a small hydrophobic pocket (aa 25-
109) that interacts with an amphipathic α-helix present in the amino terminal portion of 
p53 (Kussie et al., 1996). In addition, MDM2 can also bind to the E2F1 transcription factor 
to prevent its proteasomal degradation (Zhang et al., 2005). 
 
A nuclear localisation signal (NLS) and a nuclear export signal (NES) encoded by aa 178-
192 as well as a nucleolar localisation signal within the C-terminal RING domain allow a 
regulated nuclear-cytoplasmic shuttling of the protein important for p53-dependent and 
independent functions of MDM2 (Roth et al., 1998).  
 
The central acidic (aa 237-288) and zinc finger domain (aa 289-331) are located towards 
the centre of the polypeptide and regulate p53 activity in two ways. On one hand, they 
repress DNA damage induced and sequence specific transactivation of p53 by binding to 
and inhibiting p300/CBP-p53 complex formation (Kobet et al., 2000). On the other hand, 
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the acidic domain was also found to directly mediate p53 degradation in a RING-
independent fashion (Argentini et al., 2001). 
 
The C-terminal part of MDM2 consists of a “really interesting new gene” (RING) domain 
(aa 438-491) that has intrinsic E3 ubiquitin ligase activity. RING domains typically contain 
seven cysteines and one histidine to coordinate two zinc cations required for catalysis 
(Borden and Freemont, 1996). This feature can also be found in MDM2 in the form of two 
zinc binding sites: (I) Cys438, Cys441, Cys461 , Cys464  and (II) His452, His457, Cys475, Cys478 
(Shloush et al., 2011). As an E3 ubiquitin ligase, MDM2 can transfer ubiquitin moieties 
from an E2 ligase like UBE2D1 onto target proteins to mark them for degradation by the 
proteasome. The most prominent target of MDM2 ubiquitination is p53, but it can also 
transfer ubiquitin onto other proteins including itself depending on the cellular signals 
conveyed to it via post-translational modifications (Fang et al., 2000; Honda et al., 1997).  
 
 
 
Fig.II.1.2 Domain architecture of MDM2. 
The MDM2 protein consists of an N-terminal p53-binding domain, a nuclear localisation and export signal, an 
acidic domain, a Zinc (Zn) finger domain as well as a C-terminal RING domain harbouring a nucleolar 
localisation signal. 
 
 
A structurally related protein to MDM2 called MDMX (or MDM4) was identified as a p53 
binding partner in 1996 and is thought to have evolved by gene duplication over 440 
million years ago (Momand et al., 2011; Shvarts et al., 1996). The MDMX gene is located 
at chromosomal location 1q32 and encodes for a 490 amino acid long protein. MDMX 
shares a high sequence homology with MDM2 and contains similar domain architecture. 
Like MDM2, it contains a p53 binding domain in its N-terminus as well as a C-terminal 
RING finger. Unlike MDM2, the RING domain in MDMX does not contain E3 ubiquitin 
ligase activity but it is thought to act as an E4 protein supporting the addition of ubiquitin 
chains to monoubiquitinated substrates (Wang et al., 2011). With regard to p53, MDMX 
inhibits p53 transactivation, whereas MDM2 can also cause proteasomal degradation of 
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p53 via ubiquitination (Marine et al., 2006). MDM2 and MDMX can form heterodimers that 
prevent auto-ubiquitination of MDM2 to increase its stability and its negative regulation 
towards p53 (Sharp and Kratowicz, 1999; Tanimura et al., 1999). 
 
II.1.3 Regulatory network of p53 and MDM2 
 
In unstressed cells, levels and activity of p53 are kept under tight control by a number of 
mechanisms including intracellular localisation, protein-protein interactions as well as 
post-translational modifications (Lavin and Gueven, 2006).  
 
The MDM family proteins MDM2 and MDMX are the main negative regulators of p53 in 
the cell. Both MDM proteins can interact with the N-terminus of p53, masking its 
transactivation domain thereby inhibiting its function (Momand et al., 1992; Oliner et al., 
1993). A more recent study has also described a conformational change in p53 by the 
acidic domain of MDM2 causing p53 to lose DNA binding ability, thus further impairing its 
activity as a transcription factor (Cross et al., 2011). 
 
In addition, MDM2 and MDMX form heterodimers via their RING domains resulting in a 
more stable and active MDM2 that ubiquitinates p53. At low levels of MDM2, 
monoubiquitination of  six C-terminal lysine residues on p53 exposes a nuclear export 
signal in its oligomerisation domain resulting in its cytoplasmic translocation (Li et al., 
2003; Lohrum et al., 2001). At high levels of MDM2, p53 is marked for proteasomal 
degradation by polyubiquitin chains (Haupt et al., 1997; Honda et al., 1997; Li et al., 
2003). 
 
The different mechanisms by which MDM2 regulates p53 are further complicated by the 
establishment of a negative feedback loop between the two proteins (Fig.II.1.3). MDM2 is 
not only a negative regulator of p53 stability and activity but also a transcriptional target of 
active p53 tetramers (Wu et al., 1993).  
 
 
Fig.II.1.3 The auto-regulatory feedback loop of p53 and MDM2.  
The stability and activity of the tumour suppressor p53 is regulated by 
MDM2. An activation of p53 induces expression of the target gene 
MDM2 and the increase of MDM2 protein levels mark p53 for 
proteasomal degradation. 
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In response to genotoxic stress in a cell, p53 is stabilised and activated as a transcription 
factor (Fig.II.1.4). Mediator kinases ATM, ATR, and CHK1&2 activated in response to 
damage, phosphorylate p53 at several residues, most of which are found in its N-terminus 
(e.g. Ser15 and Ser20). These modifications inhibit the interaction between p53 and its 
negative regulators MDM2 and MDMX. In the absence of this repression, p53 forms 
homotetramers via its oligomerisation domain and binds to p53 response elements in 
target gene promotors (reviewed in Vogelstein et al. 2000; Horn & Vousden 2007; Bieging 
et al. 2014).  
In addition, phosphorylation of MDM2 at Ser395 and MDMX at Ser403 (near the RING 
domain)  by the mediator kinase ATM switch them from negative to positive regulators of 
p53, promoting p53 mRNA translation and proper folding of the nascent peptide (Gajjar et 
al., 2012; Malbert-Colas et al., 2014).  
 
Fig.II.1.4 The p53 and MDM2 regulatory network.  
(1) In the absence of stress signals, p53 is kept at very low levels by active MDM2 (and MDMX, not shown for 
simplification). Under genotoxic stress conditions, MDM2 is inactivated (2) and p53 can induce target gene 
expression in the nucleus (3). In order to return to basal levels quickly, a negative feedback loop is in place. 
(4) In response to active p53, MDM2 is expressed and if not inactivated by damage signalling kinases, it can 
continue to inhibit p53 activity and stability. 
 
In addition to activating phosphorylations, p53 is further modified by acetylation, 
sumoylation, neddylation, methylation, and ubiquitination. The variety and combination of 
different modifications is thought to provide a “code” that allows suitable transcriptional 
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programs depending on the type of damage experienced by a cell (Meek and Anderson, 
1994).  This mechanism is best seen in the example of DNA damage signalling. Upon 
genotoxic stress, the DNA damage signalling cascade activates p53 as described above. 
Under mild stress conditions, p53 induces the expression of transcriptional targets that 
halt the cell cycle. The gene product of CDKN1A, p21, is a potent CDK inhibitor that 
arrests cells in G1 phase of their cell cycle, wheras another product called 14-3-3-σ 
induces a G2 arrest by inhibiting the CDC25C  phosphatase required for progression into 
mitosis (Harper et al., 1995; Hermeking et al., 1997).  
The transcriptional program in response to severe damage is very different and the cell 
undergoes programmed cell death. The pro-apoptotic transcriptional program of p53 
induces the expression of target genes like Puma, Noxa, and Bax that trigger the release 
of cytochrome c from mitochondria. Released cytochrome c binds to the p53-targets Apaf 
and caspase 9 forming an apoptosome that initiates the caspase cascade for apoptosis 
initiation (Rozenfeld-Granot et al., 2002).  
 
II.1.4 p53-independent functions of MDM2 on genome integrity 
 
Although the best known role of MDM2 is to regulate p53 on various levels, more 
evidence for p53-independent roles of MDM2 have emerged. First hints for these roles 
were observed in tumours lacking p53 but nevertheless overexpressing MDM2, as well as 
the existence of splice variants of MDM2 that are unable to bind to p53 but capable of 
transforming cells (Cordon-Cardo et al., 1994; Lu et al., 2002; Sigalas et al., 1996).  Since 
then, MDM2 has been described to play a role in various processes, some of which will 
be mentioned here (Jain and Barton, 2016; Li and Lozano, 2013).  
 
The overexpression of MDM2 in a cell causes genomic instability by inhibiting DNA repair 
and suppressing cell cycle arrest regardless of its p53 status. Evidence for increased 
genomic instability was found by overexpressing MDM2 in fibroblasts as well as in 
transgenic mice in the form of increased chromosomal abnormalities as well as 
aneuploidy (Jones et al., 1998; Lushnikova et al., 2011). 
In 2005, Alt et al. analysed interaction partners of endogenous MDM2 in a mass 
spectrometry approach and precipitated all three components of the MRN complex 
involved in DNA repair: Nbs1, Mre1, Rad50. Through a direct interaction with the Nbs1 
component, MDM2 localises to sites of DNA damage which in turn dampens DNA 
damage signalling and delays repair of the damaged site mediated by the MRN complex 
(Alt et al., 2005; Eischen, 2017).  
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In addition to its role in modulating DNA repair, MDM2 can also influence cell cycle 
progression independently of p53. A direct interaction of MDM2’s acidic domain (aa 254-
264) and the C-terminal portion of retinoblastoma protein (RB; aa 785-803) prevents the 
interaction of RB with E2F1 via the same domain (Sdek et al., 2004; Xiao et al., 1995). RB 
binds to several E2F transcription factors to inhibit their cell cycle specific transcriptional 
program. By sequestering RB and stimulating E2F1, MDM2 relieves a block on cell cycle 
progression in an unscheduled manner and causes genomic instability by missegregation 
of chromosomes in the following mitosis (Hernández-Monge et al., 2016; Martin et al., 
1995).  Additionally, MDM2 can also mark RB as well as other cell cycle inhibitors like p21 
and hnRNP K for proteasomal degradation (Bouska and Eischen, 2009; Li and Lozano, 
2013; Uchida et al., 2005). 
 
A third pathway MDM2 can act on independently of p53 is apoptosis. MDM2 levels are 
inversely correlated with the forkhead transcription factor FOXO3a in breast cancer cells 
due to active degradation of FOXO3a by MDM2 (Yang et al., 2008). By this, MDM2 
counteracts FOXO3a-mediated apoptosis and allows tumour progression. Another level of 
suppressing apoptosis mediated by MDM2 is by enhancing the translation of the anti-
apoptotic XIAP (Gu et al., 2009). 
 
II.1.5 p53-independent functions of chromatin-bound MDM2 
 
More recently, two different p53-independent roles for transcriptional regulation have 
been described for chromatin-bound MDM2 (Jain and Barton, 2016).  
On one hand, MDM2 is required for stemness maintenance in the induction of pluripotent 
stem cells (iPSCs), osteoblasts, as well as for the proliferative capacity of cancer cells. 
Mechanistically, MDM2 seems to interact with the chromatin modifying complexes of the 
Polycomb group to repress target gene expression in a RING-dependent manner 
(Wienken et al., 2016). 
Another group showed that MDM2 has an increased half-life of more than three hours in 
its chromatin-bound state and that the acidic domain within MDM2 is required for 
chromatin interactions. In this study, chromatin recruitment of MDM2 is shown to regulate 
transcriptional programs involved in serine metabolism as well as redox homeostasis 
(Riscal et al., 2016). 
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II.1.6 p53 and MDM2 – guardian and attacker of the genome? 
 
The tumour suppressor p53 acts to protect the genomic integrity of a cell in various ways. 
A plethora of different post-translational modifications and the ability to induce a large 
repertoire of different target genes allow p53 to react to cellular stress with a suitable 
response. This ensures that the overall population of cells retain their genome integrity by 
repairing lesions when possible or eliminating damaged cells before they can divide any 
further. In a normal cell, p53 activity is tightly regulated by MDM2 (and other pathways not 
discussed here) to ensure an immediate and short response only when necessary.  
 
MDM2 on the other side has been described as a hub-oncogene due to its many 
interaction partners and regulatory functions (Fåhraeus and Olivares-Illana, 2014). To 
achieve such a large number of different interactions (some of which were mentioned in 
this chapter), MDM2 is present in several isoforms due to differential promotor usage as 
well as alternative splicing and is also heavily post-translationally modified. 
Untransformed cells contain only very low levels of MDM2 in the absence of stress 
signalling. In tumours on the other hand, MDM2 is often amplified and expressed at high 
levels and associated with genome instability (Bouska et al., 2008; Momand et al., 1998). 
 
It seems like the balance of p53 and MDM2 is essential in maintaining genome integrity 
and is often disrupted in transformed cells by a mutation in p53 or the upregulation of 
MDM2 but it remains unclear how direct this effect is. Both p53 and MDM2 are known to 
interact with DNA/chromatin and could have more direct effects on the genome of a cell. 
Genome integrity is at highest risk during DNA synthesis in the S-phase of the cell cycle. 
So far, not much is known about the role of p53 and MDM2 after the cell passes the G1/S 
checkpoint, however some evidence exists that p53 has altered transactivation ability in 
S-phase under stress conditions (Gottifredi et al., 2001).  
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II.2 Polycomb proteins 
 
Polycomb group (PcG) proteins were first identified as developmental mutants in 
Drosophila with segmentation defects similar to the Polycomb mutant described in the late 
1940s (Jürgens, 1985; Lewis, 1978, 1949). The importance of these genes in 
development was further highlighted by the finding that the deletion of many of these 
genes causes early embryonic lethality in mice (Faust et al., 1995; O’Carroll et al., 2001; 
Pasini et al., 2004). It is now known that PcG proteins in Drosophila, as well as their 
highly conserved counterparts in vertebrates, act as negative regulators of developmental 
transcription factors of the Hox clusters as well as many other target genes involved in 
development (Boyer et al., 2006; McKenzie Duncan, 1982; Schwartz et al., 2006).  
 
PcG proteins are commonly found in multiprotein complexes including the Polycomb 
repressor complexes 1 (PRC1) and 2 (PRC2). Both complexes act as negative regulators 
on target gene expression by altering the chromatin structure around the transcriptional 
start sites via histone modifications. The PRC2 complex is thought to mediate di- or 
trimethylation of histone 3 at lysine 27 (H3K27me2/3) and the PRC1 complex 
monoubiquitinates histone 2A at lysine residue 119 (H2AK119ub1; Schuettengruber and 
Cavalli, 2009). 
 
II.2.1 Polycomb repressor complex 2 
 
Polycomb repressor complex 2 consists of four core proteins in both Drosophila and 
mammals: the catalytic subunit EZH1 or EZH2 and the regulatory subunits SUZ12, EED, 
and RbAp46/48. Accessory proteins like JARID2, AEBP2, and PCL interact with core 
components in a transient manner and additionally regulate recruitment as well as activity 
of the complex (Fig.II.2.1; Margueron & Reinberg 2011).  
 
The catalytic subunits EZH1 and 2 have methyltransferase activity in their SET domain 
and can mediate both di- and trimethylation reactions. EZH1 can be found in both dividing 
and differentiated cells, whereas EZH2 is only present in proliferating cells.However, 
EZH1 has a much lower methyltransferase activity compared to EZH2 and is thought to 
be responsible for re-establishing histone marks after histone exchanges or 
demethylation, whereas EZH2 mediates methylation reactions in response to cellular 
signalling (Margueron et al., 2008). 
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Fig.II.2.1 Polycomb repressor complex 2.  
Mammalian core components of the PRC2 complex 
highlighted in colour: The catalytic subunit EZH2 
contains a SET domain for methyltransferase 
activity. Regulatory subunits EED, SUZ12, and 
RbAp46/48 can interact with accessory components 
JARID2, AEBP2, and PCLs to further modify PRC2 
recruitment and target gene specificity. 
 
 
 
The methylation of H3K27 is processive so that a trimethylation is catalysed by a 
monomethylation of H3K27me2. Monomethylated H3K27 is a mark for constitutive 
heterochromatin that is more stable in its repression and usually found in gene-poor 
regions of the genome. Both di- and trimethylated H3K27, are associated with facultative 
heterochromatin, a compact region of chromatin that is regulated by developmental cues 
(Trojer and Reinberg, 2007; Zee et al., 2010).  
 
II.2.2 Polycomb repressor complex 1 
 
Polycomb repressor complex 1 composition in mammals is more complex than the one of 
PRC2 and is rather a family of complexes (Schuettengruber et al., 2007). The core 
proteins identified in Drosophila (Polycomb, Polyhomeotic, Posterior sex combs, and 
dRing) have at least two homologues each (Levine et al., 2002; Shao et al., 1999). In 
mammalian cells, the catalytic component RNF2 (or RING1B) is an E3 ubiquitin ligase 
that is responsible for the monoubiquitination of H2A at lysine 119, a histone mark that 
silences target genes (Wang et al., 2004). Interaction partners of RNF2 within the PRC1 
complex include the RING finger proteins BMI1, MEL18, and NSPC1 (Fig.II.2.2; Simon & 
Kingston 2009).  
 
CBX proteins, homologues to the Drosophila Polycomb, contain a chromodomain that can 
specifically recognise trimethylated H3K27 (Fischle et al., 2003). Even though PRC1 and 
PRC2 share many target genes, it is now believed that recruitment of PRC1 does not 
depend on prior activity of PRC2 but rather on response elements in the target gene 
promotor (Margueron and Reinberg, 2011; Sing et al., 2009). 
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Fig.II.2.2 Polycomb repressor complex 1.   
The catalytic subunit RNF2 has E3 ubiquitin 
ligase activity. Interaction with RING proteins 
BMI1, MEL18 or NSPC1 as well as the 
chromodomain containing CBX proteins 
(CBX2, CBX4, CBX6, CBX7, and CBX8) 
diversify target gene specificity. 
 
 
II.2.3 Polycomb proteins and MDM2 
 
As an ubiquitin ligase, MDM2 not only transfers ubiquitin onto p53 and other proteins for 
their proteasomal degradation, but it can also transfer moieties to histones to regulate 
chromatin compaction. A study by Minsky and Oren in 2004 showed that MDM2 can 
physically interact with histones and transfer ubiquitin onto H2A in vitro and onto H2B 
both, in vitro and in vivo. As a result, transcription is repressed in a p53-independent and 
MDM2-RING-dependent mechanism (Minsky and Oren, 2004).  
 
Since then, direct interactions of MDM2 with catalytic components of the PRC1 (RNF2) 
and PRC2 (EZH2) have been demonstrated (Wen et al., 2014; Wienken et al., 2016). In 
addition, MDM2 not only binds to the complexes but enhances their activity for 
trimethylation of H3K27 and monoubiquitination of H2AK119 of target genes. Such effects 
were seen in both mouse embryonic fibroblasts as an example for development as well as 
in a human colon carcinoma cell line (Wienken et al., 2016). As a result, MDM2 shares a 
regulatory profile with PRC complexes in the maintenance of stemness and repression of 
proliferation.  
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II.3 Genome integrity  
 
The cellular genome is challenged by a variety of external and internal factors causing 
DNA damage and mutations on a daily basis. The genetic material within a cell needs to 
be maintained without any damage and replicated exactly once per cell cycle to allow 
controlled proliferation and growth of tissues and organisms. Errors in replication result in 
mutations that can impair the functionality and cell cycle progression of the cell affected. 
Surveillance mechanisms are in place to monitor alterations in DNA structure and to 
activate signalling cascades initiating cell cycle arrest, DNA repair, as well as apoptosis. 
When mutations hit regulatory factors and render them inactive, the affected cell 
proliferates extensively. Uncontrolled proliferation not only harms surrounding tissues but 
also provides a basis for accumulating more mutations and tumourigenesis.  
 
DNA, the molecular carrier of genetic information, consists of four nucleotides formed 
from nitrogen-containing bases cytosine, guanine, adenine, and thymine attached to a 
deoxyribose sugar moiety and a phosphate group. Covalent bonds between nucleotides 
in a chain as well as hydrogen bonds between two chains give rise to the characteristic 
double helix structure of DNA. DNA damage, characterised amongst others by alterations 
in the chemical structure of DNA bases, causes changes in the structure and poses 
problems for transcription and replication machineries using this stretch of DNA as a 
template. Natural (or endogenous) sources of damage arise from a variety of metabolic 
processes and include reactive oxygen and nitrogen species (ROS and NOS), reactive 
carbonyl species, as well as products of lipid peroxidation. An accumulation of ROS in a 
cell leads to oxidation of DNA bases, most frequently 8-oxoguanine, which causes 
mispairing of bases and thus leads to mutagenesis. The repair of these alterations with 
specialised enzymes like MTH1 (for 8-oxo-GTP) produce single stranded break (SSBs) in 
the cell, further contributing to genomic instability. Both altered bases as well as breaks  in 
the DNA template are obstacles to DNA replication (De Bont, 2004).  
 
In addition to endogenous sources of damage, a cell is also exposed to a plethora of 
exogenous damage sources, among which are ionising and ultraviolet irradiation as well 
as genotoxic compounds. The resulting double stranded breaks (DSBs) and 
misincorporation of bases lead to problems with DNA replication, rendering them 
vulnerable in S-phase (Dobbelstein and Sørensen, 2015).  
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Cells sense and repair DNA lesions by a number of pathways collectively known as the 
DNA damage response (DDR; Fig.II.3.1). Common to all pathways involved, is the order 
of events taking place. First, a sensor - one or multiple proteins - identifies the lesion and 
transduces the signal via several mediators. Signal transduction within the signalling 
cascade is often mediated via post-translational modifications, e.g. phosphorylations by 
kinases. Eventually, an effector protein triggers a cellular response in the form of cell 
cycle arrest, DNA repair, chromatin remodelling, and apoptosis (Zhou and Elledge, 2000). 
Cells with defects in their DDR due to mutations are much more susceptible to DNA 
damage and accumulate unrepaired lesions over time.  
 
 
 
 
Fig.II.3.1 The DNA damage response (DDR) – a signalling 
cascade.   
As in many other types of signalling cascades, the DNA 
damage response involves a hierarchical signal transduction 
by different types of proteins. Sensors detect the damage at 
the lesion site and signal to mediators that in turn activate 
further mediators and eventually effectors. The signal is 
transduced by a number of post-translational modifications 
(most commonly phosphorylation) on substrates. This array of 
signalling allows a sustained response to damage by 
amplifying the signals until it is resolved. 
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II.3.1 DNA replication 
 
Eukaryotic replication initiates from thousands of replication origins interspersed 
throughout the genome to allow the replication of long linear chromosomes (Méchali, 
2010). Tight spatial and temporal regulation of replication in a two-step fashion ensures 
that the genome of a cell is replicated exactly once per cell cycle – no less and no more.  
 
The first step of replication occurs in G1 phase of the cell cycle, where replication origins 
are “licensed”. For this, a pre-replication complex (pre-RC) is assembled at the origin sites 
(Fig.II.3.2; Méndez & Stillman 2000). The complex itself consists of six origin recognition 
(ORC) proteins, Cdc6, Cdt1, as well as the hexameric helicase MCM2-7. It is assembled 
onto the origin in an ATP-dependent manner (Masai et al., 2010). Genome wide studies 
have identified a number of characteristics of metazoan origins including a specific origin 
G-rich repeat (OGRE) motif that is present in most origins and recognised by ORC 
proteins (Cayrou et al., 2011, 2012). 
 
 
Fig.II.3.2 Formation of the pre-replication 
complex.  
 
Origin recognition (ORC) proteins recruit Cdc6 and 
Cdt1 to the replication origin that can load the 
MCM2-7 helicase onto the DNA with energy from 
ATP-hydrolysis to form a pre-replication complex 
(pre-RC). 
 
 
 
 
 
In S-phase, a coordinated CDK response involving Cdc7 and CDK2 as well as other 
kinases and phosphatases (not discussed here) activates a subset of replication origins 
by phosphorylation of the MCM helicase (Montagnoli et al., 2006). Even though all 
potential origins are licensed, only about 10% of licensed origins are activated (“fired”) 
under unperturbed replication conditions, whereas the remaining 90% serve as backup 
mechanisms for replicative stress conditions (Branzei and Foiani, 2005; Ge et al., 2007; 
McIntosh and Blow, 2012; Woodward et al., 2006). 
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Active replisomes move forward bi-directionally from the origins of replication. The MCM 
helicase acts to unwind the double strand using the energy from ATP hydrolysis and 
releases stretches of single stranded DNA (ssDNA) that are coated with replication 
protein A (RPA) immediately (Fig.II.3.3). DNA polymerases specific for leading (Pol ε) and 
lagging strand (Pol δ) use ssDNA stretches as templates for synthesis of new strands. 
Replication continues until two forks converge and terminate their activity by releasing the 
DNA template.  
 
 
Fig.II.3.3  Schematic diagram of a replication fork (simplified).  
A replication fork consists of two antiparallel DNA strands (leading and lagging strand) opened up by the 
MCM2-7 helicase. Stretches of ssDNA exposed by the unwinding of the helix are coated by RPA to protect 
from degradation. DNA polymerases (ε for leading strand and δ for the lagging strand) are loaded onto and 
kept in proximity to the template DNA by the PCNA clamp loading complex for DNA synthesis. 
 
 
 
II.3.2 Replicative stress 
 
Replication forks are very vulnerable to impediments they encounter while sliding along 
their DNA template. These obstructions can occur in the form of DNA damage at the level 
of single bases, breaks in one or both strands, secondary structures in the template, as 
well as proteins that are bound to the DNA preventing the progression of the replication 
fork. Stalled replication forks stop at the lesion or obstacle but are able to resume 
replication when it is repaired or removed. Collapsed replication forks have lost the ability 
to resume DNA synthesis as the core replication machinery dissociates from the template 
at the lesion (Petermann and Helleday, 2010).  
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Downstream of a stalled replication fork, the MCM helicase continues to unwind the 
double strand for a few hundred bases. Single stranded DNA exposed by this separation 
of the two strands extends the short ssDNA stretches that occur during replication and 
serves as signal for replicative stress. RPA coats ssDNA and interacts with the main 
mediator kinase Ataxia Telangiectasia and Rad3-related (ATR) via ATR-binding and RPA 
Interacting Protein (ATRIP; Byun et al. 2005). Upon activation, ATR phosphorylates 
hundreds of substrates at a Ser/Thr-Glu motif to activate further mediators and effectors 
in the damage signalling cascade (Matsuoka et al., 2007). Common readouts for 
replicative stress are proteins downstream of the ATR response inlcuding checkpoint 
protein 1 (CHK1), RPA, or the histone variant H2AX (γH2AX; pH2AX-Ser139) as well as 
an accumulation of stalled replication forks, firing replication origins, and persistent 
ssDNA (Dobbelstein and Sørensen, 2015; Maréchal and Zou, 2013). 
 
In order to prevent genomic instability, an intra-S-phase checkpoint delays the 
progression of S-phase in response to replicative stress (Fig.II.3.4). The checkpoint works 
in two pathways downstream of the main  damage mediator kinases ATR and Ataxia 
Telangiectasia Mutated (ATM; Tasat & Yakisich 2010). 
 
In response to DSBs, ATM is recruited to sites of damage by the sensor complex MRN 
and its kinase activity is enhanced in response (Lee and Paull, 2005). Substrates such as 
CHK2, BRCA1, and p53 are phosphorylated by ATM to mediate effects on repair, cell 
cycle arrest, and apoptosis (Lavin, 2008; Shiloh, 2003). ATR on the other hand is 
activated by single stranded breaks or in response to replicative stress in form of excess 
ssDNA. This leads to phosphorylation of CHK1 at serine residues 317 and 345 as well as 
ATM at serine 1981 (Stiff et al., 2006; Zhao and Piwnica-Worms, 2001).  
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Fig.II.3.4 The intra-S checkpoint.   
Double strand breaks bound by the MRN complex 
recruit and activate ATM kinase. Single stranded 
DNA arising from stalled replication forks or single 
stranded breaks are bound by ATR via ATRIP and 
activate kinase activity. Both ATM and ATR, 
phosphorylate a large range of substrates including 
the mediator kinases CHK1 and CHK2. Crosstalk 
between the two kinases as well as ATR and ATM 
exists and promotes a sustained response to DNA 
damage until the lesion is resolved. The 
phosphorylation of the CHK1/2 substrate CDC25A 
leads to its proteasomal degradation. The loss of 
CDC25A activity fails to activate CDK2, which 
normally induces CDC45-mediated DNA 
polymerase recruitment. Additionally, CHK1 also 
phosphorylates and inhibits CDC7, thus S-phase 
progression is halted in two ways. 
 
Both pathways are heavily interlinked and converge on the mediator kinases of the 
second wave: CHK1 and CHK2.  These kinases are responsible for the phosphorylation 
of CDC25A causing it to be degraded by the proteasome (Mailand et al., 2000). CDC25A 
is a phosphatase which removes an inhibitory phosphate group from CDK2, a kinase 
essential for CDC45-dependent recruitment of DNA polymerases for origin firing (Falck et 
al., 2002; Owens et al., 1997; Takisawa et al., 2000). In addition, CHK1 phosphorylates, 
and by that inhibits, CDC7, a kinase that phosphorylates the pre-RC complex for 
recruiting further factors in conjunction with CDK2 (Petermann et al., 2010). As a result, 
activation of ATR and ATM kinases by DNA damage and replicative stress cause a 
signalling cascade that acts as a checkpoint in S-phase.  
 
II.3.3 Replicative stress in cancer 
 
Genome instability is now considered as one of the hallmarks of cancer but whether it is 
cause or consequence of tumourigenesis has long been under debate (Hanahan and 
Weinberg, 2011; Tomlinson and Bodmer, 1999). More recent evidence suggests that 
DNA damage arises as a result of replicative stress early on in transformation but can be 
kept under control by an intact DDR (Bartkova et al., 2005; Gorgoulis et al., 2005). 
Many oncogenes drive uncontrolled proliferation and induce replicative stress as a result. 
The activation of checkpoints and damage signalling increase selective pressure on the 
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system to mutate important mediators of the DDR to provide further proliferative 
advantages. Subsequently, cells lacking checkpoints no longer arrest their cell cycle for 
repair or die from apoptosis but rather accumulate even more damage by replicative 
stress and drive tumourigenesis forward (Bartkova et al., 2006; Dobbelstein and 
Sørensen, 2015; Halazonetis et al., 2008). Most drugs that are currently used in the 
clinics to treat cancers, damage DNA and cause replicative stress either directly or 
indirectly (Dobbelstein and Sørensen, 2015). Examples of direct interference with 
replication are outlined below.  
 
Direct modifications of DNA bases by platinum compounds (e.g. carboplatin, cisplatin) or 
alkylating agents (e.g. mitomycin C, cyclophosphamide) cause crosslinking between 
bases or DNA strands making replication of the affected stretches difficult (Fu et al., 2012; 
Henry-Mowatt et al., 2003; Wang and Lippard, 2005). Intra-strand crosslinks prevent 
accurate base pairing and their replication requires the recruitment of specialised 
translesion polymerases to the site. Polymerases of this kind are more flexible to accept 
incorrect base pairing. However, these polymerases catalyse these reactions in a less 
processive and more error prone way as they lack a proofreading activity (Lehmann et al., 
2007). Inter-strand crosslinks (ICL) on the other hand prevent the dissolution of the two 
strands in the double helical structure and thus the accessibility of the template DNA 
(Deans and West, 2011).  
 
Antimetabolites are another class of chemotherapeutic compounds used to induce 
replicative stress in cancer cells. Structural analogues of DNA bases are incorporated 
during DNA synthesis but block further elongation and cause replication fork stalling. The 
nucleoside analogue 2’-2’-difluoro-deoxycytidine (Gemcitabine) additionally inhibits 
ribonucleotide reductase (RNR), an enzyme important for maintaining dNTP pools. Other 
drugs like hydroxyurea and 5-fluorouracil (5-FU) have similar mechanisms of action 
inhibiting nucleoside synthesis by targeting RNR and thymidylate synthetase, respectively 
(Ewald et al., 2008). 
 
Topoisomerase inhibitors, including camptothecin and etoposide, present another class of 
chemotherapy drugs. Topoisomerases relax DNA supercoiling that arises around the 
replication fork due to unwinding of the double helix by breaking and re-ligating DNA 
strands. Inhibitors bind to these enzymes and the resulting complexes form a physical 
barrier to replication triggering a repair response (Pommier, 2013). Efforts of removing the 
complexes often result in DSB formation which further adds to genomic instability 
(Regairaz et al., 2011). 
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III.3.4 Replication and transcription – similarities and differences 
 
In many physiological settings, a crosstalk between two processes occurring 
simultaneously provides advantages, as seen e.g. with transcription-coupled repair. 
However, there can also be negative consequences when two processes occur at the 
same time and genomic location. This is the case for transcription and replication, both of 
which are processes that require access to the DNA strands as templates. Both 
processes involve a specialised polymerase for the synthesis of a complementary strand 
and DNA-RNA intermediate structures.   
 
RNA polymerase that is responsible for transcription binds to dsDNA and opens up the 
helix within its active site. The synthesis of a complementary RNA strand results in a 
highly dynamic short stretch of DNA:RNA hybrid structures of about 10 nucleotides in 
length. As the RNA chain elongates, it loses its association with the DNA, is bound by 
RNA-binding proteins and exits the polymerase via a separate channel as its DNA 
complement to avoid the persistence of DNA:RNA hybrids (Alberts et al., 2007; Stryer et 
al., 2002; Westover, 2004). 
 
DNA polymerase, the enzyme catalysing DNA synthesis, consists of two polymerase 
subunits (δ and ε in mammalian cells) that synthesise complements to ssDNA templates 
that have been unwound by the MCM helicase. At the leading strand, one long 
complementary strand of DNA is synthesised. At the lagging strand on the other side, only 
short fragments of DNA (called Okazaki fragments) are synthesised as the polymerase 
needs to wait for the helicase to unwind the strands further to initiate the next segment to 
be replicated. This initiation of replication is mediated by the synthesis of short 
complementary RNA stretches by DNA primase that serve as primers for the lagging 
strand polymerase ε. These DNA-RNA hybrids are very short (about 10 nucleotides) and 
have a short half-life as they are rapidly degraded by RNase H (Alberts et al., 2007; Stryer 
et al., 2002). 
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III.3.5 Replication-transcription conflicts – when separation goes wrong 
 
Both transcription and replication are dependent on the template sequence of DNA 
molecules and direct access in order to synthesise complementary strands. How these 
two processes can co-exist and how conflicts between them are regulated has been a 
longstanding question and is solved differently in different organisms.  
In mammalian cells, transcription and replication are spatially and temporally separated in 
S-phase cells to prevent encounters of the two multiprotein complexes sliding along the 
DNA (Smirnov et al., 2014). Detailed analysis of nascent transcripts showed that regions 
transcribed in early S-phase are replicated in late S-phase and vice versa (Meryet-
Figuiere et al., 2014). A dysregulation of this pattern leads to conflicts between both 
processes and is a source of genomic instability.  
 
As mammalian transcription and replication is bi-directional, collisions of replisomes with 
transcription complexes can occur co-directionally or “head-on”, the latter of which is more 
detrimental (Merrikh et al., 2011; Srivatsan et al., 2010). In both scenarios, the replication 
fork stalls as it cannot progress past the transcription complex. In co-directional collisions, 
the replication fork is able to restart after transcription is terminated, whereas head-on  
collisions result in transcription-associated recombination (TAR) accompanied by a 
collapse of the replication fork (Prado and Aguilera, 2005).  
 
Even though the term “collision” implies a physical contact of the two polymerase 
complexes, it is not entirely known whether this is the case or whether the effects 
observed are solely due to changes in the chromatin environment of the approaching 
complexes (García-Muse and Aguilera, 2016). Torsional stress generated by positive and 
negative supercoiling around the RNA polymerase is normally relieved by topoisomerases 
of type I or II, catalysing single or double strand breaks, respectively. Inefficient resolution 
of negative supercoiling can result in DNA melting and by that a change in the helical 
structure of the DNA to a non-B form (García-Muse and Aguilera, 2016; Pannunzio and 
Lieber, 2016). An example of a structure that is formed as a result of transcriptional 
supercoiling is G-quadruplexes. These structures consist of a repeat of guanine resides 
that form four-strand interactions posing as obstacles to replication (Kim and Jinks-
Robertson, 2011; Yadav et al., 2014). 
 
Another type of non-B structure that develops due to local DNA melting are so-called R-
loops. Unwound DNA double strands facilitate the re-annealing of complementary RNA 
molecules that exit RNA polymerase as a nascent transcript in the absence of 
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ribonucleoprotein particles (Huertas and Aguilera, 2003). The consequence is a DNA-
RNA hybrid structure with a displaced ssDNA strand (Fig.II.3.5).  
 
Hybrids between DNA and RNA are thermodynamically more stable than dsDNA and 
adopt a structural intermediate between A and B form dsDNA that impairs replication 
(Roberts and Crothers, 1992; Shaw and Arya, 2008). Their special conformation serves 
as a recognition element for specialised enzymes that remove R-loops in energy-
consuming reactions. Among these enzymes is RNase H1, an endonuclease that cleaves 
the RNA moiety of the R-loop (Wahba et al., 2011).  
 
 
 
Fig.II.3.5 Thread-back model of R-loop formation.  
Co-transcriptional R-loops form when the nascent mRNA is incompletely coated by ribonucleoproteins and 
inserts back into a complementary DNA duplex. The resulting hybrid of DNA and RNA is a very stable 
structure and stops replication fork progression. 
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II.4 Project Aim 
 
The aim of this thesis is to determine a role of p53 in protecting a cell’s genome from 
damage during DNA replication. Preliminary data from my Master’s thesis suggested that 
p53 has a supportive role in DNA replication. This thesis expands on these initial findings 
by studying the progression of single replication forks in a number of cell systems in the 
absence and presence of the tumour suppressor p53.  
 
The osteosarcoma cell line U2OS is used as an example for transformed cells with high 
intrinsic replicative stress conditions and wildtype p53 expression. In addition, we also 
make use of primary thymocytes isolated from mice carrying p53 knockout alleles and 
their wildtype littermates. A third system to study the effect of p53 depletion are mouse 
embryonic fibroblasts from genetically modified embryos carrying floxed p53 alleles. Cre-
recombination in vitro allows us to study short-term effects of p53 depletion in primary 
cells.  Using these cell systems, we will try to understand whether p53 protects cells from 
endogenous DNA damage during replication and whether it does so by acting as a 
transcription factor in S-phase. DNA fiber assays used to analyse effects on single 
replication forks provide a readout in the form of the length of a replicated stretch of DNA 
in a given time. Differences in length can result not only from impaired replisomes that 
progress along the template more slowly, but also from a less stable association of the 
replisome with its template and obstacles that cause it to stall. 
 
Given that the mechanism by which p53 seems to support DNA replication is unknown, it 
is essential to distinguish between replication fork velocity and processivity of the DNA 
polymerase. The development of a “fork stalling fiber assay” allows us to analyse the two 
parameters separately and draw more accurate conclusions on how replication is 
affected.  
 
As p53 is a transcription factor, we hypothesise that it is highly likely that p53 supports 
DNA replication through one of its target genes. Therefore we aim to identify a 
transcriptional target of p53 that is essential for supporting DNA replication and the 
mechanism by which it does so. MDM2, a transcriptional target of p53, has a non-
canonical role in modifying chromatin compaction. As chromatin modifications can also 
affect replication fork progression, we will assess the role of MDM2 in DNA replication to 
find a mechanism by which p53 acts as a pro-active guardian of the genome.   
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III. Materials  
III.1 Technical devices 
Device   Producer 
Blotting chamber Biozym 
Cell counting chamber Neubauer improved Bran 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Chemiluminescence imager Chemidoc XRS+ Biorad 
Chemiluminescence imager Chemocam HR 16 3200 Intas Science Imaging  
Electrophoresis system for SDS-PAGE Amersham Biosciences 
Freezer -20°C Liebherr 
Freezer -80°C Heraeus, Thermo Scientific 
Heating Block Thermomixer comfort Eppendorf 
Ice machine B100 Ziegra 
Laminar flow cabinet Hera safe Heraeus, Thermo Scientific 
Light microscope Axovert 40C Zeiss 
Magnetic Stirrer Variomag Mono Komet 
Microscope,  Axio Scope.A1 Zeiss 
Pathway HT Cell Imaging System BD Biosciences 
PCR machine for qPCR CFX96, C1000 BioRad 
PCR machine Thermocycler T Personal Biometra 
pH meter inoLab WTW GmbH 
Pipet Aid Portable #4XXX-200 Drummond 
Pipets, Eppendorf Research Eppendorf 
Power Supply Biometra 
Refridgerator 4°C Liebherr 
Roller RM5-30V CAT 
Scales Acculab ALC-6100.1 Sartorius 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon 
Sonication device Bioruptor Diagenode 
Spectrophotometer NanoDrop ND-1000 PeqLab 
Thermomixer Comfort Eppendorf 
Timer Oregon Scientific 
Vortex Genie 2 Scientific Instruments 
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III.2 Consumables 
 
Consumable Producer 
96-well imaging plate Becton Dickinson 
96-well plate for qPCR 
Cell culture dishes (10cm, 15cm) 
4titude  
Greiner 
Bacteria culture dish (10cm) Sarstedt 
Cell culture plate (6-well, 12-well) Greiner 
Cell culture plate 24-well Costar 
Cell scraper (16cm, 25cm) Sarstedt 
Coverslips Menzel, Roth 
Cryo-tubes for cell freezing Nunc 
Glass pipets (5ml, 10ml, 25ml) Sarstedt 
Glass Slides Superfrost Menzel 
Parafilm Sigma-Aldrich 
Pipet tips (10 μL, 20-200 μL, 1,000 μL) Greiner 
Protran nitrocellulose transfer membrane Whatman 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf 
Reaction tube (15 mL, 50 mL) Greiner 
Safe-lock reaction tube (1.5 mL) Eppendorf 
Sterile filter (0.2μM and 0.45μM) Millipore 
Syringe canula  B.Braun 
Whatman paper Whatman 
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III.3 Chemicals and reagents 
 
Chemical Producer 
Acetic acid Roth 
Agar Sigma-Aldrich 
Agarose Roth 
Albumin Fraction V (Bovine Serum Albumine, BSA) Roth 
Ammonium persulfate (APS) Roth 
Ampicillin Roth 
Chlorodeoxyuridine (CldU) Sigma-Aldrich 
Chloroform Roth 
Deoxynucleotide triphosphates (dNTPs) Primetech 
Dimethyl sulfoxide (DMSO) AppliChem 
DNA ladder GeneRuler Fermentas 
EdU (5-ethynyl-2’-deoxyuridine) Thermo Fisher 
Ethanol 99.8% Roth 
Formaldehyde, 37% solution Roth 
Glycerol >99% p.a. Roth 
Glycine >99% p.a. Roth 
Hydrogen chloride (HCl) Roth 
Iododeoxyuridine (IdU) Sigma-Aldrich 
Isopropanol Roth 
Lipofectamine 2000/3000 Invitrogen 
Methanol >99% (MetOH) Roth 
Milk powder Roth 
MitoSOX red mitochondrial superoxide indicator Thermo Fisher 
Nailpolish essence 
Nuclease-free H2O Ambion 
PageRuler Prestained Protein Ladder Fermentas 
Paraformaldehyde  (PFA) 37% Sigma-Aldrich 
Pefablock SC protease inhibitor Roth 
Pepstatin A AppliChem 
Ponceau S Roth 
Potassium Chloride AppliChem 
Potassium hydrogenphosphate (KH2PO4) Roth 
Random hexamer primers Thermo Scientific 
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Rotiphorese Gel 30 Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate AppliChem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium dodecyl sulphate (SDS) BioRad 
Sodium ethylene diamine tetra-acetic acid (Na-EDTA) Roth 
Sodium hydrogenphosphate monohydrate (NaHPO4 x H2O) Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium(di-)hydrogenphosphatedihydrate (Na2HPO4)x 2H2O Roth 
SYBR green Invitrogen 
Tetramethylethylenediamine (TEMED) Merck 
Trehalose dehydrate Usb Corp. 
Trisamine (Tris) Pufferan >99% p.a. Roth 
Triton-X100 AppliChem 
TRIZOL Invitrogen 
Tween 20 Applichem 
Vectashield mounting medium Vector Laboratories 
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III.4 Buffers and Solutions 
 
 
 
 
 
 
 
Ponceau S 
Ponceau S 0.5% 
acetic acid 1% 
in ddH2O  
  
  
RIPA Lysis Buffer 
Triton X-100 1% 
Na-deoxycholate 1% 
NaCl 150mM 
EDTA 10mM 
Tris, pH 7.5 20mM 
in ddH2O  
  
  
SDS-PAGE Running Buffer 
Tris 25mM 
glycin 86.1mM 
SDS 3.5mM 
in ddH2O  
  
  
Tris Buffered Saline (TBS) + Tween20 
(TBS-T) 
Tris 50mM 
NaCl 150mM 
Tween20 0.1% 
in ddH2O  
  
  
Western Blot Transfer Buffer 
Tris 25mM 
glycin  192mM 
MetOH 20% 
in ddH2O  
  
  
FACS binding buffer 
Hanks balanced solution +  
CaCl2 5mM 
MgCl2 5mM 
BSA 1% 
  
  
Cell lysis buffer 
urea 2.5M 
RIPA lysis buffer 60% 
Pefa 1% 
PA 1% 
L/A 0.1% 
  
  
Fibre Assay Blocking Solution 
BSA 3% 
Tween20 0.1% 
in PBS pH 7.4  
  
  
Fibre Assay Fixative 
MetOH 75% 
Acetic Acid 25% 
  
  
Fibre Assay Spreading Buffer 
Tris pH 7.4 200mM 
EDTA 50mM 
SDS 0.5% 
in ddH2O  
  
  
6x Laemmli Buffer 
Tris pH 6.8 0.35M 
glycerine 30% 
SDS 10% 
dithiotreitol 9.3% 
bromophenol blue 0.02% 
in ddH2O  
  
  
Phosphate Buffered Saline (PBS) 
NaCl 24mM 
KCl 0.27mM 
Na2HPO4 x 7H2O 0.81mM 
KH2PO4 0.15mM 
in ddH2O  
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III.5 Enzymes and reaction buffers 
 
Enzyme Buffer Producer 
M-MuLV reverse transcriptase 10x MuLV buffer 
New England Biolabs 
(NEB) 
Taq DNA Polymerase for qPCR 
10x Taq buffer (+KCl,  
- MgCl2) Primetech, Fermentas 
 
 
III.6 Commercial Kits 
 
Name Producer 
  
Click-iT EdU Alexa488 HCS assay kit Thermo Fisher 
Immobilon Western HRP Substrate Peroxide Solution Millipore, Merck 
Pierce BCA Protein assay kit Thermo Fisher 
PureYield Plasmid Midiprep System Promega 
SuperSignal Western Femto Maximum Sensitivity Substrate  Thermo Fisher 
TruSeq RNA LT SamplePrep Kit Illumina 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
III.7 Chemotherapeutics and Pharmacological inhibitors  
 
Name Target Producer 
DRB (5,6-Dichlorobenzimidazole 1-β-D-
ribofuranoside) 
CDK9 Sigma 
DZNep EZH2 Cayman Chemicals, 
EPZ6438 EZH2 Selleckchem 
Gemcitabine (2',2'-difluorodeoxycytidine 
(dFdC)) 
 Eli Lilly 
Hydroxyurea RNR Sigma 
LDC067 CDK9 
Selleckchem 
 
Nutlin-3a Mdm2 
Sigma Aldrich 
 
PHA-766491 CDK7 Selleckchem 
PTC-209 BMI1 
Selleckchem 
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III.8 Oligonucleotides 
Name siRNA ID Target Sequence 
ctrl#1 & 2 neg. control#1 & 2  undisclosed 
EED#1 s16624 EED 
GCUUUACGAUUAUGGAAUAtt 
UAUUCCAUAAUCGUAAAGCat 
EED#2 s16625 EED 
GGCAUAAUUAGGAUAAUAAtt 
UUAUUAUCCUAAUUAUGCCtc 
EED#3 s16626 EED 
CAUUAGUGUUUGCAACUGUtt 
ACAGUUGCAAACACUAAUGga 
EZH2#1 s4916 EZH2 
GCUGACCAUUGGGACAGUtt 
UACUGUCCCAAUGGUCAGCgg 
EZH2#1 s4917 EZH2 
GUGUAUGAGUUUAGAGUCAtt 
UGACUCUAAACUCAUACACct 
EZH2#1 s4918 EZH2 
GGCACUUACUAUGACAAUUtt 
AAUUGUCAUAGUAAGUGCCaa 
Mdm2#1 custom select MDM2 
GCCAUUGCUUUUGAAGUUAtt 
UAACUUCAAAAGCAAUGGCtt 
Mdm2#2 s224037 MDM2 
AGACCCUGGUUAGACCAAAtt 
UUUGGUCUAACCAGGGUCUct 
Mdm2#3 s8629 MDM2 
AGUCUGUUGGUGCACAAAAtt 
UUUUGUGCACCAACAGACUtt 
p53#1 s605 p53 
GUAAUCUACUGGGACGGAAtt 
UUCCGUCCCAGUAGAUUACca 
p53#2 s607 p53 
GGUGAACCUUAGUACCUAAtt 
UUAGGUACUAAGGUUCACCaa 
RNF2#1 s12067 RNF2 
GGCUAGAGCUUGAUAAUAAtt 
UUAUUAUCAAGCUCUAGCCca 
RNF2#2 s12068 RNF2 
CAAACGGACCAAAACAUCUtt 
AGAUGUUUUGGUCCGUUUGtt 
RNF2#3 s12069 RNF2 
GGAGUGUUUACAUCGUUUUtt 
AAAACGAUGUAAACACUCCtt 
SUZ12#1 s23967 SUZ12 
GGAUGUAAGUUGUCCAAUAtt 
UAUUGGACAACUUACAUCCtt 
SUZ12#2 s23968 SUZ12 
GGACCUACGUUGCAGUUCAtt 
UGAACUGCAACGUAGGUCCct 
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III.9 Plasmids 
 
Name Publication Source 
pcDNA3, pLenti-GFP  Invitrogen 
pCMV-MDM2 wt Oliner et al. 1992 Addgene # 16441  
pCMV-MDM2 C464A Boyd et al. 2000  Addgene #12086 
pLenti6-V5-DEST-RNF2 Scott et al. 2011 Addgene #31216 
pICE-RNaseHI-WT-NLS-
mCherry 
Britton et al. 2014 Addgene #60365 
pICE-RNaseHI-D10R-E48R-
NLS-mCherry 
Britton et al. 2014 Addgene #60367 
 
III.10 Antibodies 
III.10.1 Antibodies for Western Blot 
 
Antibody Source  Dilution  Producer Catalogue nr. 
Ezh2 (D2C9) XP rabbit 1:1000 Cell Signalling 5246 
H2AK119ub1 rabbit 1:1000 Millipore ABE569 
H2AX pS319 rabbit 1:1000 Cell Signalling 2577 
H3K27me3 rabbit 1:1000 Diagenode pAb-069-050 
HSC70 mouse 1:15,000 Santa Cruz sc-7298 
MDM2 mouse 1:300 Calbiochem OP#46 
p21 mouse 1:1000 Cell Signalling 2947 
p53 (DO-1) mouse 1:1000 Santa Cruz sc126 
p53-CM5p rabbit 1:200 Vector 
Laboratories 
n/a anymore 
RING1B rabbit 1:500 Cell Signalling 5694 
SUZ12 rabbit 1:1000 Cell Signalling 3737 
β-actin mouse 1:50,000 abcam ab6276-100  
mCherry mouse 1:20,0000 abcam ab125096 
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III.10.2 Antibodies for Fiber Assay 
 
Antibody Source  Dilution  Producer Catalogue nr. 
BrdU/CldU 
BU1/75 
rat 1:500, 1:300 AbDSerotec OBT0030 
 1:1000 abcam ab6326 
BrdU/IdU B44 mouse 1:500 Becton Dickinson 347580 
ssDNA mouse 1:1000 Millipore MAB3034 
 
III.10.3 Secondary Antibodies for Western Blot 
 
Antibody Dilution  Producer Catalogue nr. 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti 
mouse IgG (H+L) 
1:10,000 Jackson Immunoresearch 711-036-152 
HRP-coupled AffiniPure 
F(ab')2 fragment, anti rabbit 
IgG (H+L) 
1:10,000 Jackson Immunoresearch 715-036-150 
 
III.10.4 Secondary Antibody for Fiber Assay 
 
Antibody Dilution  Producer Catalogue nr. 
Alexa-Fluor-488 goat anti 
mouse  
1:250 Invitrogen, Life 
Technologies 
A-11017 
Alexa-Fluor-555 goat anti 
mouse  
1:250 Invitrogen, Life 
Technologies 
A-11003 
Alexa-Fluor-647 goat anti 
mouse 
1:250 Învitrogen, Life 
Technologies 
A-21236 
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III.1 Cell culture 
III.11.1 Cell lines 
 
Cell line Source 
U2OS human osteosarcoma cell line, p53-proficient, ATCC 
HCT116 p53-/- 
human colon carcinoma cell line, p53-deficient (Bunz et al., 
1998), ATCC 
H1299 
human non-small lung cell carcinoma cell line, homozygous 
deletion of p53 gene, ATCC 
p53-/- MEF 
p53-/- Mdm2-/- MEF 
p53-/- Mdm2C462A/C462A MEF 
p53-deficient mouse embryonic fibroblasts with Mdm2 
knock-out/ RING finger mutation knock-in; generated by 
Zhang lab, UNC Medial School, North Carolina, USA (Clegg 
et al., 2012) 
p53-/- thymocytes 
isolation from animals at 3-4 weeks of age (Klusmann et al., 
2016) 
p53loxP MEF isolation from animals at E13.5 (Klusmann et al. 2016) 
 
III.11.2 Media and reagents for cell culture 
 
Reagent Producer 
Ciprofloxacin Bayer 
DMEM GlutaMAX Gibco, Life Technologies 
DMEM powder Gibco, Life Technologies 
FCS Gibco, Life Technologies 
L-glutamine Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Puromycin Gibco, Life Technologies 
RPMI 1640 w Hepes w/o Glut Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
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Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM powder 10g/l 
NaHCO3 3.7g/l 
HEPES 5.96g/l 
 
Dulbecco’s Modified Eagle’s Medium (DMEM) with supplements 
DMEM   
FCS 10% 
Penicillin/Streptomycin (Pen/Strep) 50U/ml 
L-glutamine 200μM 
Ciprofloxacin 10μg/ml 
in ddH2O  
 
RPMI with supplements 
RPMI  
FCS 10% 
Penicillin/Streptomycin (Pen/Strep) 50U/ml 
L-glutamine 200μM 
in ddH2O  
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III.12 Bacteria 
 
III.12.1 Bacterial strains used for plasmid amplification 
 
Bacteria strain Source 
DH10BTM chemically competent cells Thermo Scientific 
  
III.12.2 Bacteria growth medium 
 
2YT medium 
Tryptone 1.6% 
yeast extract 1% 
NaCl 0.5% 
 
2YT agar 
YT agar 15% 
2YT medium 100% 
 
III.13 Software and Databases 
Name Producer 
Adobe Illustrator, InDesign, Photoshop CC Adobe 
AttoVision image acquisition software Becton Dickinson 
Axio Vision Zeiss 
ChemoStar Imager  Intas 
Excel Microsoft 
GraphPad Prism GraphPad Software 
Image Lab 5.2.1 Biorad 
ImageJ General Public License 
NanoDrop Software  Peqlab  
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IV Methods 
 
Parts of methods in this chapter have previously been described in my Master’s thesis 
(2015) as well as in the full version of the publication in chapter V.I published in Cell 
Reports (Klusmann et al., 2016). 
 
IV.1 Cell Biology 
 
IV.1.1 Cell culture 
 
Cells were cultivated at 37°C, 5% CO2, and humidified conditions in culture media listed in 
Table IV.1. For sub-cultivation, cells were washed with pre-warmed PBS and detached 
from the culture dish with 0.1% trypsin/EDTA and incubation at 37°C for 5 minutes. Once 
detached, the reaction was stopped by the addition of FCS-containing culture medium. 
Cells were re-seeded at dilutions between 1:2 to 1:10 three times per week. For 
experiments, cells were seeded into culture dishes at the appropriate density. All cell 
culture work was carried out under sterile conditions.  
 
Table IV.1 Cell culture media 
Cell line Culture medium 
U2OS DMEM with supplements 
HCT116 p53-/- RPMI with supplements 
H1299 DMEM with supplements 
p53-/- MEF 
p53-/- Mdm2-/- MEF 
p53-/- Mdm2C462A/C462A MEF 
DMEM with Pen/Strep, L-glutamine, 
and sodium pyruvate 
p53-/- thymocytes RPMI with supplements 
p53loxP MEF DMEM Glutamax with supplements 
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IV.1.1.1 Isolation and sources of mouse embryonic fibroblasts  
 
Mouse embryonic fibroblasts (MEFs) were isolated from p53loxP mice (B6.129P2-
Trp53tm1Brn/J, Jackson Laboratories) at E13.5 (Jonkers et al., 2001). Littermates were 
used to prepare MEFs from a C57Bl6N/129SV background (50%-50%, N2 Backcross). 
For this, abdominal parts of murine embryos at E13.5 were dissected and incubated in 
pre-warmed trypsin/EDTA for 30 min at 37°C and 5% CO2. Subsequently, cells were 
isolated further by pipetting and transferred to 10cm cell culture dishes with pre-warmed 
DMEM medium with supplements but without antibiotics for 6 hours. Medium is changed 
once more and cells kept at 37°C, 5% CO2 overnight. Cells were split once before 
experiments and freezing for storage in liquid nitrogen.  
MEFs from p53-/- , p53-/- Mdm2-/-, and p53-/- Mdm2-C462A/C462A mice with a C57BL/6 
background were obtained from Y. Zhang, University of North Carolina (Itahana et al., 
2007; Wienken et al., 2016). MEF cultures were maintained in DMEM supplemented with 
10% FCS, L-glutamine, sodium pyruvate, and antibiotics.  
IV.1.1.2 Isolation of murine Thymocytes 
Thymocytes were isolated from three to four weeks old Trp53tm1Tyj mice (Jackson 
Laboratories), carrying a deletion of the p53-encoding gene (Jacks et al., 1994). The 
thymus was isolated and strained through a 40μM mesh. Isolated cells were washed with 
PBS and transferred into pre-warmed RPMI 1640 (Invitrogen/Gibco, Life Technologies) 
supplemented with 10% FCS. Cells were used for experiments immediately after isolation. 
All experiments were carried out in full agreement with the Göttingen University Animal 
Care Committee and the Institutional Guidelines for Humane Use of Animals in Research.  
 
IV.1.2 Transient transfections 
For the transient knockdown of gene expression in human cells, a reverse transfection 
protocol was followed using the cationic liposome formulation Lipofectamine 2000 (in 
chapter V.I) and Lipofectamine3000 (in chapter V.II). For this, a transfection mix with a 
final siRNA concentration of 10nM was prepared by separately incubating siRNA (Solution 
A.1) and Lipofectamine (Solution B; Table IV.1.2) in DMEM without supplements, before 
combining the two solutions and an additional 15 minute incubation. Cells were seeded 
with the transfection mix into medium containing supplements. Culture medium was 
exchanged after 24 hours and experiments were carried out 48 hours post siRNA 
transfection. 
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For the ectopic expression of plasmid DNA in chapter V.II, a forward transfection protocol 
was used according to manufacturer’s instructions. For this, a transfection mix was 
prepared from 2μg of plasmid DNA and the P3000 reagent (solution A.2), and a second 
mix containing Lipofectamine3000 (solution B) in DMEM without supplements. They were 
combined (solutions A.2 & B) and incubated for 15 minutes. The transfection mix was 
added drop-wise onto adherent cells and experiments carried out 30 hours post 
transfection.  
 
Table IV.2 Transfection mix per reaction  
Solution Components Protocol 
A.1 (siRNA) 
0.5μl 50μM siRNA 
250μl DMEM 
vortex 
 
A.2 (DNA) 
2μg plasmid DNA 
5μl P3000 
250μl DMEM 
B 
5μl Lipofectamine2000/3000 
250μl DMEM 
 
Transfection mix 
 
Solutions A and B 
 
vortex, incubate 10’ RT 
 
IV.1.3 Chemical Treatments  
Pharmacological inhibitors used for cell treatments were dissolved in H2O or DMSO and 
aliquots prepared according to manufacturer’s instructions. Treatments were prepared by 
adding the drug to pre-warmed medium as indicated in Table IV.1.3. For control samples, 
the respective solvent was added instead of the drug 
 
Table IV.3 Drug concentrations and solvents 
Name Stock concentration Solvent 
Gemcitabine 64mM, 126.8µM H2O 
Nutlin-3a 20mM DMSO 
Hydroxyurea 1M H2O 
PHA-766491 10mM DMSO 
EPZ6438 10mM DMSO 
DZNep 10mM DMSO 
DRB (5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside) 50mM DMSO 
LDC067 20mM DMSO 
PTC-209 20mM DMSO 
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IV.1.4 Cell Lysates for SDS-PAGE Analysis 
For protein analysis via immunoblot, crude cell lysates were prepared from cells grown in 
6-well dishes. All steps of harvesting were performed on ice and with pre-cooled solutions 
to minimise protein degradation. Cells were washed twice with ice-cold PBS and detached 
from the culture dish by using a 16cm cell scraper. Detached cells were resuspended in 
75-100 μl cell lysis buffer (Table III.4) and sonicated for 10 minutes at high power and 30 
second intervals. Samples were subsequently stored at -80°C.   
 
IV.1.5 Cell synchronisation 
For synchronization of cells at the G1/S transition in chapter V.I, U2OS cells were 
incubated with 2 mM thymidine in DMEM with supplements for 16 h, then washed and 
incubated in DMEM+ for 8h, and then again incubated with 2 mM thymidine for 16h 
(double-thymidine block). For release, thymidine was removed by washing and incubation 
with DMEM+.  
 
IV.1.6 Flow cytometry 
For cell cycle analysis, cells were fixed with ethanol over night. Subsequently, samples 
were centrifuged and the pellet rehydrated with PBS for 10 minutes. After centrifugation, 
the cell pellet was resuspended in PBS with RNase A (200μg/ml) and incubated at 37°C 
for 30 minutes. Propidium iodide staining was performed with a 30μg/ml solution for 5-15 
minutes at room temperature in the dark. Flow cytometry was performed using the Guava 
PCA 96 System (Millipore). The percentage of cells in each phase of the cell cycle was 
determined using the Guava Express Pro software.  
For detection of mitochondrial reactive oxygen species, live cells were incubated with 5M 
MitoSOX™ Red Mitochondrial Superoxide Indicator  in FACS binding buffer (Table III.4) at 
37°C and 5% CO2 for 40 minutes. After washing with PBS (37°C) twice, the cells were 
detached with 0.5% trysin/EDTA, followed by flow cytometry as described above. 
 
IV.1.7 High-Content Immunofluorescence Microscopy 
Cells were grown in 96-well imaging plates (Becton Dickinson) for 24h and treated with 
10μM Nutlin-3a for 6, 12, and 24 hours. For the last 2 hours, 5μM 5-ethynyl-2’-
deoxyuridine (EdU) was added to the media. After fixation in 4% paraformaldehyde/PBS, 
cells were permeabilized with 0.5% Triton-X100/PBS. Actively replicating cells were 
detected by using the Click-iT EdU Alexa488 HCS assay kit (Life Technologies, C10351). 
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Hoechst staining was performed to detect cell nuclei. Automated microscopy was 
performed by using a Pathway HT Cell Imaging System in conjunction with the AttoVision 
image acquisition software (Becton Dickinson) and a single cell based image analysis. 
Quantification of DNA replication was determined in quadruplicate by background-
corrected EdU signal intensity. 
 
IV.1.8 Quantitative image-based cytometry (QIBC)  
Quantitative image-based cytometry (chapter V.II) was carried out and described by 
Federico Teloni and Matthias Altmeyer (University of Zurich) with reagents indicated. 
IV.1.8.1 EdU incorporation for QIBC  
For pulsed EdU (5-ethynyl-2'-desoxyuridine) (Thermo Fisher Scientific) incorporation, cells 
were incubated for 20 minutes in medium containing 10 μM EdU. The Click-iT EdU Alexa 
Fluor Imaging Kit (Thermo Fisher Scientific) was used for EdU detection. EdU-positive 
cells as detected by QIBC were considered the S-phase population. 
IV.1.8.2 Quantitative image-based cytometry (QIBC) analysis 
GFP-RNAseH1 D210N cells were grown on sterile 12 mm glass coverslips, pre-extracted 
in ice-cold 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 2 minutes on ice to wash out 
detergent-sensitive, non-chromatin-bound proteins, washed twice in PBS, and fixed in 3% 
formaldehyde in PBS for 15 minutes at room temperature. Primary and secondary 
antibodies (Alexa fluorophores, Life Technologies) were diluted in filtered DMEM 
containing 10% FBS and 0.02% Sodium Azide. Antibody incubations were performed for 2 
hours (primary antibodies) or 1 hour (secondary antibodies) at room temperature. After 
antibody incubations, coverslips were washed once with PBS and incubated for 10 
minutes with PBS containing 4',6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, 0.5 
μg/ml) at room temperature to stain DNA. Coverslips were mounted on 5 μl Mowiol-based 
mounting media (Mowiol 4.88 (Calbiochem) in Glycerol/TRIS). H2AX Phospho S139 
antibody (mouse, Biolegend 613401, 1:1000) was used to detect DNA damage signaling. 
Automated multichannel wide-field microscopy for QIBC was performed on an Olympus 
ScanR Screening System equipped with an inverted motorized Olympus IX83 
microscope, a motorized stage, IR-laser hardware autofocus, a fast emission filter wheel 
with single band emission filters, and a digital monochrome Hamamatsu ORCA-FLASH 
4.0 V2 sCMOS camera (2048 x 2048 pixel, 12 bit dynamics) as described previously 
(Pellegrino et al., 2017). For each condition, image information of large cohorts of cells 
was acquired under non-saturating conditions with a UPLSAPO 10x (NA 0.4) objective. 
Identical settings were applied to all samples within one experiment. Images were 
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analyzed with the Olympus ScanR Image Analysis Software Version 2.5.1, a dynamic 
background correction was applied and nuclei segmentation was performed using an 
integrated intensity-based object detection module using the DAPI signal. All downstream 
analyses were focused on properly detected interphase nuclei or mitotic chromosomes 
containing a 2C-4C DNA content as measured by total and mean DAPI intensities. 
Fluorescence intensities were quantified and are depicted as arbitrary units. Color-coded 
scatter plots of asynchronous cell populations were generated with Spotfire data 
visualization software (TIBCO). Within one experiment, similar cell numbers were 
compared for the different conditions. Representative scatter plots and quantifications of 
independent experiments, typically containing several thousand cells, are shown. 
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IV.2 Biochemistry  
 
IV.2.1 Bicinchoninic acid assay 
 
Relative protein concentrations were determined colorimetrically using a bicinchoninic 
acid assay. In this method, the reduction of Cu2+ to  Cu+ by protein in alkaline medium is 
made visible through the addition of  bicinchoninic acid which chelates one cuprous ion 
(Cu+) and forms a purple-coloured reaction product (Smith et al., 1985). Protein samples 
were adjusted to equal protein concentrations with RIPA buffer and 6x Laemmli buffer was 
added. Samples were subsequently used for SDS-PAGE or stored at -80°C. 
 
IV.2.2 Separation of proteins by SDS-PAGE  
SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis), developed by 
Shapiro et al. in 1967, is a method for separating proteins according to their 
electrophoretic mobility (Shapiro et al., 1967). For this, proteins are denatured by 
incubation at 95°C for 5 minutes in the presence of SDS.  
The anionic detergent SDS binds to all proteins and confers a negative charge to them so 
that all proteins migrate towards the anode, when an electric field is applied. As a result, 
proteins migrate relative to their molecular weight with little influence of internal charges. 
The gel used for electrophoresis, is divided into a stacking gel with 5% acrylamide and pH 
6.8 and the resolving gel with 12% acrylamide and pH 8.8. Larger pores in the stacking 
gel allow the proteins to be focused between the leading chloride and trailing glycine ions 
that “stack” the proteins at the edge of the resolving gel. The smaller pore size of the 
resolving gel allows the actual size-dependent separation of the proteins.  
SDS-PAGE gels were casted between two clean glass plates. For this, the resolving gel 
was cast first and overlaid with 2-propanol for an even surface. Once polymerised, the 
propanol was discarded and the stacking gel cast on top. A 10- or 15-well comb was 
inserted and left to polymerise.  
 
Adjusted protein samples (20-40μl) were loaded into wells of the stacking gel together 
with a pre-stained protein ladder Electrophoresis was carried out with a constant voltage 
of 80V for stacking and 120V for separation. 
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Table IV.4 Composition of gels for SDS-PAGE 
Component stacking gel resolving gel 
acrylamide-bisacrylamide 5% 12% 
1M Tris-HCl, pH 6.8 126mM  
1.5M Tris-HCl, pH 8.8  375mM 
10% SDS 0.1% 0.1% 
10% APS 0.1% 0.1% 
TEMED 0.3% 0.4% 
 
 
IV.2.3 Immunoblotting 
Separated proteins in the SDS-PAGE gel were further analysed by immunoblotting, a 
technique first used by Renart et al. in 1979 and further developed by Towbin et al. in the 
same year (Renart et al., 1979; Towbin et al., 1979). 
With this method, proteins are transferred from their position on the gel onto a 
nitrocellulose membrane (Bittner et al., 1980). For the transfer the membrane was laid on 
top of the gel and covered by Whatman paper and sponges on both sides. The stack was 
placed into a tank blot chamber filled with Western Blot Transfer Buffer (Table III.4) and 
an electric field with a constant voltage of 90-100V was applied for 90-180 minutes at 4°C. 
The membrane was subsequently stained with Ponceau S solution (Table III.4) to check 
for protein transfer efficiency.  
 
IV.2.4 Immunostaining 
 In order to detect specific proteins on the membrane, a two-component antibody system 
was used. In this, the primary antibody is specific for the protein or post-translational 
modification of interest, whereas the secondary antibody recognises the constant region 
of the primary antibody which is specific for the animal host in which the antibody was 
raised. The conjugation of the secondary antibody to horseradish peroxidase (HRP) 
allows the detection of antibody binding by chemiluminescence. Upon the addition of a 
substrate solution, HRP catalyses the oxidation of luminol by peroxide. The light emitted 
during this reaction can be captured by a camera and is visualised as bands with varying 
intensity according to protein levels with the Intas ChemoStar Imager Software (chapter 
V.I) and the Image Lab 5.2.1 Software by Biorad (chapter V.II).  
To avoid unspecific binding of the antibody to the protein membrane, the membrane was 
first incubated in 5% milk in TBS-T (Table III.4) for one hour at room temperature. 
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Subsequently, the primary antibody incubation was carried out at 4°C overnight using 
concentrations stated in Table III. 10.1. Afterwards, the membrane was washed three 
times in TBS-T for 10 minutes before incubation with the corresponding secondary 
antibody for one hour at room temperature (Table III. 10.3). Before visualisation, the 
membrane was again washed three times in TBS-T for 10 minutes.  
Two substrate solutions were used depending on signal intensity - Immobilon Western 
HRP Substrate Peroxide Solution for intense signals and SuperSignal West Femto 
Maximum Sensitivity Substrate for weaker signals.  
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IV.3. Molecular Biology  
 
IV.3.1 RNA extraction, reverse transcription, and real time quantitative PCR  
Total RNA was extracted from cells using TRIzol®. mRNA was reverse-transcribed using 
oligo-dT and random hexameric primers, followed by qRT-PCR analysis using SYBR 
Green (Invitrogen). Gene expression levels were normalized to the mRNA encoding 36B4, 
and the analysis was conducted using the ΔΔCt method. qRT-PCR primer sets were 
chosen as follows: 
Table IV.5 Primer sequences for gene expression studies in human cells 
Gene name Primer sequence 
36B4 
For- GAT TGG CTA CCC AAC TGT TG 
Rev - CAG GGG CAG CAG CCA CAA A 
CDKN1A/p21 
For- CCT GGC ACC TCA CCT GCT CTG CTG 
Rev- GCA GAA GAT GTA GAG CGG 
 
IV.3.2 RNA sequencing  
For RNA-sequencing, the quality of total RNA was determined using the Bioanalyzer 2100 
from Agilent. All samples analyzed exhibited a RNA Integrity Number > 8. Library 
preparation was conducted using the TruSeq RNA LT SamplePrep Kit, starting from 1000 
ng of total RNA. Barcodes for sample preparation were used according to the indications 
given by the protocol. Accurate quantitation of cDNA libraries was performed with the 
QuantiFluor™dsDNA System (Promega). The size range of final cDNA libraries was 
determined applying the DNA 1000 chip on the Bioanalyzer 2100 (Agilent; 290-310 bp). 
cDNA libraries were amplified and sequenced via cBot and HiSeq 2000 (Illumina; SR, 
1×50 bp, 6 Gb/sample ca. 30 million reads per sample). Sequence images were 
transformed with Illumina software BaseCaller to bcl files, which were demultiplexed to 
fastq files with CASAVA (version 1.8.2). Quality check was performed via FastQC (version 
0.10.1, Babraham Bioinformatics). Fastq files were mapped to the human reference 
transcriptome (UCSC hg19) using Tophat (Galaxy Version 0.9; Kim et al., 2013). Read 
counts for each sample and each gene were aggregated using a htseq-count (Anders et 
al., 2014). DESeq2 (version 1.10.1) was used for measuring differential expression (Love 
et al., 2014). RNA library preparation and sequencing was done by the Transcriptome 
Analysis Laboratory (TAL, Göttingen). 
 
49 
 
IV.3.2 DNA Fiber Assay 
DNA fiber assays were used to study replication speed and progression in cells subjected 
to different treatments. This method, first published by Jackson et al. in 1998, involves two 
labelling pulses with the nucleoside analogues 5-Chloro-2′-deoxyuridine (CldU) and 5-
Iodo-2′-deoxyuridine (IdU; Jackson & Pombo, 1998). Their incorporation into newly 
replicated DNA provides a mark that can be used for immunostaining at a later stage.  
After treatment and labelling (cf. IV.3.5.1) of cells in culture and subsequent harvesting, 
cells were lysed and their DNA spread out on glass plates. Fixed slides can subsequently 
be used for immunostaining by denaturation, blocking, and antibody incubation steps. 
Both, CldU and IdU are specifically recognised by anti-BrdU antibodies (CldU by rat-a-
BrdU and IdU by mouse-a-BrdU). Fluorescent secondary antibodies allow visualisation of 
incorporated CldU and IdU with a fluorescent microscope. Structures observed under the 
microscope and their identity, are indicated in Fig. VI.3.1. 
Pre-treatment of the cells before labelling will affect both CldU and IdU label length and 
the effect of the treatment given can be analysed by comparing the average replication 
fork progression of treated and control samples. 
 
 
 
 stalled fork 
1st label termination 
 
 
 ongoing fork 
unidirectional 
 
 ongoing fork 
bidirectional, 1st label origin 
  ongoing fork 
bidirectional, 2nd label origin 
 
 
 2nd label termination 
 
 
Fig. IV.3.1  Representative images of DNA fibers and a schematic diagram of structures observed in 
fiber assays after a two-label protocol 
CldU labelled DNA was detected with a red (Alexa555) and IdU with a green (Alexa488) fluorescent antibody. 
Only unidirectional ongoing forks were used for replication speed analysis. 
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IV.3.2.1 Pulse Labelling 
For DNA fibre assays, cells were seeded into 25cm2 cell culture flasks at a density of 
500,000 cells per flask for when labelling was performed the next day. For siRNA 
experiments,  400,000 cells per flask were seeded 48 hours prior to fiber assay 
experiments. Media containing CldU (25µM) and IdU (25-250µM) were incubated at 37°C, 
5% CO2 and humidity for at least 12 hours prior to use. Drugs and inhibitors were added 
to both media in a 6-well plate and mixed well just before the labelling procedure and 
added at different points during the experiment depending on the experiment.                       
IV.3.2.1.1 Labelling for fork progression analysis 
For pulse labelling, CldU containing medium was applied to the cells for 20 minutes, 
aspirated, and IdU medium applied for 1-2 hours as indicated in the schematic labelling 
diagram in the figures. IdU was used at a tenfold concentration compared to CldU in 
chapter V.I but at equal concentrations in chapter V.II as we identified that it is not 
necessary to outcompete the first label with a higher concentration of the second one.  
IV.3.2.1.2 Labelling for fork processivity analysis 
In order to assess fork stalling, alternating labels of CldU and IdU were incorporated to 
obtain a striped pattern.  For this, both CldU and IdU containing media were prepared at 
the same concentration of 25µM. A first long label was incorporated by incubation with 
CldU-containing medium for one hour. Subsequently, IdU and CldU media were changed 
six more times after an incubation time of 10-15 minutes each, to result in an overall 
labelling time of 2-2.5 hours and seven incorporated labels (Fig. IV.3.2) 
 
 
 
 
 
 
Fig.  IV.3.2 Representative image of a fiber observed in the fork stalling assay with seven alternating 
labels of CldU and IdU 
CldU labelled DNA was detected with a red (Alexa555) and IdU with a green (Alexa488) fluorescent antibody. 
The number of labels was counted and used for the  analysis of fork processivity. 
 
 
 
51 
 
IV.3.2.2 Harvest of labelled cells 
After the labelling procedure, cells were harvested by washing twice with cold PBS and 
scraping in 2ml cold PBS. A cell pellet obtained by centrifugation at 4°C and 4,400rpm for 
5 minutes was resuspended to a final concentration of 500,000 cells per ml in PBS.  
IV.3.2.3 Spreading 
Cells were spread onto a Superfrost glass slide by applying a 2µl drop of cell suspension 
on top of the slide and airdrying for about 3 minutes. Cells were lysed by applying DNA 
Fiber spreading buffer (Table III.4) and incubation for 2 minutes at room temperature.  
Cells in lysis buffer were spread over the slide by tilting it slightly for the drop to run down 
slowly (about 3cm/min). Upon drying under a fume hood cells burst and release DNA at 
their relative position. Finally, the slides were fixed in a Fiber assay fixative solution (Table 
III.4) for 10 minutes at room temperature before storage at 4°C for up to one month.  
IV.3.2.4 Immunostaining 
Fixed slides were rehydrated by incubation with ddH2O twice for 5 minutes. Next, the 
samples were denatured to obtain single stranded DNA by equilibrating the slides with 
2.5M HCl for 5 minutes and incubation at room temperature for 80 minutes.  To remove all 
acid, the samples were washed twice with PBS and subsequently incubated with Blocking 
solution (Table III.4) twice for 5 minutes.  
Prior to immunostaining, the slides were blocked for one hour to avoid unspecific antibody 
binding.  Primary antibodies recognising epitopes on CldU and IdU specifically, were 
applied to slides in 150µl blocking solution with a 1:200-1000 dilution (Table III.10.2) and 
incubated at 37°C for one hour. Samples were rinsed with PBS and fixed in a 4% 
paraformaldehyde solution for 10 minutes. The slides were again rinsed with PBS and 
incubated with blocking solution three times for 5 minutes. Fluorescently labelled  
secondary antibodies AlexaFluor488 goat-anti-mouse and AlexaFluor555 goat-anti-rat 
(Table III. 10.4)  recognise primary antibodies from rat origin and were applied to slides in 
150µl with a dilution of 1:250 and incubated for 2 hours at room temperature.  
Final washing steps of rinsing once with PBS, washing twice with blocking solution for 5 
minutes, rinsing with PBS and water were conducted prior to mounting with Vectashield 
mounting medium.  
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IV.3.2.5 Microscope analysis 
Each slide was analysed with an Axio Scope A1 microscope (Zeiss) with filters for 488 
and 555nm, a EC Plan-Neofluar 40x objective (Zeiss) and an Axio Cam MRc/503 camera 
(Zeiss). Eight to twenty images were taken from all parts of the slide and from at least two 
slides per sample. Measurements of fiber and label length as well as their occurrence 
were carried out using Image J and its cell counter plugin (Kurt de Vos, University of 
Sheffield, UK). All data was further processed using Microsoft Excel and GraphPad Prism.  
 
IV.4 Statistical Analysis 
 
Statistical analysis was carried out using the GraphPad Prism Software (Versions 6 and 
7). Statistical significance was assessed by applying the unpaired 2-sided Student’s t-test 
and a cutoff value of p=0.05, under which differences are counted as significant. P-values 
calculated for each experiment are indicated in result figures.  
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V.I.1 Abstract 
p53 induces cell death upon DNA damage, but this may not confer all of its tumor 
suppressor activity. We report that p53 activation enhances the processivity of DNA 
replication, as monitored by multi-label fiber assays, whereas removal of p53 reduces fork 
progression. This was observed in tumor-derived U2OS cells, but also in murine 
embryonic fibroblasts with heterozygous or homozygous p53 deletion, and in freshly 
isolated thymocytes from mice with differential p53 status. Mdm2, a p53-inducible gene 
product, similarly supported DNA replication even in p53-deficient cells, suggesting that 
sustained Mdm2-expression is at least one of the mechanisms allowing p53 to prevent 
replicative stress. Thus, p53 helps to protect the genome during S phase, by preventing 
the occurrence of stalled or collapsed replication forks. These results expand p53’s tumor-
suppressive functions, adding to the ex-post model (elimination of damaged cells) an ex-
ante activity, i.e. the prevention of DNA damage during replication. 
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V.I.2 Introduction 
 
No other gene is as frequently mutated across most tumor species as TP53. Thus, p53 
must prevent tumor initiation and/or progression. Current concepts summarize the 
function of p53 largely as a mediator of cell death or permanent cell cycle arrest whenever 
cells suffer intolerable stresses, most notably when DNA damage occurs. DNA damage 
induces the activation of p53 as a transcription factor. Many of the p53-inducible genes 
mediate apoptosis. This ensures the elimination of cells that had suffered extensive DNA 
damage, conceivably avoiding the accumulation of cells with heavily mutated DNA that 
might otherwise give rise to malignant growth. Thus, the initial designation of p53 as a 
“guardian of the genome” (Lane, 1992) only applies to a whole organism, when damaged 
cells are eliminated to avoid danger to the whole body. From the perspective of a single 
cell, the “guardian” has a destructive role. According to currently accepted models, p53 is 
acting largely “ex post” by destroying damaged cells, but not “ex ante” to avoid DNA 
damage in the first place. Although DNA repair has now become another well 
acknowledged activity promoted by p53 (Bieging et al., 2014), this does still not imply that 
p53 actually prevents DNA damage, rather than merely reacting to it. 
However, some observations at least argue that p53 not only eliminates cells with 
damaged DNA but exerts some of its tumor suppressive activity by precluding such 
damage. Mice with a constitutive deletion of p53 develop largely normally. At 4-6 months 
of age, however, tumors occur (Donehower et al., 1992). In mice with switchable p53 
alleles, p53 function can be turned on and off at will, allowing the establishment of time 
windows during which p53 is essential or dispensable for tumor suppression (Martins et 
al., 2006). Using this system, established lung tumors were only temporarily halted by 
reintroducing wild type p53 (Junttila et al., 2010), arguing that p53 may have a more 
important role in preventing the formation of tumor cells rather than destroying them ex 
post. Investigating mouse strains with targeted deletions of key p53 target genes further 
challenged our current concept of p53-mediated tumor suppression. Even when the major 
mediator of cell cycle arrest, CDKN1A/p21, and the key proapoptotic gene product, 
BBC3/Puma, were both eliminated, p53 was still capable of suppressing T cell lymphomas 
that otherwise occur almost without exception when p53 itself is deleted (Valente et al., 
2013). Similarly, an acetylation-deficient p53 mutant that is largely unable to induce cell 
cycle arrest or apoptosis can still suppress T cell lymphomas in mice (Li et al., 2012). 
Thus, neither the proapoptotic nor the cell cycle regulatory function of p53 may be key to 
its tumor suppressive activity.  
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In further support of a protective function of p53 towards individual cells, the elimination of 
p53 does not always enhance cell survival. Rather, removing p53 in the colon cancer-
derived cell line HCT116 increases the sensitivity of cells towards certain 
chemotherapeutics, most notably doxorubicin and cisplatin (Bunz et al., 1999). The 
sensitivity of p53-deficient cells towards topoisomerase inhibitors was recently 
characterized in depth by a drug screen and mechanistic analysis (Yeo et al., 2016). 
siRNA screens revealed that the depletion of some gene products decreases the viability 
of p53-/- cells to a higher degree than their p53-proficient counterparts. These genes are 
involved in nucleotide synthesis, e.g. UMPS (Bartz et al., 2006), DNA replication, e.g. 
Geminin (Krastev et al., 2011), or DNA repair by homologous recombination, e.g. BRCA1 
and RAD51 (Xie et al., 2012). Thus, p53 may support cell survival by preventing the 
accumulation of DNA damage during challenges to DNA replication. 
Our previous results indicate that p53 can protect cells towards chemotherapeutics. These 
drugs still represent the mainstay of cancer treatment (Dobbelstein and Moll, 2014), and 
the induction of replicative stress is a key mechanism of many chemotherapies 
(Dobbelstein and Sørensen, 2015). When we activated p53 using the pharmacological 
Mdm2 inhibitor Nutlin-3a (Nutlin; Vassilev et al., 2004), we observed decreased 
cytotoxicity of gemcitabine (Kranz and Dobbelstein, 2006), UV-irradiation (Kranz et al., 
2008), and Wee1 inhibitors (Li et al., 2015). Initially, we ascribed this mostly to the cell 
cycle arrest function of p53, keeping the cells out of S phase.  
Here, we investigated whether p53 can influence the accumulation of DNA damage and 
replicative stress during S phase. However, previous reports suggested that p53 activity 
might be attenuated during DNA replication. Most of these experiments used hydroxyurea, 
an inhibitor of ribonucleotide reductase, to arrest the cells in S phase. Under such 
circumstances, the induction of CDKN1A by p53 appeared reduced (Gottifredi et al., 2001; 
Mattia et al., 2007). However, this does not exclude an activity of p53 when cells proceed 
through S phase rather than being arrested in it. 
We show that p53 induces most of its target genes during S phase and increases the 
processivity of DNA replication. The absence of p53 causes replicative stress. This was 
observed not only in tumor-derived cell lines, but in fibroblasts and thymocytes from mice, 
comparing p53-proficient and –deficient genotypes. Thus, p53 protects the genome by 
ensuring undisturbed progression of DNA replication forks. 
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V.I.3 Results 
V.I.3.1 p53 is capable of inducing the majority of its target genes during S phase  
Previous reports have suggested that p53 activity might be attenuated while cells are 
replicating their DNA, but this was mostly studied in the context of exogenous replicative 
stress (Gottifredi et al., 2001; Mattia et al., 2007). To address this during ongoing, 
unperturbed S phase, we synchronized U2OS cells using a double thymidine block 
(Bootsma et al., 1964; Xeros, 1962). We then compared the expression of a bona fide p53 
target gene, CDKN1A/p21, between asynchronously proliferating cells, cells that were 
arrested by a thymidine block, and cells that had been released from the block to enter S 
phase. In each condition, the cells were treated with the Mdm2-inhibitor Nutlin-3a (Nutlin) 
to induce p53. Nutlin did not preclude the onset of S phase upon release from the 
thymidine block (Fig.V.I.1A). We found that CDKN1A/p21 mRNA levels were enhanced by 
Nutlin under all three conditions but did not grossly differ between asynchronous, arrested 
and released cells (Fig.V.I.1B). When analyzing p21 protein levels by immunoblot, we 
observed the induction by Nutlin under all three conditions again, and p21 was even more 
abundant in the cells that were released to enter S phase (Suppl. Fig.V.I.7.1A). This 
argues against the view that p53 activity might be impaired during DNA replication.  
 
 
 
 
 
 
 
 
Fig. V.I.1 p53-mediated induction of genes during S-phase. 
(A) Thymidine block and release result in comparable cell cycle distribution, independent of Nutlin 
pretreatment. U2OS cells were subjected to a double thymidine block. Four hours before release from the 
block (or maintaining the block), 10 μM Nutlin (control: DMSO alone) was added. When the block was 
removed, the previous concentration of Nutlin was maintained, followed by further incubation for 4 h. The 
cellular DNA content was determined by propidium iodide staining and flow cytometry. (B) Nutlin induces 
comparable CDKN1A/p21 mRNA levels in proliferating cells, thymidine-arrested cells, and during S phase. 
U2OS cells were treated as in A or grown asynchronously. Subsequently, CDKN1A/p21 mRNA (RT-PCR) and 
protein (cf. Suppl. Fig. V.I.7.1A; immunoblot analysis) levels were determined in triplicate (n=2). 
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To broaden this analysis, we performed next generation RNA sequencing to identify 
Nutlin-inducible genes in thymidine-blocked vs. released cells. The induction of most p53-
responsive genes was largely unchanged regardless of the thymidine block. Less than ten 
genes were no longer found induced by Nutlin when the cells were allowed to proceed in 
S phase (Fig.V.I.1C, Suppl. Fig.V.I.7.1B, Suppl. Table 1).  
 
Thus, most capabilities of p53 to activate transcription are preserved while cells replicate 
their DNA. Previous investigations have mostly used hydroxyurea to arrest cells in S 
phase. Then, the expression of p53-responsive genes was indeed found attenuated 
(Gottifredi et al., 2001; Mattia et al., 2007). We propose that unperturbed S phase, but not 
an intra S phase arrest, permit full p53 activity.  
 
Fig. V.I.1 p53-mediated induction 
of genes during S phase.  
 
(C) RNA deep sequencing analysis 
reveals comparable induction of 
genes by Nutlin, in thymidine-block 
as well as during S phase. U2OS 
cells were treated as in A, followed 
by reverse transcription and next 
generation sequencing (Illumina). 
The heat map reflects fold induction 
of the indicated genes by Nutlin 
according to the color scheme (color 
and blue line, log 2). Genes 
displaying an induction of greater 
than 2-fold and a p-value <0.05 
(based on at least two independent 
samples for each condition) in 
thymidine-blocked cells (Suppl. Table 
S1) were included in the analysis. 
Most of these genes were induced by 
p53 to a similar degree when the 
cells had been released to enter S-
phase. The genes were sorted 
according to their p-value identified in 
released cells. Only a small 
proportion of genes (bottom of the 
heat map) were inducible only in non-
released cells but not in S phase. 
 
non-released S-phase 
C 
log
2 
fold induction 
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V.I.3.2 p53 activation enhances DNA replication processivity 
Next, we asked whether p53 might exert a genome-protective function during S phase by 
affecting DNA replication. U2OS cells were first treated by Nutlin to induce p53 activity, as 
confirmed by accumulation of p53 and its target gene products (Fig.V.I.2A). 
 
 
 
Fig.V.I.2 Enhanced replication fork progression upon p53 
activation. 
(A) U2OS cells were treated with 8μM Nutlin or the DMSO solvent for 
14 hrs and subjected to immunoblot analysis, detecting Mdm2, p53, 
p21, and β-actin to reveal the induction of p53 and its target gene 
products. A representative result of three biological replicates is 
shown. 
 
 
Subsequently, the characteristics of DNA replication were assessed by DNA fiber assays. 
The cells were sequentially incubated with two different nucleoside analogues. Upon 
spreading of the DNA on glass slides, we determined the length of DNA tracks that were 
detected by antibodies due to incorporation of the labels (Fig.V.I.2B). Strikingly, the 
replication fork rate, indicating the distance that a replication fork moves within a given 
amount of time, consistently increased when the cells had been treated with Nutlin before 
adding the labelling nucleosides (Fig.V.I.2C-D). Of note, increased fork rate was only 
observed when Nutlin treatment was long enough to fully induce its target genes p21 and 
Mdm2, while DNA replication still continued (Suppl. Fig.V.I.7.2A-F). We cannot exclude, 
however, that Nutlin may have shifted a majority of DNA-replicating cells towards the late 
S phase. Shortening the incubation time with the second label IdU still allowed the 
observation of an increased fork rate upon Nutlin treatment (Suppl. Fig.V.I.7.2G-I). 
Conversely, the rate of origin firing, as determined by a stretch of first label flanked by two 
stretches of second label, was reduced upon Nutlin treatment (Fig.V.I.2E). This is in 
agreement with the frequent observation that replication fork progression rate and origin 
firing are inversely correlated (Petermann and Helleday, 2010). However, interfering with 
origin firing by an inhibitor of Cdc7, as described previously (Montagnoli et al., 2008), did 
not compromise the increased fork progression rate in the presence of Nutlin, whereas 
Cdc7 inhibition was itself sufficient to induce p53 and to enhance the fork rate (Suppl. 
Fig.V.I.7.3A-C). Thus, the increased fork rate by p53 does not strongly depend on origin 
firing. Counterstaining of the non-labeled fibers confirmed the notion that the labeled track 
A 
Mdm2 
p53 
p21 
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β-actin 
- 
100 
55 
25 
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is part of a larger, intact DNA fiber (Suppl. Fig.V.l.7.3D). Taken together, the activation of 
p53 enhances the ability of replication forks to move along the template DNA. 
 
Fig.V.I 2 Enhanced replication fork progression upon p53 activation. 
(B) U2OS cells were treated as described in A and further incubated with 5-Chloro-3’deoxy-uridine (CldU, 25 
μM, 20 mins) followed by Iodo-deoxy-uridine (IdU, 250 μM, 120 mins) as indicated, to label newly synthesized 
DNA. (C) Tracks of newly synthesized DNA were visualized by immunostaining of CldU (red) and IdU (green). 
(D) Fork progression was determined through the length of the second label (IdU; kilobases/min). Nutlin 
pretreatment caused a highly significant increase in the fork rate. Note that fork progression is not identical to 
fork velocity, since shortening the observed track length can be a result of either slower replication or 
otherwise of sudden fork stalling. In addition to the experiment shown here, two replicates are shown in Suppl. 
Fig. 2D. (E) The proportion of first pulse origins, characterized by 1st label in the middle flanked by 2nd label 
at both sides, among all labelled structures was determined. Nutlin-pretreated cells had a lower proportion of 
firing origins, in agreement with lower replicative stress. The number of evaluated fibers with labelled tracks 
from five independent experiments is indicated below each box. 
 
 
In principle, two phenomena can affect the movement of a replication fork. Either, the 
speed by which the polymerases move along the template might vary. Otherwise, 
however, the frequency by which replication stalls entirely can also affect the outcome of a 
fiber assay when stalling occurs during the period of DNA labeling (Suppl. Fig.V.I.7.3E). 
To distinguish between these two possibilities, we modified the fiber assay. We incubated 
the cells with two different nucleosides, with repeated changes every 15 min (Fig. 
V.I.7.2F-G). In this way, we distinguished the reasons for increased track length upon p53 
activation. Longer “stripes” containing one label would indicate faster polymerization, 
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whereas a higher rate of fibers that contain all stripes with the two colors would indicate 
less fork stalling, i. e. higher processivity. Upon induction of p53 activity by Nutlin, we 
found a higher percentage of fibers with the maximum number of labels (Fig.VI.2H-I; 
Suppl. Fig.V.I.7. 3F; Suppl. Tables 2 and 3). In contrast, the length of the individual labels 
2-5 did not significantly differ between the treatments with Nutlin or DMSO alone (Fig.V.I. 
2J; Suppl. Tables 2 and 3). Thus, activation of p53 reduces the frequency of fork stalling 
and increases the processivity of DNA replication. 
 
 
Fig.V.I 2 Enhanced replication fork progression upon p53 activation.  
 (F) Fiber assay to distinguish the speed of fork progression from the frequency of fork discontinuation 
(processivity; cf. Suppl. Fig.V.I.7.3E). After treatment as in A, the cells were subjected to one long first CldU 
label and then repeatedly incubated with IdU and CldU for 15 min each. (G) As a result of fiber staining, a long 
red track is followed by “stripes” that reflect CldU and IdU incorporation during the subsequent 15 min pulses. 
Stalled forks are reflected by fibers with less than 7 labels. (H) The number of forks that proceeded through n 
labels is displayed for DMSO-treated and Nutlin-treated cells. 7 labels reflect full progression of the fork 
throughout the entire labeling time. Numbers lower than 7 indicate that the replication fork had discontinued 
during the labeling time. (I) The proportion of prematurely stalled forks (less than 7 labels) indicates that 
Nutlin-treatment reduced fork stalling and enhanced the processivity of DNA replication. Results from three 
independent experiments are summarized by the mean and the standard error of the mean. In each 
experiment, the rate of prematurely stalled forks was determined for DMSO-treated or Nutlin-treated cells, and 
the relative decrease in this rate upon Nutlin treatment was calculated. (J) Fork speed was determined 
through the length of labels two to five (kilobases/min). Nutlin treatment did not change the fork speed 
significantly, in contrast to its impact on fork processivity (H, I). 
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V.I.3.3 p53 depletion hampers replication fork progression, and so does Mdm2 
depletion in a p53-deficient background 
We then sought to determine whether the depletion of p53 might also modulate the ability 
of cells to replicate their DNA. First, we depleted p53 from U2OS cells by siRNA. One set 
of cells was also treated with gemcitabine, a nucleoside analogue that induces replicative 
stress by false incorporation and by inhibition of ribonucleotide reductase. To assess the 
DNA damage response, we determined the levels of phospho-H2AX by immunoblot 
analysis. As expected, gemcitabine induced the accumulation of phospho-H2AX and also 
increased the levels of p53. Strikingly, however, phospho-H2AX was further increased 
when p53 had been knocked down (Fig.V.I.3A). We conclude that p53 depletion 
augments the DNA damage response upon treatment with an inducer of replicative stress. 
 
To directly determine the impact of p53 depletion on DNA replication, we performed fiber 
assays in the presence or absence of gemcitabine (Fig.V.I.3B). In both cases, we 
observed a significant decrease in replication fork progression (Fig.V.I.3C-D; Suppl. Fig. 
V.I.7.4A-F). Thus, baseline levels of p53 carry out a protective function against replicative 
stress in U2OS cells. The depletion of p53 did not detectably alter the cell cycle 
distribution of U2OS cells (Suppl Fig.V.I.7.3G-H), and in some contrast with a previous 
report (Sablina et al., 2005), we did not observe changes in the levels of mitochondrial 
reactive oxygen species (ROS) upon depletion of p53 (Suppl. Fig.V.I.7.4I). 
We then determined whether p53 might affect fork regression upon stalling, as has been 
reported in BRCA1-deficient cells (Chaudhuri et al., 2016).  
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Fig.V.I.3 Increased replicative stress upon p53 depletion, and upon depletion of Mdm2 from p53-
deficient cell. 
 (A) U2OS cells were treated with siRNA to knock down p53, or control siRNA, for 48 h, followed by treatment 
with 400nM gemcitabine for 2 h and immunoblot analysis. Upon p53 knockdown, decreased amounts of 
Mdm2 and increased levels of phosphoH2AX (γH2AX) were observed. A representative result out of >5 
replicates is shown. (B) Upon depletion of p53 (or control siRNA transfection), newly synthesized DNA was 
labeled with CldU and IdU. Gemcitabine was added during the IdU label only. (C) DNA fibers were 
immunostained under the conditions described in A and B. (D) Fork progression was determined through the 
length of the second label (IdU; kilobases/min. p53-depleted cells showed a highly significant reduction in fork 
progression. This experiment was repeated as shown in Suppl. Fig.V.I.7.4C. 
 
However, the interruption of DNA synthesis by transient treatment with hydroxyurea (HU; 
Fig.V.I.3E) after the first label did not decrease the proportion of replication forks that 
proceeded to incorporate the second label, regardless of p53 depletion (Suppl. Fig.V.I.7. 
5A-C), nor did it shorten the track that was labeled before HU addition (Suppl. Fig.V.I.7. 
5D-H), as would have been seen in the case of fork regression (Chaudhuri et al., 2016). 
However, the depletion of p53 decreased the speed of fork progression after release from 
the HU block (Fig.V.I.3F-G; Suppl. Fig.V.I.7.5I).  
64 
 
 
Fig.V.I.3 Increased replicative stress upon p53 depletion, and upon depletion of Mdm2 from p53-
deficient cells. 
 
(E) U2OS cells were treated with control and p53 siRNA for 48 hours, after which they were labelled with 
25μM CldU for 20 mins. Subsequently, cells were treated with 4mM hydroxyurea (HU) for 2 h to arrest 
replication forks. Upon release from the HU block, the cells were labelled with 25μM IdU for another hour. 
Control cells were labelled with CldU and IdU without interrupting replication by HU. (F) Labeled replication 
tracks were immunostained to visualize CldU in red and IdU in green. (G) Fork progression was determined 
through the track length corresponding to the second label (IdU). P53 depletion significantly reduced the 
progression of replication forks. This effect was even more pronounced after an HU block. Similar results to 
this experiment were found independently in Suppl. Fig.5I. 
 
One of the most well-studied p53-responsive genes is Mdm2, encoding a p53 antagonist. 
Indeed, even the baseline expression levels of Mdm2 were found to depend on p53 (cf. 
Fig.V.I.3A). We have recently reported an unexpected function of Mdm2 as a chromatin 
modifier (Wienken et al., 2016), raising the possibility that Mdm2 might affect DNA 
replication as well. To test this, we depleted Mdm2 from cells and determined the DNA 
replication fork progression rate. However, knocking down Mdm2 in p53-proficient cells 
would inevitably have led to robust and long-term activation of p53. Therefore, we 
subjected a cell line with a targeted deletion of p53 (Bunz et al., 1998) to siRNA 
transfection, thus knocking down Mdm2 in a p53-deficient background (Suppl. Fig.V.I.7. 
5J). Strikingly, the depletion of Mdm2 reduced the fork rate of HCT116 p53-/- cells and 
exacerbated gemcitabine-mediated replicative stress (Fig.V.I.3H-J). The transcription of 
known replicative stress response genes was not affected by Mdm2 depletion (Suppl. Fig. 
V.I.7.5K).This suggests that Mdm2 may act as at least one mediator that allows p53 to 
protect DNA replication, perhaps through its ability to modify histones and chromatin 
structure (Wienken et al., 2016).  
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Fig.V.I.3 Increased replicative stress upon p53 depletion, and upon depletion of Mdm2 from p53-
deficient cells.  
(H) HCT116 cells with a targeted deletion of p53 were transfected with siRNA to Mdm2 or control siRNA. 
Subsequently, fork progression was determined in the presence or absence of gemcitabine. Similar results 
were obtained with independent siRNAs to Mdm2 (not shown). (I) Representative labeled tracks are shown as 
in in C and F. (J) Box plot analysis of the fork rates, as determined by the tracks derived from the second 
label, revealed reduced replication fork progression in response to Mdm2 depletion. 
 
V.I.3.4 p53 promotes the progression of DNA replication forks in murine embryonic 
fibroblasts 
 
To validate a possible influence of p53 on DNA replication in non-transformed cells, we 
employed murine embryonic fibroblasts (MEFs). Wildtype MEFs were treated with Nutlin 
to induce p53 activity, followed by DNA fiber assays (Fig.V.I.4A). Strikingly, the median 
DNA replication fork rate was increased 1.5-fold by Nutlin treatment, indicating that p53 is 
capable of strongly augmenting the movement of DNA replication forks in these cells 
(Fig.V.I.4B-C).  
 
To test whether baseline p53 levels also affect fork progression, we employed MEFs from 
mice with a conditional p53 knockout (Jonkers et al., 2001). In these cells, the cre-
recombinase can be induced by 4-hydroxy-tamoxifen (4-OHT). We were comparing cells 
that contained wildtype p53 with cells that had had been modified (“floxed”) by LoxP-
insertions on both p53 alleles, as well as heterozygous cells, in the presence or absence 
of gemcitabine When cells had been treated with 4-OHT to delete the floxed alleles, we 
observed that replication fork progression was severely impaired in MEFs with a 
homozygous p53 deletion (Fig.V.I.4D-F, Suppl. Fig.V.I.7.6A-B). Similarly, the impact of 
gemcitabine on fork progression was aggravated by loss of p53, even in MEFs where only 
one allele was lost by recombination (Fig.V.I.4G-I, Suppl. Fig.V.I.7.6C). Some increase in 
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the proportion of cells in S phase was also observed in cells that lack one or two p53 
alleles (Suppl. Fig.V.I.7.6D-E). In sum, p53 supports DNA replication in primary cells, and 
for this task, haploinsufficiency of the p53 gene was observed. 
 
 
Fig.V.I.4 p53-supported DNA replication in murine embryonic fibroblasts. 
 (A) Wild type murine embryonic fibroblasts (MEFs) were treated with Nutlin or the DMSO control for 14h, 
followed by two-label fiber assays as indicated.  (B) Fork progression was determined by immunostaining of 
CldU (red) and IdU (green). (C) The degree of fork progression was increased by Nutlin pretreatment, on a 
highly significant level. The indicated numbers of labelled fibers were evaluated independently by two 
independent evaluators. 
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Fig.V.I.4 p53-supported DNA replication in murine embryonic fibroblasts. 
 
(D) MEFs with floxed p53 and a Cre-ERT2 fusion gene driven by the ubiquitously active Rosa26 promoter 
were first treated with  4-hydroxy-tamoxifen (4-OHT; 200 nM, 48 h) to excise p53 exons 2-10 (Jonkers et al., 
2001). Moreover, ethanol was used as a solvent control to 4-OHT. Subsequently, the cells were labelled with 
CldU (25μM, 20 mins) and IdU (250μM, 2h). In the indicated experiments, 400nM gemcitabine was added to 
the second label. (E) Labelled DNA tracks were immunostained to detect CldU (red) and IdU (green). (F) 
When comparing MEFs with two floxed p53 alleles before and after treatment with 4-OHT to excise p53, a 
strong reduction in fork progression was observed. This was true in otherwise untreated cells and also upon 
treatment with gemcitabine. A replicate of this experiment is shown in Suppl. Fig.V.I.7.6B. (G) Cells with two 
wildtype p53 alleles (wt/wt) and with a mixed genotype (wt/fl) were investigated in comparison with the fl/fl p53 
genotype. 4-OHT treatment was applied to excise p53 exons 2-10, followed by labelling with CldU (25μM, 
20mins) and IdU (25μM), in the presence of gemcitabine, for 2h. (H) Labelled tracks of newly synthesized 
DNA were stained with antibodies against CldU and IdU. (I) Labelled track lengths were significantly reduced 
upon removal of one or both p53 alleles. The result was confirmed in Suppl. Fig.V.I.7.6C. 
 
To assess the role of Mdm2 in DNA replication, we again used a p53-deficient cell system 
to avoid p53 induction by loss of mdm2. When comparing MEFs with a targeted deletion 
of p53 alone (single knockout) with cells that lack both p53 and mdm2 (double knockout) 
(Montes de Oca Luna et al., 1995), we observed a marked decrease in DNA replication 
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fork rate in mdm2-deficient cells (Fig.V.I.4J-L). Genes with relevance to replicative stress 
were not found to be transcribed differentially upon Mdm2 deletion (Suppl. Fig.V.I.7.6F), 
based on our previous analyses (Wienken et al., 2016). In conclusion, and similar to 
HCT116 p53-/- cells (cf. Fig.V.I.3H-J), Mdm2 is required for efficient DNA replication fork 
progression and may thus serve as a mediator allowing p53 to enhance replication 
processivity. 
 
Fig.V.I.4 p53-supported DNA replication in murine embryonic fibroblasts. 
 
(J) MEFs with a p53-/- (single knockout) or a p53-/- mdm2-/- (double knockout) genotype were incubated with 
the CldU and IdU labels as indicated, followed by analysis of DNA fork progression. Note that these MEFs are 
not directly comparable to the preparations used in Panels A-I, due to differences in passage numbers and 
genetic background, as specified in the Materials and Methods. (K) Representative tracks are shown for each 
genotype. (L) Quantification of fiber lengths revealed that the absence of mdm2, on the p53-/- background, led 
to a marked loss in replication fork progression. 
 
V.I.3.5 p53 increases DNA replication fork processivity in murine thymocytes before 
the occurrence of T cell lymphoma  
Finally, we sought to test the impact of p53 on replication fork progression under 
conditions that are as close as possible to a living organism, and in cells that are prone to 
cancer formation in animals that lack p53. To this end, we employed thymocytes freshly 
isolated from p53-/- mice or their p53-proficient littermates, at 4 weeks of age, i. e. at a 
time point prior to the occurrence of pre-cancerous cell clones (Dudgeon et al., 2014). 
Thymocytes from p53-/- mice had a higher level of phosphorylated H2AX than the 
corresponding p53+/+ cells (Fig.V.I.5A), at least compatible with the view that the deletion 
of p53 leads to enhanced replicative stress in vivo. This was not accompanied by changes 
in mitochondrial ROS (Suppl. Fig.V.I.7.7A).  
Of note, p53-/- thymocytes showed a markedly impaired progression of DNA replication 
forks, in the presence or absence of gemcitabine, (Fig.V.I.5B-E, Suppl. Fig.V.I.7.7B-G).  
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Fig.V.I.5 Replicative stress in murine thymocytes lacking p53. 
 (A) Immunoblot analysis revealing enhanced H2AX phosphorylation in p53-/- thymocytes. Freshly isolated 
thymocytes from mice with the indicated genotype were subjected to immunoblot analysis to detect p53 and 
phospho-Ser 139 Histone 2A (γH2AX). Total protein staining by Ponceau S served as a loading control. (B) 
Thymocytes were subjected to fiber assays immediately after their isolation from 4 weeks old mice with 
different p53 status (homozygous knockout, heterozygous, or wild type). The labeling (CldU and IdU, 25 μM 
each) was performed in the presence or absence of 100 nM gemcitabine. (C) Labeled DNA tracks were 
immunostained to visualize incorporated CldU (red) and IdU (green). (D) Fork progression was assessed by 
the length of the IdU fibers and displayed by box plots. Decreased fork progression was observed in 
homozygous knock-out cells, at a highly significant level, in untreated cells, and (E) in gemcitabine-treated 
thymocytes (confirmation in Suppl. Fig.V.I.7.7C-D). 
 
We also determined the processivity of replication forks by frequent changes in the label 
(Fig.V.I.5F-J), an assay that we had first performed in U2OS cells (cf. Fig.V.I.2F-J). When 
p53-/- thymocytes were repeatedly incubated with different labels of newly synthesized 
DNA, it turned out that the number of stalled replication forks increased in comparison to 
p53-proficient cells (Fig.V.I.5H, summarized in Fig.V.I.5I). In contrast, the replication 
speed observed in continuous tracks was not detectably affected by the p53 status 
(Fig.V.I 5J), nor did we observe gross changes in cell cycle distribution (Suppl. 
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Fig.V.I.7.7H-I). Thus, p53 increases the processivity of DNA replication in cells from the 
thymus. We propose that the resulting replicative stress in response to p53 loss might 
contribute to the occurrence of chromosomal damage in these cells (Dudgeon et al., 
2014), in accordance with the formation of T cell lymphomas, observed later in the lives of 
more than 90% of p53-/- mice (Donehower et al., 1992). 
 
 
 
Fig.V.I.5 Replicative stress in murine thymocytes lacking p53. 
(F) To determine fork processivity, multiple labels were performed as in Fig.V.I.2F-J, with a total of 5 labels. 
(G) Immunostaining allowed the clear distinction of up to five CldU/IdU-labeled tracks. (H) The number of 
prematurely stalled replication forks (less than 5 labels) was found increased in thymocytes from p53-/- mice, 
compared to cells from p53 proficient mice. (I) The proportion of prematurely stalled replication forks was 
significantly increased in p53-deficient thymocytes. Results from three independent experiments are 
summarized by the mean and the standard error of the mean. In each experiment, the rate of prematurely 
stalled forks was determined for cells from mice with a p53 +/+, +/- and -/- genotype, and the relative decrease 
in this rate depending on the deletion of the p53 alleles was calculated. (J) As observed in U2OS cells 
(Fig.V.I.2J), the replication speeds observed in single tracks, here determined by labels 2-4, were unchanged. 
71 
 
V.I.4 Discussion 
 
P53 is active during S phase, and it strengthens the processivity of DNA replication. This 
was not only observed in p53-proficient cancer cells, but also in primary cells. Even 
thymocytes, the precursors of the most frequently found tumor species in p53-/- mice, 
displayed impaired DNA replication. These observations all support the view that p53 is 
not only acting ex post, by eliminating or repairing cells that suffered DNA damage. 
Rather, p53 appears to avoid replicative stress and associated damage ex ante. 
Our previous studies had already indicated that p53 activation by Nutlin can protect p53-
proficient cells from the cytotoxic effects of gemcitabine (Kranz and Dobbelstein, 2006), 
and also from the combined effects of Wee1 inhibitors and gemcitabine (Li et al., 2015). 
However, in those experiments, we had pretreated the cells with Nutlin for an extended 
period of time, largely avoiding their entry into S phase. It appears obvious that cells are 
resistant to replicative stressors when not in S. Here, however, we show that p53 activity 
reaches far beyond cell cycle arrest to protect the cell against nucleoside analogues. Even 
under conditions where cells still undergo DNA replication, p53 still exerts protection 
against replication fork stalling. 
The vast majority of mice that lack p53 will develop T cell lymphoma, at ca. six months of 
age (Donehower et al., 1992). Deep sequencing analysis revealed that the first clones 
with rearranged DNA become detectable at nine weeks after birth (Dudgeon et al., 2014). 
Our results show that replicative stress occurs in the bulk of thymocytes even earlier, i.e. 
at four weeks of age. This strongly argues that replicative stress precedes the occurrence 
of detectable premalignant cell clones in p53 -/- mice. It is at least conceivable that 
replicative stress in thymocytes plays a causal role for tumor formation. In such a 
scenario, the attenuation of replicative stress would represent an essential part of the 
tumor suppressive activity of p53. Accordingly, it is noteworthy that even the triple deletion 
of the p53 target genes cdkn1a, pmaip1/noxa and bbc3/puma does not recapitulate the 
phenotype of p53 null mice. The triple deletions do not give rise to T cell lymphoma or 
other cancers (Valente et al., 2013). Rather, p53 target genes that support DNA 
replication, e.g. mdm2, might represent mediators of tumor suppression in vivo. 
It would be tempting to speculate that p53 can support DNA replication by physical 
association with the replication fork. It has long been noticed that p53 is capable of 
interacting with insertion/deletion mismatches which may form during replication (Lee et 
al., 1995), and with the “chickenfoot” structure at retracted replication forks (Subramanian 
and Griffith, 2005) in vitro. However, in our hands, no visible fork regression was found 
when depleting p53 (Suppl. Fig.V.I.7.5D, H), and the accumulation of p53 only affected 
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DNA replication fork progression if it had lasted for half a day (cf. Fig.V.I.2A-D and Suppl. 
Fig.V.I.7.2A-F), an amount of time required to enhance the mRNA levels corresponding to 
most p53 target genes (Zhao et al., 2000). While not excluding transcription-independent 
contributions of p53, e.g. by suppressing excessive homologous recombination (Arias-
Lopez et al., 2006; Bertrand et al., 2004; Janz and Wiesmüller, 2002), we therefore 
propose that p53-target genes are at least necessary for the impact of p53 on DNA 
replication. And indeed, one of the genes with the strongest p53-inducibility, Mdm2, was 
found to facilitate DNA replication independent of its ability to antagonize p53 (Fig.V.I.3 H-
J, Fig.V.I.4J-L). Interestingly, Mdm2 acts as a chromatin modifier, as we have shown 
recently (Wienken et al., 2016), and chromatin modifications are capable of interfering 
with DNA replication in multiple ways (Alabert and Groth, 2012). However, Mdm2 is also 
capable of binding Nbs1 (Bouska et al., 2008), raising the possibility that it might support 
the functions of the MRN complex in resolving replication (Bruhn et al., 2014) or in 
activating ATR-Chk1-signaling (Duursma et al., 2013). Mdm2’s anti-oxidative activity 
(Riscal et al., 2016) may also contribute to smooth DNA replication, although we have not 
observed increased ROS upon removal of p53 (Suppl Fig.V.I.7.4I and 7A). Curiously, 
Mdm2 was also reported to enhance replicative stress when overexpressed (Frum et al., 
2014). However, transgenic overexpression of Mdm2 has long been known to yield 
paradoxical growth arrest rather than its physiological oncogenic function (Brown et al., 
1998), and similar effects might be responsible for the observed replication stress in 
overexpression systems. In our study, we thus avoided Mdm2 transgenes, and all 
observations were made by exploring Mdm2 from an endogenous source.  
Perhaps similarly, a recent report described the deceleration of replication fork 
progression as a response to p53 activity (Hampp et al., 2016), in seeming contrast with 
our observations and with another report on a role for p53 in avoiding conflicts of 
transcription and replication (Yeo et al., 2016). However, the majority of the experiments 
reported by (Hampp et al., 2016) were carried out using transgenic overexpression of p53, 
which might well have led to non-physiological situations, or in cell systems other than 
those described in our study. In contrast, we have performed our assays in the very same 
cells from p53-deficient animals that give rise to cancer later in life, i. e. thymocytes 
(Fig.V.I.5). There, endogenous wild type p53 contributed to DNA replication with greater 
processivity than in p53-deficient thymocytes. We therefore propose that in a cancer-
relevant system, p53 acts to protect DNA replication forks against stalling and collapse, 
thus preserving the genome during this highly vulnerable phase. 
On top of Mdm2, additional p53 target genes might be involved in the p53-driven support 
of DNA replication. Candidates include the ribonucleotide reductase p53R2, capable of 
increasing the available dNTP pool (Nakano et al., 2000; Tanaka et al., 2000).  
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Similarly, the p53-inducible lncRNA NEAT1 dampens replicative stress through 
paraspeckle formation and ATR activation (Adriaens et al., 2016). On the other hand, the 
p53-inducible gene product p21/CDKN1A was reported to enhance rather than inhibit 
replicative stress, at least under circumstances that involve UV irradiation (Mansilla et al., 
2013) or senescence (Galanos et al., 2016). Thus, the impact of p53 on DNA replication 
may also depend on the exogenous stressors and the cell-specific set of p53-responsive 
genes.The relatively long time periods of labeling replicating DNA used in many of our 
experiments might conceivably have led to the collision of forks, considering average 
replication origin distances (Conti et al., 2007; Lebofsky and Walter, 2007). However, we 
rarely observed such collisions, perhaps pointing to different replication origin distances 
between cell species, and also to the slower progression of replication forks between 
closely situated origins (Conti et al., 2007). 
 
How could replicative stress lead to cancer? In addition to nucleotide misincorporations, 
cells with incompletely replicated DNA might enter irregular mitosis, giving rise to 
chromosomal instability. In agreement, sites of replicative stress often coincide with 
common fragile sites, i.e. breakpoints of chromosome rearrangements (Glover et al., 
2005). The removal of p53 strongly compromises the G2-M checkpoint which normally 
prevents the onset of mitosis when DNA is damaged or incompletely replicated (Taylor et 
al., 1999). Thus, p53 may prevent the accumulation of chromosomal rearrangements by 
avoiding fork stalling and also premature mitosis. In support of this model, the thymocytes 
in p53 -/- mice indeed accumulate chromosomal rearrangements, and even 
chromotrypsis, at ages before full-blown T cell lymphomas arise (Dudgeon et al., 2014).  
At least in MEFs, even a heterozygous p53 deletion was capable of increasing replicative 
stress (Fig.V.I.4). This is similar to the situation in patients suffering from Li-Fraumeni 
syndrome. There, all somatic cells carry one allele with a p53 mutation and another allele 
with an intact TP53 gene. So far, the occurrence of cancer in these patients was mostly 
ascribed to a loss of heterozygosity. In contrast, our results suggest that even the 
heterozygous situation may increase replicative stress at least in some cell species and 
thus enhance the probability of mutations or chromosomal rearrangements. Thus, a 
subset of cells in such patients may be cancer-prone even before the intact allele of p53 is 
lost. About half of all human malignant tumors carry a p53 mutation. However, tumor 
progression studies such as those on colorectal cancer revealed that, in general, p53 
undergoes mutations late during tumor development (Fearon and Vogelstein, 1990). One 
reason for this phenomenon might be that the presence of p53, through its ability to 
ensure unperturbed DNA replication, can support the initial survival of cancer cells. Only 
at late stages, the tumor cell might be able to tolerate the loss of p53 and the concomitant 
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replicative stress. It might then take advantage of the enhanced genomic variability and 
the consequent ability of adaptation, e.g. during invasion and metastasis. Our results also 
point to a selective vulnerability of p53-deficient cells towards chemotherapeutics that 
enhance replicative stress. Indeed, enhanced sensitivity of p53 -/- cells towards selected 
chemotherapeutics was described more than 15 years ago (Bunz et al., 1999). Recently, 
this phenomenon was ascribed to an ability of p53 to prevent interference between 
transcription and DNA replication which would otherwise require topoisomerase activity to 
be resolved (Yeo et al., 2016). Here, we identify p53 as a supporter of DNA replication 
processivity, in primary cells that undergo tumor formation when p53 is deleted. 
 
P53 has long been known as a guardian of the genome. However, most of these 
protective functions appeared retroactive from the point of a single cell, as if a guardian 
killed his injured master after an attack. Here, however, we identify a proactive way of how 
p53 prevents DNA damage even before it occurs. 
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V.I.7 Supplemental Figures 
 
 
 
Suppl. Fig. V.I.7.1 p53-
responsive gene 
expression during S 
phase. Related to Fig. 
V.I.1 
(A) U2OS cells were 
synchronized by a double 
thymidine block as 
described in the legend to 
Fig. 1, or left 
asynchronous. Four hours 
before release from the 
block, all three sets of cells 
(S-phase, non-released 
and asynchronous) were 
treated with 10μM Nutlin-3a 
(and the DMSO solvent 
alone as a control). After 
the release, the previous 
concentrations of Nutlin 
was maintained. The cells 
were harvested 4 h after 
the release from the 
thymidine block. 
Immunoblot analysis was 
performed to detect p53 
and its target gene product 
p21/CDKN1A, as well as β-
actin as a loading control. 
Samples were processed in 
duplicate to ensure the 
reproducibility of the 
detection levels.  
 
 
 
 
 
(B) Upon treatment as in A and RNA deep sequencing analysis, genes displaying an induction of greater than 
2-fold and a p-value <0.05 in thymidine-blocked and subsequently released cells (Suppl. Table S1) were 
included in the analysis (left panel). Most of these genes were induced by p53 to a similar degree when the 
cells had not been released to enter S-phase (right panel). The genes were sorted according to their p-value 
identified in arrested, non-released cells. As a result, all genes found to be inducible during S phase were also 
induced in arrested cells.  
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Suppl. Fig.  V.I.7.2 Impact of Nutlin on DNA replication in U2OS cells. Related to Fig. V.I.2 
(A) U2OS cells were treated with Nutlin for 3h or 14 h. Immunoblot analysis revealed comparable p53 
accumulation but only less extensive accumulation of p21 and Mdm2 when comparing the 3h incubation with 
the 14 h incubation (Blots as in Fig. 2A but including the 3h incubation). (B) Nutlin treatment decreases DNA 
synthesis, but not completely. U2OS cells were treated with Nutlin for the indicated periods of time, followed 
by incubation with the nucleoside analogue EdU and staining of newly synthesized DNA. The proportion of 
DNA-synthesizing cells was determined at each time point. (C) Nutlin treatment increases fork progression, as 
in Fig.V.I.2B-D. U2OS cells were treated with 8 μM Nutlin for 14h, followed by DNA-labelling with 25μM CldU 
for 20 min, and then 250μM IdU for 2 h. (D) Quantification of fiber lengths from two independent experiments, 
as in Fig.2D.  
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Suppl. Fig.  V.I.7.2 continued (E) Three hours of Nutlin treatment do not suffice to increase replication fork 
progression. U2OS cells were treated with 8μM Nutlin for 3h, followed by incubation with CldU (25μM, 20mins) 
and IdU (250μM, 2h). (F) The fork rate was not affected by Nutlin treatment for 3 hours. (G) Increased fork 
rate upon 14 h Nutlin treatment is still visible by a short (i.e. 20 min) labeling protocol. U2OS cells treated with 
8μM Nutlin for 14 hours were subjected to short pulses of CldU and IdU (both 25μM, 20 mins). Gemcitabine 
was added to the IdU label as indicated. (H) Immunostaining of CldU (red) and IdU (green) was performed to 
visualize labeled replication tracks. (I) Nutlin treatment significantly increased fork progression during short 
labeling times, too, in the presence or absence of gemcitabine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
Suppl. Fig. V.I.7.3. Impact of Nutlin on replication processivity in U2OS cells. Related to Fig. V.I.2 
(A) Abolishing origin firing by Cdc7 inhibition does not affect Nutlin-driven fork progression. Fiber assays were 
carried out with U2OS cells treated with 8μM Nutlin for 14 hours, followed by labelling with CldU (25μM, 20 
mins) and IdU (25μM, 2h). A Cdc7 inhibitior, Cdc7i, 5μM PHA-767491, was added to avoid replication origin 
firing (Montagnoli et al., 2008) during the IdU label. (B) As revealed by box plot analysis of the obtained track 
lengths, Nutlin treatment increased fork progression even in the presence of the Cdc7 inhibitor. Note that the 
Cdc7 inhibitor alone also increased for progression, in parallel to its ability to enhance p53 levels (cf. Panel C).  
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Suppl. Fig. V.I.7.3. continued (C) Immunoblot analysis of samples treated as in Panel B to detect the 
following proteins: p53 and its target gene products p21 and Mdm2; phosphorylated Mcm2 (Ser53), a bona 
fide substrate of Cdc7 (Lei et al., 1997); and HSC70 as a loading control. P53 was not only induced by Nutlin, 
but also by Cdc7 inhibition, in agreement with previously published observations (Montagnoli et al., 2004; 
Rodriguez-Acebes et al., 2010).  
(D) Counterstaining of DNA fibers carrying labelled tracks. After incubating U2OS cells with the labels CldU 
and IdU, we performed fiber assays as in Fig.V.I.2B-D. Before mounting the fibers, we stained the (denatured) 
DNA with a third primary antibody, directed against single stranded DNA, followed by a fluorescently labeled 
(Alexa647) secondary antibody. This made the fibers visible in far red (presented in blue in the composite 
image) and showed that the labeled tracks were part of a longer DNA fiber. (E) Scheme depicting two different 
scenarios that could explain a shortened 2nd label track. When compared to an unperturbed replication fork (1 
top), slower DNA fork progression would lead to a shortened fiber (2 middle). However, premature fork stalling 
within the second labeling period could also lead to shortened fibers, even if the speed of replication forks 
remains the same (3 bottom). (F) Additional images to document fork processivity and document the feasibility 
of multiple changes of label, as described in the legend to Fig.V.I.2F-J. For quantification, cf. Suppl. Tables 2 
and 3.   
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Suppl. Fig. V.I.7.4 Depletion of p53 impairs DNA replication. Related to Fig. V.I.3 
(A) To replicate the assays shown in Fig.V.I.3 B-D, U2OS cells were transfected with siRNA to knock down 
p53, or with control siRNA. Newly synthesized DNA was labeled by 25μM CldU for 20 min and then 250μM 
IdU supplemented with Gemcitabine for 2 h and controls for 1h, followed by fiber assays. (B) Immunostained 
replication tracks of CldU (red) and IdU (green). (C) The lengths of IdU-labeled tracks were used to assess 
replication fork progression upon p53 knockdown or control siRNA transfection. In the presence or absence of 
gemcitabine, p53 depletion yielded reduced fork rates.  
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Suppl. Fig. V.I.7.4 continued (D) P53 depletion and fiber assays were carried out as in Panel A, but shorter 
labeling pulses were applied, i.e. incubations for 20 minutes with CldU and then IdU (both 25μM). 
Gemcitabine was added to the second label (IdU) only. (E) Immunostaining revealed short red (CldU) and 
green (IdU) tracks. (F) The fork rates, as determined by the lengths of the IdU tracks, are displayed as 
boxplots. Despite the shorter labeling time (and thus reduced likelihood of fork collapse during it), p53-
dependent differences were still observed. (G) Cell cycle profiles of U2OS cells upon p53 knockdown or 
control transfection for 48 hours. The cells were fixed, incubated with the DNA-intercalating dye propidium 
iodide and subjected to flow cytometry. Histograms reflect the proportion of cells within windows of DNA 
content. (H) The profiles obtained in Panel G were summarized to display the proportion of cells in each phase 
of the cell cycle. No changes were observed upon depletion of p53. (I) p53 does not detectably affect 
mitochondrial reactive oxygen levels. Upon transfection with siRNA to p53 vs. control siRNA, U2OS cells were 
incubated with the dye MitoSox to detect mitochondrial superoxide, followed by flow cytometry. As a positive 
control, cells were treated with 40 μM antimycin A during the incubation with MitoSox. For a negative control, 
MitoSox was omitted.  
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Suppl. Fig. V.I.7.5 Depletion of p53 does not alter fork restart or reversal; Mdm2 mediates fork 
progression . Related to Fig. V.I.3 
(A) The rate of fork restart after transient inhibition of ribonucleotide reductase is not affected by p53 
depletion. U2OS cells were transfected to knock down p53 or control-transfected for 48 hours. Labeling with 
25μM CldU (20 mins) and IdU (1h) was interrupted or not by treatment with 4mM hydroxyurea (HU) for 2 h.  
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Suppl. Fig. V.I.7.5  continued (B) Immunostaining of CldU (red) and IdU (green) visualized the continuation 
of replication after the HU block. (C) The rate at which forks continue to replicate after the HU block was 
determined by quantification of red-only (stalled) and red-green (continuing) structures. No difference were 
observed between the four samples.  
(D) Lack of fork regression upon HU treatment. The length of the first label track (before HU block) was 
determined to reveal any possible fork regression. Regardless of HU treatment or p53 depletion, the length of 
the first, CldU-labeled track was unaffected. Hence, p53 depletion does not give rise to degradation of stalled 
replication forks, unlike the depletion of BRCA1 (Chaudhuri et al., 2016). (E) Cells were treated as in Panel A. 
Instead of one short pulse of CldU prior to HU treatment, the cells were subjected to three short (20 mins) 
pulses of CldU, IdU, and CldU (all 25μM) before a 2h block with 2mM HU and a subsequent 1h IdU labeling 
(25μM). Controls were labeled with IdU for 1h directly after the last CldU label. (F) Immunostaining revealed 
the expected pattern of red (CldU) and green (IdU) labels to indicate that replication continued after the HU 
block. (G) The rate of fork restart after the HU label was assessed by quantifying all structures with three short 
labels only (no restart) and the ones with three short and one long green label (restart). No reduction in the 
restart rate was seen upon p53 depletion. (H) Lack of fork regression regardless of p53 proficiency. After 
treatment as in Panel N, the ratio of the 3rd label (20 min CldU) and the 2nd label (20 min IdU) was 
determined. As expected, this ratio was close to 1, suggesting that the 3rd track was not subject to fork 
regression during the HU block. This ratio was not diminished as a result of p53 knockdown. (I) Replication 
progression was assessed by measuring the length of the last IdU label (1h), confirming that the preceding HU 
block impairs the progression of DNA replication, and that p53 depletion further exacerbates replicative stress 
in this context. (J) Depletion of Mdm2 from HCT116 cells with a targeted deletion of p53. The cells were 
transfected with siRNA to Mdm2 or control siRNA, followed by immunoblot analysis. The cells were then 
subjected to fiber assays, as outlined in Fig.V.I.3H-J. (K) RNA levels corresponding to the pathways 
responding to replicative stress. Upon siRNA-mediated depletion of Mdm2 from p53-deficient HCT116 cells, 
RNA samples were subjected to deep sequencing analysis. No significant differences in the mRNA levels 
corresponding to the indicated genes were observed. The data were derived from our previous work (Wienken 
et al., 2016). logFC, logarithm of gene expression ratio (fold change). 
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Suppl. Fig. V.I.7.6 P53 depletion decreases DNA replication fork progression in murine embryonic 
fibroblasts (MEFs). Related to Fig. V.I.4  
(A) As in Fig.V.I.4D-F, MEFs with ER-cre and floxed p53 were treated with 200nM 4-OHT to remove the 
floxed p53 gene, or control-treated, for 48 hours. This was followed by incubation with normal media for 24 
hours, and subsequent incubation with 25uM CldU for 20 min, followed by 250uM IdU for 2 h. During the 
second labeling period, 400nM Gemcitabine was added as indicated. (B) MEFs with two floxed p53 alleles, 
treated with 4-OHT and/or gemcitabine, were compared as to their DNA replication, as in Fig. 4F. The removal 
of p53 by 4-OHT decreased fork progression.  
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Suppl. Fig. V.I.7.6  continued (C) Fiber lengths are displayed comparing 4-OHT treated cells with two, one or 
no floxed p53-allele, treated with gemcitabine, as in Fig. 4I. Even one floxed p53 allele compromised DNA 
replication, and two floxed alleles did so to a greater extent. (D) The cell cycle distribution of MEFs treated 
with 4-OHT was determined by propidium iodide and flow cytometry, and summarized in Panel E. No increase 
in S phase fractions was observed in p53-deficient MEFs. (F) The deletion of mdm2 on a p53-/- MEF 
background does not detectably alter the mRNA levels corresponding to genes that are relevant to replicative 
stress. The expression levels were determined by RNA sequencing analysis as in Suppl. Fig.V.I.7 5K, based 
on the data from (Wienken et al., 2016). 
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Suppl. Fig. V.I.7.7 Impact of p53 on DNA replication in thymocytes. Related to Fig. V.I.5  
(A) p53 does not detectably affect mitochondrial ROS levels in thymocytes. Flow cytometry to detect ROS was 
carried out as in Suppl. Fig.V.I.7.4I.  (B) Replicates from Fig.V.I.5B-E, in independent experiments using 
thymocytes from different mice. Thymocytes were isolated from mice with differernt p53 status (wild type, null, 
or heterozygous). Immediately after isolation, replicating DNA was labeled using 25 μM CldU for 20 min, 
followed by 25 μM IdU for 2 h. Fiber lengths are displayed as blox plots in Panel C. The results from an 
analogous experiment, but with 400 nM gemcitabine added to the second label, are shown in Panel D.  (E) 
Short pulses of CldU and IdU (25μM, 20 mins each) were used to confirm enhanced replicative stress in p53-
deficient thymocytes. Gemcitabine was added together with the IdU label as indicated. (F) Immunostaining 
was performed to detect the (short) labeled tracks of CldU (red) and IdU (green).  
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Suppl. Fig. V.I.7.7 continued (G) Despite the short 2nd pulse and concomitant decreased likelihood of fork 
stalling, reduced fork progression was observed when evaluating the length of the IdU-labeled tracks in 
gemcitabine-treated cells. (H) The cell cycle distribution of the thymocytes was determined by propidium 
iodide and flow cytometry, and summarized in Panel I. No increase in S phase fractions was observed in p53-
deficient thymocytes.  
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V.II.1 Abstract 
The p53-Mdm2 system is key to tumor suppression. We have recently reported that p53 
as well as Mdm2 are capable of supporting DNA replication fork progression. On the other 
hand, we found that Mdm2 is a modifier of chromatin, modulating polycomb repressor 
complex (PRC)-driven histone modifications. Here we show that, similar to Mdm2-
knockdown, the depletion of PRC members impairs DNA synthesis, as determined in fiber 
assays. In particular, the ubiquitin ligase and PRC1 component RNF2/Ring1B is required 
to support DNA replication, similar to Mdm2. Moreover, the Ring finger domain of Mdm2 is 
not only essential for its ubiquitin ligase activity, but also for proper DNA replication. 
Strikingly, Mdm2 overexpression can rescue RNF2 depletion with regard to DNA 
replication fork progression, and vice versa, strongly suggesting that the two ubiquitin 
ligases perform overlapping functions in this context. The depletion of Mdm2 elicits the 
accumulation of RNA/DNA hybrids, suggesting R-loop formation as a mechanism of 
impaired DNA replication. Accordingly, RNase H overexpression or the inhibition of the 
transcription elongation kinase CDK9 each rescues DNA replication upon depletion of 
Mdm2 or RNF2. Taken together, our results suggest that chromatin modification by Mdm2 
and PRC1 ensures smooth DNA replication through the avoidance of R loop formation. 
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V.II.2 Significance Statement 
 
Accurate DNA replication is a pre-requisite for cell proliferation and genetic stability, but 
obstacles to smooth replication fork progression are frequent. The oncogenic activity of 
Mdm2 has been largely ascribed to its ability of antagonizing the tumor suppressor p53. 
This report, however, points out a p53-independent activity of Mdm2 in suppressing R-
loops, a structure that includes DNA:RNA hybrids and has recently emerged as a key 
obstacle to DNA replication. Accordingly, Mdm2 is required for sustaining DNA replication. 
Our results also reveal that Mdm2 and the Polycomb Repressor Complexes act in parallel 
to not only modify histones but also support DNA replication. Thus, chromatin modifiers 
that were traditionally implied in transcription regulation are enabling unperturbed DNA 
replication as well.  
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V.II.3 Introduction 
 
The tumor suppressor p53 is unique with regard to its mutation rate in human 
malignancies, exceeding 50%. Its activity is balanced by the ubiquitin ligase Mdm2, the 
product of a p53-inducible gene. Some tumors overexpress or activate Mdm2 as part of 
an oncogenic mechanism, most notably to antagonise p53.  
More recently, however, p53-independent activities of Mdm2 were discovered. Our lab 
described a chromatin modifier function of Mdm2 which contributes to histone H2A 
ubiquitination at K119, as well as to histone H3 trimethylation at K27 (Wienken et al., 
2016, 2017). Accordingly, Mdm2 physically associates with the protein complexes that 
confer these chromatin modifications, i. e. the members of the polycomb repressor 
complexes (PRCs) 1 (Wen et al., 2014) and 2 (Wienken et al., 2016). These modifications 
were mostly characterized as mediating transcriptional repression, along with stemness 
(Blackledge et al., 2015; Schwartz and Pirrotta, 2013). 
On the other hand, we have also identified a p53 function that broadens the traditional 
view on the “guardian of the genome”. On top of eliminating cells with damaged DNA by 
apoptosis or senescence, p53 is also capable of enhancing the processivity of DNA 
replication forks (Klusmann et al., 2016). Other groups reported similar findings, 
considering various mechanisms of how p53 might enhance DNA replication, e. g. through 
avoiding topological stress (Yeo et al., 2016), inducing DNA polymerase eta and 
translesion synthesis (Lerner et al., 2017), orchestrating fork restart (Roy et al., 2018) or 
enhancing the levels of pCDKN1A/p21 and its association with PCNA (Mansilla et al., 
2016). In other systems, p53 can also compromise DNA replication through p53-
associated exonuclease activity and DNA polymerase iota (Hampp et al., 2016), and 
forced CDKN1A/p21 synthesis impairs DNA replication in UV-irradiated cells (Mansilla et 
al., 2013). These findings are at least not easy to reconcile, underscoring the need for 
further investigations on how the p53-Mdm2-system affects DNA replication. In our hands, 
the p53 target gene product Mdm2 is supporting DNA replication fork progression, similar 
to p53 itself (Klusmann et al., 2016). This suggests that the induction of Mdm2 constitutes 
a major mechanism of how p53 supports replication. This notion, however, did not answer 
the question by what mechanism(s) Mdm2’s impact on DNA replication could be 
explained. 
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Conflicts between transcription and DNA replication appear to represent a major cause of 
replication stress (Bermejo et al., 2012). Such conflicts may not simply result from 
collisions between RNA- and DNA-polymerases, but rather from the co-transcriptional 
occurrence of DNA:RNA hybrids with an additional single DNA strand, so-called R-loops. 
R-loops seem to hinder DNA replication forks from progressing (reviewed in Aguilera and 
Garcia-Muse 2012). This raises the possibility that chromatin modifications, e. g. through 
Mdm2 or PRCs (Wienken et al., 2016), might help to avoid R-loops and ease DNA 
replication fork progression. 
Here we show that Mdm2 and PRCs act similarly to sustain DNA replication fork 
progression. The Ring finger domain of Mdm2, conferring the ubiquitin ligase function, is 
essential for smooth DNA replication. Furthermore, Mdm2 and the PRC1 component 
RNF2 can substitute for each other in this function, suggesting that both ubiquitin ligases 
employ similar mechanisms to facilitate DNA replication through chromatin modification. 
And indeed, the depletion of either ubiquitin ligase induces R-loops, whereas DNA 
replication is restored by RNase-mediated removal of R-loops. Integrating these findings, 
we propose that Mdm2 and PRC1 contribute to DNA replication fork processivity through 
the avoidance of R-loops by chromatin modification. 
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V.II.4 Results 
V.II.4.1 Depletion of Mdm2 or Polycomb repressor complex 2 members similarly 
decreases DNA replication fork progression 
 
Our previously published results suggested that Mdm2 induces chromatin modifications 
with a pattern analogous to PRCs, through a mechanism that involves the physical 
association between Mdm2 and PRC2 (Wienken et al., 2016). On the other hand, we 
observed that p53 and Mdm2 are required to support DNA replication fork progression 
(Klusmann et al., 2016). To understand whether the chromatin modifier activity of Mdm2 
might also be involved in the support of DNA replication, we first compared the depletion 
of Mdm2 and PRC2 members regarding their impact on DNA replication fork progression 
(Fig.V.II.1A-B).  
 
 
 
 
Fig.V.II.1 Compromised DNA replication fork progression upon depletion of Mdm2 or PRC2 members 
(A) Schematic diagram of the main components of the PRC2 complex and its interaction partner Mdm2 that 
have been subjected to replication studies. siRNA transfections targeting Mdm2, EZH2, SUZ12, and EED as 
well as an inhibitor targeting the SET domain of EZH2 were used. (B) H1299 cells were transfected with two 
siRNAs each against the targets Mdm2, EZH2, SUZ12, and EED for 48 hours and subjected to immunoblot 
analysis. Knockdowns were confirmed by staining for the target proteins as well as the target of active PRC2, 
i. e. trimethylated histone 3 (H3K27me3).  
 
To address this, we employed the p53-/- lung large cell carcinoma cell line H1299 (Gazdar 
et al., 2010) to knock down Mdm2 or the PRC2 components EZH2, EED, or SUZ12 by 
siRNA, followed by fiber assays for DNA replication (Fig.V.II.1C, Suppl. Fig.V.II.1A-G). 
Strikingly, the depletion of all tested PRC2 components led to a marked decrease in DNA 
replication fork progression, to a similar extent as the removal of Mdm2 (Fig.V.II.1E-D).  
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Fig.V.II.1 Compromised DNA replication fork progression upon depletion of Mdm2 or PRC2 members. 
(C) Cells were treated as in (B) and incubated with 5’-chloro-2’-deoxy-uridine (25M CldU, 20 min) followed by 
iodo-deoxy-uridine (25M IdU, 60 min) as indicated. (D) Tracks of newly synthesized DNA were visualized by 
immunostaining of CldU (red) and IdU (green). (E) Fork progression was determined from the track length of 
the second label (IdU; kb/min) and displayed in a boxplot with 10-90 percentile whiskers. 
 
In the case of EZH2, this is consistent with a recently published result indicating that 
EZH2-depleted cells resume replication to a lesser extent upon temporary fork stalling 
(Rondinelli et al., 2017). Similarly, a pharmacological inhibitor of EZH2 catalytic activity as 
a histone methyl transferase compromised DNA replication (Fig.V.II.1F-I, Suppl. 
Fig.V.II.1I-M). Thus, interfering with PRC2 and its activity phenocopies the impact of 
Mdm2 depletion on DNA replication, providing a first hint that Mdm2 and PRC2 might 
affect DNA replication by similar pathways. 
 
 
Fig.V.II.1 Compromised DNA replication fork progression upon depletion of Mdm2 or PRC2 members. 
(F) H1299 cells were treated with the EZH2 inhibitor EPZ-6438 at 5M for 48 hours, followed by incubation 
with CldU and IdU as in (C). (G) Representative labelled tracks were immunostained as described in (D). (H) 
Boxplot analysis of the fork progression during the time of IdU label with 10-90 percentile whiskers.(I) Cells 
were treated as in (F) and subjected to immunoblot analysis of H3K27me3 as a readout for inhibitor activity.  
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V.II.4.2 Interfering with the polycomb repressor complex 1 slows down DNA 
replication forks and cell proliferation  
Besides the trimethylation of histone H3 at K27, Mdm2 also supports the ubiquitination of 
histone H2A at K119 (Wienken et al., 2016), perhaps as a result of direct ubiquitin ligase 
activity (Minsky and Oren, 2004). This site is mostly known for its ubiquitination by PRC1, 
typically through its RNF2 component (Blackledge et al., 2015). To test whether RNF2 
knockdown might affect DNA replication in a similar manner as Mdm2 depletion, we 
performed fiber assays and found reduced DNA replication fork progression again 
(Fig.V.II.2A-E, Suppl. Fig.V.II.2A-B). Analogous observations were made in the presence 
of a pharmacological inhibitor of Bmi1, another PRC1 component (Fig.V.II.2F-H, Suppl 
Fig.V.II.2C-D).  
 
.  
 
 
 
Fig.V.II.2 Decreased fork progression upon RNF2 depletion or Bmi1 inhibition. 
(A) Diagram of the catalytic subunit of the PRC1 complex, RNF2, that was targeted by siRNA transfections as 
well as another component of the complex, BMI1, targeted by an inhibitor. (B) H1299 cells were depleted of 
endogenous RNF2 by siRNA transfection for 48 hours and  labelled with CldU (20 min) and IdU (60 min) for 
fiber analysis. (C) Immunoblot analysis of RNF2 after treatment described in (B), confirming the depletion of 
RNF2 with two siRNAs. (D) Representative images of labelled tracks after immunostaining of CldU (red) and 
IdU (green). (E) Boxplot analysis of IdU-labelled tracks upon RNF2 depletion with 10-90 percentile whiskers. 
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Fig.V.II.2 Decreased fork progression upon RNF2 depletion or Bmi1 inhibition. 
 (F) H1299 cells were treated with 1M of the BMI1 inhibitor PTC-209 for 48 hours, followed by immunoblot 
analysis detecting monoubiquitinated histone 2A (H2AK119ub1) as a readout of inhibitor activity. (G) Fork 
progression analysis of the IdU label in cells treated with 1M BMI1i for 48 hours, with representative images 
in (H).  
 
In order to assess whether the differences seen in fork progression rates are a result of 
increased fork stalling or decreased velocity of the replication fork, we applied a modified 
labelling protocol for DNA fiber assays as described in (Klusmann et al., 2016), changing 
the label of newly synthesized DNA for multiple brief periods of time, allowing the exact 
determination when a replication fork had stalled. Mdm2 depletion led to an increase in 
fork stalling indicated by fibers with less than 7 labels incorporated (Fig.V.II.2I-L). Fork 
velocity in continuously replicating stretches (labels 2-5 only) was affected by either 
depleting Mdm2 or RNF2 from the cells (Fig.V.II.2M). In conclusion, Mdm2 is required for 
proper DNA replication fork processivity and also velocity, whereas RNF2 primarily 
contributes to fork velocity. 
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Fig.V.II.2 Decreased fork progression upon RNF2 depletion or Bmi1 inhibition. 
(I) Fork processivity was analyzed as described previously (Klusmann et al. 2016). First, cells were 
transfected with scrambled siRNA (control) or siRNAs targeting Mdm2 and RNF2 for 48 hours and then 
labelled with CldU for 1 hour, followed by short (10 minute) pulses of IdU and CldU for a total of 7 labels. From 
this, the length of labels 2-5 is used for fork progression analysis and the number of labels incorporated for 
fork stalling analysis. (J) Representative images of replicated stretches that have incorporated all 7 labels as 
well as stalled ones that contain less than 7 labels. (K) The number of forks that proceeded through n labels is 
displayed for control, Mdm2 and RNF2 knockdown. 7 labels reflect full progression of the fork throughout the 
entire labelling time. Numbers lower than 7 indicate premature termination during the labelling time. (L) The 
percentages of forks with less than 7 labels indicate that Mdm2 and RNF2 knockdowns cause replication to 
run in a less processive manner than cells transfected with scrambled (control) siRNA. (M) Fork velocity was 
determined through the length of labels two to five (kilobases/min) which ensures that fork stalling (as seen in 
(K) and (L)) is not affecting velocity measurements.  
 
In addition to direct effects on replication forks, cells depleted of Mdm2 and RNF2 were 
also less able to give rise to progeny (Fig.V.II.2N, Suppl. Fig.V.II.2E-G). This effect was 
also seen when exogenous replicative stress was induced by a 24 hour gemcitabine 
treatment (Fig.V.II.2O).  
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Fig.V.II.2 Decreased fork progression upon RNF2 depletion or Bmi1 inhibition. 
H1299 cells were transfected with siRNAs against Mdm2 and RNF2. 24 hours post transfection, cells were 
treated with 10nM Gemcitabine (in H2O) for another 24 hours. Confluence of transfected cells (N) and with 
additional Gemcitabine treatment (O) was analysed every 24 hours.  
 
V.II.4.3 The Ring finger domain of Mdm2 is necessary to sustain DNA replication 
The chromatin modifier function of Mdm2 requires its Ring finger domain, suggesting that 
the E3 ubiquitin ligase activity of this domain is involved (Wienken et al., 2016). We 
therefore sought to test whether the same is true for the support of DNA replication by 
Mdm2. We first employed murine embryonic fibroblasts (MEFs) from animals that either 
had wild type mdm2 on a p53-/- background, or otherwise lacked both mdm2 and p53, or 
had the p53-/- background with a biallelic point mutation in the Mdm2 gene that gave rise 
to the mutation C464A, disrupting the Ring finger structure (Itahana et al., 2007) 
(Fig.V.II.3A). Strikingly, the knock-out of Mdm2, as well as the Ring finger knock-in, each 
led to reduced DNA replication fork progression compared to p53 single knockout cells 
(Fig.V.II.3B-C, Suppl. Fig.V.II.3A-B). Similar results were obtained with H1299 cells. While 
Mdm2 overexpression had little effect on DNA replication, the overexpression of Mdm2 
with a Ring finger mutation markedly reduced fork progression, presumably as a result of 
a dominant negative effect (Fig.V.II.3D-G, Suppl. Fig.V.II.3C-D). Taken together, these 
results strongly suggest that Mdm2 requires the Ring finger domain and its ubiquitin ligase 
activity to sustain DNA replication independent of p53. 
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Fig.V.II.3  Requirement for the Ring finger domain of Mdm2 to support replication fork progression. 
(A) Mouse embryonic fibroblasts lacking p53, alone or in combination with a deletion of Mdm2 or a biallelic 
point mutation in the RING domain of Mdm2 (C462A), were subjected to fiber assay labelling with CldU (20 
min) and IdU (60 min). (B) Boxplot analysis o fork progression in the IdU label when either Mdm2 or just its 
RING domain were deleted with 10-90 percentile whiskers. (C) Representative images of the labelled tracks of 
CldU (red) and IdU (green). (D) H1299 cells were subjected to plasmid transfection for 30 hours, followed by 
DNA fiber assay labelling with CldU for 20 minutes and IdU for 60 minutes. (E) Immunoblot analysis upon 
transfection as in (D) confirms overexpression of Mdm2 with both a wildtype and a mutant plasmid carrying a 
point mutation in the RING finger. (F) Analysis of fork progression in the IdU label shows a significant 
reduction upon overexpression of RING-mutant Mdm2 but not wild type Mdm2. (G) Fluorescently labelled 
tracks of CldU (red) and IdU (green) in untransfected samples as well as upon transfection with of the control 
plasmid pcDNA3 or the expression plasmids pCMV-Mdm2 and pCMV-Mdm2C464A (note that human Mdm2 
carries the corresponding cysteine residue that forms part of the Ring finger structure at position 464). 
 
 
 
100 
 
V.II.4.4 Mdm2 is capable of rescuing DNA replication when RNF2 is depleted. 
To further explore whether Mdm2 might support DNA replication by a similar mechanism 
as PRC2, we performed rescue experiments upon knockdown of Mdm2 or RNF2 
(Fig.V.II.4A). As expected, the overexpression of each component reconstituted DNA 
replication when it had been depleted by siRNA. (Fig.V.II.4B-G, Suppl. Fig.V.II.4A-C). 
Although the siRNA could also target the overexpressed Mdm2, the remaining amounts of 
Mdm2 still exceeded the endogenous levels, explaining the rescue of DNA replication 
(Fig.V.II.4D). Of note, however, the overexpression of Mdm2 also rescued DNA replication 
when RNF2 had been depleted (Fig.V.II.4H-J, Suppl. Fig.V.II.4D) while overexpression of 
RNF2 partially restored fork progression upon Mdm2 knockdown (Fig.V.II.4K-M; Suppl. 
Fig.V.II.4E).   
 
Thus, enhanced Mdm2 levels can compensate for a lack of RNF2 and vice versa. Since 
both proteins are capable of enhancing H2A ubiquitination at K119 (Minsky and Oren, 
2004; Wienken et al., 2016), this at least suggests that the ubiquitination of this histone 
enables smooth DNA replication.  
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Fig.V.II.4  Mutual rescue of fork progression in Mdm2- and RNF2-depleted cells. 
(A) H1299 cells were first transfected with siRNAs, followed by a plasmid transfection after 24 hours. After 
another 30 hours, samples were subjected to fiber assay labelling with 25M CldU (20 min) and 25M IdU (60 
min). (B) Boxplot analysis of fork progression after Mdm2 depletion and plasmid transfection with pcDNA3 and 
pCMV-Mdm2 with representative images of labelled tracks in (C).  (D) Immunoblot analysis of samples after 
transfection as in (A) confirms the plasmid transfection as well as Mdm2 depletion by siRNA. A longer 
exposure reveals the presence of Mdm2 that still exceeds the endogenous levels when combining the siRNA 
with overexpression. (E) Fork progression analysis after RNF2 depletion and transfection with RNF2 plasmid, 
with representative images in (F). (G) Immunoblot analysis of RNF2 overexpression (as in (E)). 
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Fig.V.II.4 Mutual rescue of fork progression in Mdm2- and RNF2-depleted cells. 
 (H) Fork progression in the IdU label after RNF2 depletion and plasmid transfection to overexpress Mdm2. (I) 
Fluorescently labelled tracks of CldU (red) and IdU (green) displayed as boxplots with 10-90 percentile 
whiskers. (J) Immunoblot staining for Mdm2 and RNF2 confirms knockdown and overexpression described in 
(H). (K) Analysis of fork progression during the IdU label after Mdm2 depletion and RNF2 overexpression.  (L) 
Representative labelled tracks of CldU (red) and IdU (green). (M) Immunoblot analysis confirms Mdm2 
depletion and overexpression of RNF2.  
 
V.II.4.5 Mdm2 depletion enhances R-loop formation  
In search of a mechanism that might enhance DNA replication through histone 
ubiquitination, we next tested the role of R-loops, i. e. DNA:RNA hybrids that typically form 
during dysregulated transcription and can represent obstacles to DNA polymerases during 
DNA replication (Santos-Pereira and Aguilera, 2015). PRC-mediated histone 
modifications often repress transcription (Blackledge et al., 2015). In parallel, we had 
previously observed similar repression patterns and histone modifications as a function of 
Mdm2 (Wienken et al., 2016). Therefore, we reasoned that R-loop formation might occur 
in response to the depletion of PRC components or Mdm2, providing a plausible 
explanation for impaired DNA replication fork progression. Ribonuclease H1 (RNaseH1) is 
an enzyme that recognises RNA:DNA hybrid structures and cleaves the RNA moiety. 
Mutagenic modifications of the catalytic triad in its C-terminus render RNaseH1 
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catalytically inactive while retaining its RNA:DNA hybrid binding ability (Wu et al., 2001). 
We made use of an inducible cell system carrying the D210N mutation in GFP-tagged 
RNaseH1 to specifically detect R-loops by quantitative image based cytometry 
(Fig.V.II.5A-B; Nguyen et al., 2017; Pellegrino et al., 2017). 
 
Fig.V.II.5 Mdm2 depletion increases replicative stress and R-loop formation.  
(A) Schematic outline of the experimental setup for quantitative image based cytometry used to quantify DNA 
damage and R-loops upon depletion of Mdm2. U2OS cells that stably express the non-catalytic GFP-
RNaseH1-D210N mutant were transfected with siRNA against p53 and Mdm2 for 48 hours, prior to mutant 
RNaseH1 induction by doxycycline treatment for another 24 hours. Next, the cells were pulsed with EdU to 
detect DNA synthesis for 20 minutes, pre-extracted, fixed and stained. The signals from DAPI, EdU, γH2AX, 
and chromatin-bound RNaseH1-D210N were quantified by high-content microscopy. The D210N mutation 
abolishes RNase activity but retains binding to RNA:DNA hybrids and can thus be used to detect them. (B) 
Two-dimensional analysis of the fluorescent signals of EdU, γH2AX, and GFP-RNaseH1-D210N versus DAPI 
intensity allows cell cycle staging as well as S-phase-specific analysis of DNA damage and R-loops. 
 
 
In parallel to R-loops, we also detected DNA synthesis and DNA damage signalling in the 
same system. In line with our fiber studies, EdU incorporation was reduced after depleting 
Mdm2 and p53 (Fig.V.II.5C-D, Suppl. Fig.V.II.5A-B), reflecting impaired DNA replication. 
Furthermore, we observed increased levels of the DNA damage marker γH2AX 
(Fig.V.II.5E-F, Suppl. Fig.V.II.5C-D), again reflecting replication stress. Strikingly, the 
amounts of chromatin-bound RNase-H1-D210N were highly elevated in the absence of 
Mdm2, indicating that depletion of Mdm2 increases R-loop formation (Fig.V.II.5G-H, 
Suppl. Fig.V.II.5E-F). In conclusion, loss of Mdm2 increases the persistence of non-
physiological levels of R-loops. 
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Fig. V.II.5 Mdm2 depletion increases replicative stress and R-loop formation.  
(B) Two-dimensional analysis of the fluorescent signals of EdU, γH2AX, and GFP-RNaseH1-D210N versus 
DAPI intensity allows cell cycle staging as well as S-phase-specific analysis of DNA damage and R-loops. For 
this analysis, the total number of cells analysed was n=7545 in control knockdown and 7412 in p53/Mdm2-
depleted cells (C, E, G). S-phase specific data was collected from n=3457 in controls and n=2225 in 
p53/Mdm2-depleted samples (D, F, H). (C) Two-dimensional cell cycle staging was performed based on the 
EdU and DAPI signals. (D) The S-phase specific EdU signals were plotted for Mdm2/p53-depleted cells 
versus a control siRNA transfection. Horizontal lines represent averages and standard deviations. (E) Levels 
of the DNA damage marker γH2AX increase upon depletion of Mdm2 and p53 throughout the cell cycle.  (F) 
The S-phase specific γH2AX signals were plotted for Mdm2/p53-depleted cells versus a control siRNA 
transfection. Horizontal lines represent averages and standard deviations. (G) Chromatin-bound RNaseH1-
D210 marks RNA:DNA hybrids, and this signal increases when Mdm2 and p53 were depleted.  (H) The S-
phase specific signals of chromatin-bound RNaseH1-D210N were plotted for Mdm2/p53-depleted cells versus 
a control siRNA transfection. Horizontal lines represent averages and standard deviations. 
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V.II.4.6 Interfering with transcriptional elongation by CDK9 inhibition allows 
processive DNA replication despite the removal of Mdm2 or RNF2 
 
We next sought to determine whether conflicts with transcription cause replication stress 
when Mdm2 is depleted. One way of addressing these conflicts is by inhibiting CDK9, a 
kinase essential for transcriptional elongation (reviewed in Morales and Giordano, 2016). 
And indeed, CDK9 inhibition was previously found to restore DNA replication upon p53 
knockdown (Yeo et al., 2016). Importantly, we observed that two different CDK9 inhibitors 
restored DNA replication upon depletion of Mdm2 (Fig.V.II.6A-C; Suppl. Fig.V.II.6A-C) and 
RNF2 (Fig. V.II.6D-F; Suppl. Fig.V.II.6D,F). Thus, ongoing transcription and perhaps the 
resulting R-loop formation represent a prerequisite for impaired DNA replication upon 
Mdm2-depletion.  
 
 
 
Fig. V.II.6 Rescue of DNA replication by CDK9 inhibitors upon depletion of Mdm2 or RNF2.  
(A) H1299 cells were transfected with siRNA against Mdm2 for 48 hours. After 47 hours, cells are additionally 
treated with 10M LDC067 and 25M 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), two CDK9 
inhibitors, and a solvent control (DMSO). After one hour pre-incubation with the inhibitors, the cells are 
incubated with nucleoside analogues CldU (20 min) and IdU (60min) containing inhibitors and solvent control. 
(B) Representative images of labelled tracks of CldU (red) and IdU (green). (C) Fork progression analysis was 
carried out from IdU labelled tracks and displayed in a boxplot with 10-90 percentile whiskers. 
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Fig.V.II.6 Rescue of DNA replication by CDK9 inhibitors upon depletion of Mdm2 or RNF2.  
(D) H1299 cells transfected with RNF2 siRNA and pre-treated with 10M LDC067 and 25M DRB for 30 
minutes. Subsequently, labelling for Fiber assay was carried out as described in (A). (E) Representative 
images of labelled tracks of CldU (red) and IdU (green). (F) Boxplot analysis of fork progression in the IdU 
label. 
 
 
V.II.4.7 RNase H re-establishes DNA replication upon depletion of Mdm2 or RNF2  
Finally, we tested whether DNA:RNA hybrids in MDM2/RNF2-depleted cells represent an 
obstacle to DNA replication. We overexpressed RNase H1 to resolve hybrids that form 
while depleting MDM2 or RNF2. Wildtype RNaseH1 but not a catalytically inactive mutant 
of it gave rise to a robust rescue of DNA replication fork progression upon Mdm2 depletion 
(Fig.V.II.7A-D; Suppl. Fig.V.II.7A), and also upon RNF2 knockdown (Fig.V.II.7E-G; Suppl. 
Fig.V.II.7B-C). Taken together, these results strongly suggest that MDM2 prevents the 
persistence of R-loops and replicative stress.  
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Fig. V.II.7 Restored DNA replication by removing DNA/RNA hybrids in cells depleted of Mdm2 or RNF2. 
(A) H1299 cells were first transfected with siRNA targeting Mdm2/RNF2 and with a plasmid containing 
wildtype RNAseH1 (pICE-RNAseH1-NLS-mCherry) as well as a catalytically inactive mutant (pICE-RNASeH1-
D10-E48R-NLS-mCherry) and a control plasmid (pcDNA3) 24 hours after the first transfection. After another 
30 hours, samples were used for fiber assay labelling by incubation with 25M CldU (20min) and 25M IdU 
(60 min). (B) Immunoblot of samples transfected as described in (A) staining for the mCherry tag of the 
RNAseH1 plasmids and Mdm2 to check for transfection efficiency. HSC70 is used as a loading control. (C) 
Representative images of immunostained tracks of CldU (red) and IdU (green) after Mdm2 depletion 
(Mdm2#1) and RNAseH1 overexpression. (D) Boxplot analysis of fork progression in the IdU label of the fiber 
assay indicate that active RNase H restores DNA replication. (E) Immunoblot analysis of knockdown (RNF2) 
and overexpression (RNAseH1) efficiencies where HSC70 serves as a loading control. (F) Fluorescently 
labelled tracks of CldU (red) and IdU (green). Fork progression rates of samples depleted of RNF2 and with 
overexpressed RNAseH1 are shown in (G), again indicating a rescue of DNA replication.  
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V.II.5 Discussion 
 
Mdm2 and PRCs not only display similar patterns in chromatin modification and gene 
regulation (Wienken et al., 2016; Wienken et al., 2017) but also enable DNA replication 
with high processivity, independent of p53. Our results strongly suggest that these two 
activities are carried out through overlapping mechanisms. Both Mdm2 and PRC1/RNF2 
have an E3 ubiquitin ligase function, and this sustains DNA replication. Moreover, Mdm2 
and RNF2 can substitute for each other in this regard. When R-loops are removed by 
RNase H1, replication is restored despite the depletion of Mdm2 or RNF2. Thus, we 
propose that Mdm2 and PRC1 each support DNA replication through their ability to 
ubiquitinate histones and prevent supraphysiological R loop formation. 
Interestingly, members of PRC2 were found in association with DNA replication forks 
(Leung et al., 2013) and necessary for their symmetric progression (Piunti et al., 2014). 
This raises the possibility that, on top of dampening unscheduled transcription, PRC2 
might directly support DNA replication, perhaps enabling immediate histone modifications 
simultaneously with DNA synthesis. Of note, EZH2 activity recruits Mus81 to destabilize 
stalled replication forks (Rondinelli et al., 2017). This might disrupt such forks on the one 
hand, but might enable faster resumption of replication on the other hand. It is thus 
conceivable that PRC2 not only dampens transcription but also alters the dynamics of 
DNA replication by recruiting DNA processing factors. 
Curiously, the overexpression of Mdm2 has previously been found to enhance rather than 
diminish replication stress (Frum et al., 2014). Of note, however, Mdm2 has long been 
known to impair cell proliferation when overexpressed (Brown et al., 1998), whereas our 
study is mainly based on the depletion of endogenous Mdm2. We therefore propose that 
Mdm2, when present at physiological levels, actually supports DNA replication. 
Depletion of Mdm2 enhances detectable DNA:RNA hybrids, and this notion might explain 
previously reported observations. Both p53 (Yeo et al., 2016) and Mdm2 (Conradt et al., 
2013) contribute to the resistance of cells to topoisomerase inhibitors, a class of drugs 
that iniduces R-loops (Marinello et al., 2013). Moreover, depleting p53 sensitizes cells 
towards co-depletion of DHX9 (Lee and Pelletier, 2017), a helicase capable of removing 
R-loops (Cristini et al., 2018). 
 
In a broader sense, RNA metabolism is becoming a major focus in current research on 
DNA replication stress. RNA processing factors constitute a major fraction of kinase 
substrates upon DNA damage (Beli et al., 2012; Matsuoka et al., 2007), making it 
plausible that such factors might affect DNA integrity, perhaps through R-loop formation. 
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Recently, the oncogenic EWS-FLI1 fusion protein was found to cause R-loops and 
thereby DNA damage (Gorthi et al., 2018). Our results expand this concept, implying 
Mdm2 and polycomb repressors not only in the formation of a closed chromatin state, but 
also in the suppression of R-loops, thereby enabling proper DNA replication. A number of 
mechanisms were suggested for R-loops forming obstacles to DNA replication (Aguilera 
and Gomez-Gonzalez, 2017; Garcia-Muse and Aguilera, 2016). However, the exact 
nature of such conflicts between RNA:DNA hybrids and DNA replication still remains to be 
determined. 
Besides its chromatin modifier function, MDM2 is also capable of interfering with DNA 
repair through binding Nbs1, one of the MRN complex members (Alt et al., 2005; Bouska 
et al., 2008). However, this association negatively regulates MRN-mediated repair of 
double stranded DNA breaks. Since Mdm2, according to our data, is a positive factor in 
DNA replication fork progression, we propose that this function is independent of Nbs1 
binding. Formally, we cannot exclude that Mdm2 might interfere with the degradation of 
stalled replication forks, as has been reported for BRCA2 (Schlacher et al., 2011). 
However, our previous work suggested that the depletion of p53 (and thus concomitant 
reduction in Mdm2-levels) does not alter fork restart or reversal (Klusmann et al., 2016). 
Since a minimum Mdm2 level is necessary for proper DNA replication, events that lower 
the amounts of intracellular Mdm2 might confer replication stress. For instance, Mdm2 
levels drop in response to DNA damage, through phosphorylation and subsequent auto-
ubiquitination of Mdm2 (Carr et al., 2016; Li and Kurokawa, 2015). This suggests that 
impaired DNA replication might occur in response to DNA damage, not only as a direct 
result of DNA lesions, but also as a consequence of Mdm2 degradation. Furthermore, 
most cancers show impaired p53 activity, e. g. due to p53 mutations, resulting in lowered 
expression of the p53-responsive gene encoding Mdm2. Thus, the generally enhanced 
DNA damage observed in many tumours (Bartkova et al., 2005) might at least in part 
result from insufficient Mdm2 levels and the resulting DNA replication stress. Taken 
together, Mdm2 may not only serve as a p53 antagonist, but also as an effector of p53-
mediated tumour suppression, modifying chromatin, avoiding R-loops and supporting 
replication. 
On the other hand, Mdm2 represents an oncogene, and its overexpression can result from 
gene amplification, most notably in sarcomas. Our results suggest that not only the 
inactivation of p53 but also the modification of chromatin with subsequently enhanced 
DNA replication processivity may contribute to this oncogenicity. Importantly, Mdm2 has 
frequently been targeted by drug candidates, but with limited success in the clinics. To our 
knowledge, all Mdm2-targeting drugs that are currently evaluated in clinical studies 
interfere with the interaction of p53 and Mdm2, but not with the ubiquitin ligase activity of 
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the Mdm2 Ring finger domain (Burgess et al., 2016). Furthermore, our previous work 
indicates that the prototype drug of this kind, Nutlin-3a, does not interfere with the 
chromatin modifier function of Mdm2 (Wienken et al., 2016). Therefore, targeting the Ring 
finger domain rather than the p53 binding domain of Mdm2 can be expected to have a 
more profound impact on cancer cell proliferation, by targeting chromatin modification and 
interfering with DNA replication. This encourages the continued evaluation of Mdm2 as a 
drug target, regarding its various activities on p53 as well as on chromatin and on DNA 
replication. 
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V.II.7 Supplemental Figures 
 
Suppl. Fig. V.II.7.1 Compromised DNA replication fork progression upon depletion of Mdm2 or PRC2 
members.  Related to Fig.  V.II. 1. 
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Suppl. Fig. V.II.7.1 continued (A) H1299 cells were transfected with a second siRNA set to Mdm2, EZH2, 
SUZ12, and EED for 48 hours. The experiment was carried out in parallel to the one in Fig.V.II.1D-E and 
therefore shares the control sample. (B) A biological replicate to the experiment displayed in Fig.V.II.1D-E and 
panel A of this figure. Fiber analysis shows reduced fork progression after all knockdowns compared to 
scrambled siRNA knockdown. (C) Mdm2 depletion in HCT116 p53 
–/-
 reduces fork progression using different 
siRNAs. Depletion of PRC2 components EZH2 with two siRNAs (D-F) and SUZ12 (G) reduces fork 
progression in HCT116 p53 
–/- 
cells. (H) siRNA transfection targeting the non-catalytical PRC2 component 
EED for 48 hours reduces replication fork progression in H1299 cells. (I-J) Biological replicates to Fig. 1H 
shows reduced fork progression in H1299 cells treated with the EZH2 inhibitor EPZ-6438 for 48 hours. (K) A 
similar reduction can be observed in U2OS cells treated with the same conditions as in (G). (L-M) HCT116 
p53 
–/- 
cells treated with 5 µM DZnep, another EZH2 inhibitor, for 48 hours also reduces fork progression.  
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Suppl. Fig. V.II.7.2 Decreased fork progression upon RNF2 depletion or Bmi1 inhibition Related to Fig. 
V.II.2. 
RNF2 depletion in H1299 cells (A) and HCT116 p53 
–/-
 cells (B) reduces replication fork progression in the IdU 
label. (C-D) Biological replicates to Fig.V.II.2G shows H1299 cells treated with 1M of the BMI1 inhibitor PTC-
209 for 48 hours reduces fork progression. (E) Brightfield microscopy of H1299 transfected with siRNA against 
Mdm2 and RNF2 for 48 hours and a second transfection for another 48 hours (96h timepoint) shows reduced 
proliferation compared to control. (F-G) Two biological replicates of clonogenic growth assay shown in Fig. 
V.II.2N.  
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Suppl. Fig. V.II.7.3 Requirement for the Ring finger domain of Mdm2 to support replication fork 
progression.  Related to Fig. V.II.3. 
(A-B) Biological replicates to Fig. 3B shows a reduced fork progression for p53/Mdm2 double knockout MEFs 
as well as a RING mutant MEF cell line with a p53-null background. (C-D) In the human H1299 cell line, an 
overexpression of a RING mutant Mdm2 reduces fork progression as seen in Fig.V.II.3F.   
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Suppl. Fig. V.II.7.4  Mutual rescue of for progression by Mdm2 and RNF2. Related to Fig. V.II.4. 
Biological replicates to Fig. 4B (A), Fig.V.II.4E (B-C), Fig.V.II 4H (D) and Fig.V.II.4K (E) show that impaired 
replication can be rescued by overexpression of the depleted Mdm2 and RNF2 protein as well as by the 
overexpression of each other in a cross-fashion. 
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Suppl. Fig. V.II.7.5 Mdm2 depletion increases replicative stress and R-loop formation. Related to Fig. 
V.II.5. 
As in Fig.V.II.5, U2OS cells that stably express GFP-RNaseH1-D210N were transfected with siRNA against 
p53 and Mdm2 for 48 hours, prior to mutant RNaseH1 induction by doxycycline treatment for another 24 
hours. Next, cells were pulsed with EdU to detect DNA synthesis for 20 minutes, pre-extracted, fixed and 
stained and the signals for DAPI, EdU, γH2AX, and chromatin-bound RNaseH1-D210N were quantified by 
high-content microscopy. (A) Two-dimensional cell cycle staging was performed based on the EdU and DAPI 
signals. (B) The S-phase specific EdU signals were plotted for Mdm2/p53-depleted cells versus a control 
siRNA transfection. Horizontal lines represent averages and standard deviations. (C) Levels of the DNA 
damage marker γH2AX increase upon depletion of Mdm2 and p53 throughout the cell cycle. (D) The S-phase 
specific γH2AX signals were plotted for Mdm2/p53-depleted cells versus a control siRNA transfection. 
Horizontal lines represent averages and standard deviations. (E) Chromatin-bound RNaseH1-D210 marks 
RNA:DNA hybrids, and this signal increases when Mdm2 and p53 were depleted. (F) The S-phase specific 
signals of chromatin-bound RNaseH1-D210N were plotted for Mdm2/p53-depleted cells versus a control 
siRNA transfection. Horizontal lines represent averages and standard deviations.  
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Suppl. Fig. V.II.7.6 Rescue of DNA replication by CDK9 inhibitors upon depletion of Mdm2 or RNF2. 
Related to Fig. V.II.6. 
A decrease in fork progression caused by Mdm2 (A-C) and RNF2 (D-E) in H1299 cells can be rescued by 
inhibiting global transcription elongation mediated by CDK9 with two different inhibitors, DRB and LDC067.  
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Suppl. Fig. V.II.7.7 Restored DNA replication by removing DNA/RNA hybrids in cells depleted of Mdm2 
or RNF2. Related to Fig. V.II.7. 
H1299 cells were transfected with siRNA against Mdm2 (A, C) and RNF2 (B, C) for 24 hours and transfected 
with plasmids containing wildtype and a catalytically inactive mutant version of RNaseH1 for another 30 hours 
(c.f. Fig.V.II.7A). Impaired replication fork progression displayed after both Mdm2 and RNF2 knockdown was 
rescued by wildtype but not mutant RNaseH1.  
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VI. Discussion 
In this thesis, we describe a novel role of the p53-MDM2 network in supporting DNA 
replication to prevent genome instability. In particular, we show that p53 is required for 
replication processivity and its absence causes replicative stress. As a transcription factor, 
p53 induces the expression of its target genes to mediate its many tumour suppressive 
roles. MDM2, a transcriptional target of p53, is able to support DNA replication 
downstream of the p53 signalling cascade. Notably, MDM2 seems to mediate these 
effects via its RING finger domain that has intrinsic E3 ubiquitin ligase activity used to 
target proteins for proteasomal degradation and for signalling purposes. The depletion of 
MDM2 was found to significantly increase R-loops that hinder replication forks from 
progressing along the DNA template. We hypothesise that MDM2, along with its 
interaction partner of the PRC, can prevent R-loop formation and thereby support DNA 
replication by mediating repressive chromatin marks on the DNA. The details of this 
hypothesis are discussed in more detail in the following sub-chapters.  
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Fig.VI.1 The p53-MDM2 network facilitates replication fork progression by preventing R-loop 
formation. 
Schematic diagram of findings described in this thesis. p53 supports DNA replication fork processivity in a 
number of primary and tumour cell types. We found that these effects are not directly carried out by p53 but 
rather induced by its activity as transcription factor responsible for target gene expression. Downstream of 
p53, MDM2 acts to repress target gene expression in conjunction with Polycomb repressor complexes 1 and 2 
by depositing histone marks. In the absence of MDM2 and PRC components, R-loops accumulate and hinder 
replication forks from progressing along the DNA template causing replicative stress and DNA damage 
signalling.  
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VI. 1 Non-canonical roles of p53 in tumour suppression 
 
Tumour suppression by p53 was long thought to be a result of acute DNA damage 
responses including cell cycle arrest and repair. However, recent evidence suggests that 
p53 is indeed important for tumour suppression but its response to acute genotoxic stress 
is dispensable for this. Experimental evidence comes from knock-in mouse models 
carrying inactive TADs, revealing that losing the p5325,26 TAD1 impairs the ability to 
mediate cell cycle arrest and apoptosis but is still sufficient for tumour suppression, 
whereas a loss of both TADs in the p5325,26,53,54 mutant also impairs all three activities 
(Brady et al., 2011). A similar study by Li et al. demonstrated that p53 was still able to 
suppress tumour formation in mice when its DNA binding domain was mutated (Li et al., 
2012). In addition, mice deficient for key effectors of the DNA damage response 
downstream of p53 (e.g. cdkn1a, puma, noxa)  were not more prone to tumour formation 
than wildtype littermates (Valente et al., 2013). Taken together, this data highlights the 
importance of p53 in tumour suppression but suggests the likelihood of alternative 
pathways by which p53 achieves this.    
 
Various non-canonical pathways for p53-mediated tumour suppression have been 
described in recent years (Mello and Attardi, 2018). Our work and others identified a role 
of p53 in maintaining genome integrity that further adds to its role as the “guardian of the 
genome” (Lane, 1992). This is achieved by transcriptional activation of target genes 
involved in DNA repair and by supporting DNA replication as well as restricting 
retrotransposon activity (Klusmann et al., 2016; Sengupta and Harris, 2005; Wylie et al., 
2016; Yeo et al., 2016). Other studies have also attributed the title “guardian of the 
epigenome” to p53 as it seems to keep DNA methylation in check (Tovy et al., 2017). 
Furthermore, p53 can also induce metabolic changes via non-canonical pathway. p53 
inhibits both glycolysis and autophagy, processes involved in energy supply and the 
removal of damaged cellular components that are essential for tumour suppression 
(Kenzelmann Broz et al., 2013; Kruiswijk et al., 2015). In addition, p53 also inhibits 
stemness, promotes differentiation and is thought to regulate cell migration and invasion 
(Krizhanovsky and Lowe, 2009; Muller et al., 2011). Among others, these non-canonical 
roles of p53 contribute to its tumour suppressor activity but exactly how all these roles 
come together in a cell and whether they are activated in a cell type-/ or development-
specific manner remains to be elucidated.  
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VI.1.1 The non-canonical guardian of the genome supports DNA replication 
 
Maintaining genome integrity is key to tumour suppression and seems to be mediated by 
p53 in a variety of ways. Next to the canonical pathways of the DNA damage response 
and checkpoints, we have identified a novel role of p53 in protecting a cell from 
endogenous DNA damage during replication. The presence of wildtype p53 in a cell 
supports DNA replication fork processivity that leads to a higher fork progression rate and 
a lower incidence of both fork stalling and extra origin firing (Fig.V.I.2). Manipulating the 
levels of p53 in a cell also modulates fork progression rates – an accumulation of p53 
increases it, whereas a depletion of p53 reduces fork progression. As is the case for most 
other roles of p53, supporting DNA replication does not seem to be a direct effect of p53 
but rather mediated via its transactivation of target genes. One argument for this is the 
delayed effect of p53 accumulation on fork progression. A three-hour treatment with the 
MDM2 inhibitor Nutlin-3a was not sufficient to affect replication even though p53 levels 
were elevated. In contrast, a longer incubation of cells with Nutlin-3a not only accumulated 
levels of p53 but also showed an increase in target gene expression, exemplified by p21 
and MDM2, and in this time was able to increase replication fork progression significantly 
(Fig.V.I.2A-D, Suppl. Fig.V.I.2C-F). The fact that fork progression was not only modulated 
by p53 levels in U2OS cells that harbour high intrinsic replicative stress but also in primary 
non-transformed cells argues for the presence of a general role of p53 in supporting DNA 
replication that becomes even more important under replicative stress conditions found 
during tumourigenesis.  
 
 
VI.1.2 A novel strategy to distinguish between fork velocity and fork processivity 
 
In our study, we attempted to distinguish between replication fork velocity and 
processivity, both of which affect the length of the replicated tracks observed and thus the 
amount of under-replicated DNA and genome instability. Conventional fiber analysis solely 
assesses the length of two different labels in a given time and cannot distinguish between 
velocity and processivity of the DNA polymerase. The readout of a slow and a prematurely 
stalled replisome is the same – a short fiber and a low fork progression rate (Fig.VI.1.).  
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Fig.VI.1 Fiber length is determined by both fork progression and processivity. cf. Suppl. Fig. V.I.7.3E 
Fiber length measured from labelled tracks in a conventional two-label Fiber assay is affected by both speed 
and processivity of the replication fork. (1) Fast polymerase movement allows more nucleotides to be 
incorporated, thus a longer labelled stretch appears. (2) Slow progression of the replication machinery results 
in shorter labelled tracks. (3) Fast but non-processive movement of replication also results in shorter labelled 
tracks as the label is not incorporated for the entire labelling time. 
 
Conventional analysis of fork stalling involves the quantification of fibers with only the first 
label (red) incorporated. Mostly, the presence of red-only structures is accompanied by 
increased origin firing to compensate for fork stalling and can be analysed by quantifying 
green-red-green structures representing bidirectional first label origins.  Quantification of 
these types of structures can provide an estimate of the amount of fork stalling and origin 
firing present in a sample but is not particularly accurate as these structures can also arise 
from different scenarios including replication termination that is not due to obstacles on 
the template but rather the end of a replicon.  
To overcome limitations of the conventional assay, we developed a novel fiber assay 
strategy to distinguish between effects on fork velocity and processivity (Fig.V.I.2F-J; 
Fig.V.II.2I-M). Analysis with both the conventional and the novel “fork stalling fiber assay” 
revealed that p53 affects replication by supporting fork processivity rather than by 
increasing fork velocity. This effect was additionally accompanied by reduced origin firing 
seen in the conventional fiber assay. This complementing data suggests that the fork 
stalling fiber assay indeed works to dissect effects observed in the conventional fiber 
assay into fork velocity and processivity and can be used as an additional tool in future 
studies. However, a limitation of this method is the high number of samples that need to 
be analysed in order to obtain sufficient data and is therefore more suitable for providing 
additional information rather than for standard use in replication studies.  
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An ongoing replication fork can be affected in many ways. On one hand the replisome 
itself can be altered by post-translational modifications and interaction partners to 
increase its association with the template DNA. Alternatively, the removal of obstacles 
along the DNA template such as proteins or secondary structures can also increase fork 
progression. Lastly, optimising the availability of building blocks in form of dNTPs would 
also be able to increase fork progression. As we only observe an effect of p53 on 
replication fork processivity and not velocity, the latter seems less likely to affect only one 
and not both parameters. Thus, a direct modification of the replisome or the loss of 
impediments on the DNA template seemed to be possible mechanisms by which p53 
supports replication fork processivity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
VI.2 Changes in the chromatin landscape can affect replication fork 
progression 
 
The delayed effect of p53 accumulation to support DNA replication observed with our data 
(Fig.V.I.2B-D, Suppl. Fig.V.I.2C-F), argues for the involvement of transcriptional target 
genes of p53, many of which take more than six hours to be induced upon p53 activation 
(Allen et al., 2014). Taking into account that replication can be affected by the presence of 
secondary structures or proteins bound to the DNA template, we focussed on MDM2, a 
p53 target gene shown to modify chromatin compaction. Independent of p53, MDM2 
associates with the Polycomb repressor complexes via its amino terminal domain at 
respective target genes sites to enhance the placement of the repressive chromatin marks 
H3K27me3 and H2AK119ub1 (Wienken et al., 2016).  
 
MDM2 is the most important negative regulator of p53 but also its transcriptional target, 
forming a negative feedback loop between the two proteins that helps to keep p53 levels 
under tight control. In order to dissect the mechanism downstream of p53 more 
accurately, studies on the effect of MDM2 on replication had to be conducted in a p53-null 
background. Strikingly, the depletion of MDM2 in cells that had no functional p53, further 
impaired their replication, strongly suggesting that MDM2 acts to support DNA replication 
downstream of p53 (Fig.V.I.3H-J, V.I.4J-L, V.II.1C-E). Similarly, a disruption of the 
Polycomb repressor complexes 1 and 2 by siRNAs and pharmacological inhibitors 
targeting catalytic as well as accessory components, caused a significant decrease in fork 
progression rates (Fig.V.II.1C-I, 2B-G). This complements a previous studies showing an 
impaired replication fork progression after EZH2 (PRC2) depletion in association with 
decreased inter-origin distance in H-RAS transformed primary cells (Piunti et al., 2014). 
Common to both MDM2 and the PRCs is their ability to induce histone modifications to 
reversibly silence target genes in the form of facultative heterochromatin. The presence of 
facultative heterochromatin is closely linked to replication timing as it blocks the formation 
of pre-RCs (Trojer and Reinberg, 2007; Zofall et al., 2016). A study on the repressive 
H3K9me3 mark recently showed that a histone demethylase is required for these late-
replicating regions to be accessible for pre-RC formation (Wu et al., 2017). By depleting 
MDM2 and PRC components, target genes that would have otherwise been marked as 
late-replicating will no longer be repressed by chromatin compaction and their open 
chromatin structure would allow for the formation of pre-RCs earlier in S-phase. It is 
important to note that histone marks are stable and only newly deposited histones will be 
affected by a loss of MDM2/PRCs and the H3K27me3 and H2AK119ub1 marks mediated 
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by them. Thus, an effect on replication can only be observed after cells have progressed 
through at least one cell cycle. This fact matches our observations that reduced fork 
progression can only be observed after 48 hours of depleting EZH2 activity with EPZ and 
DZNep (Fig.V.II.1F-H, Suppl. Fig.V.II.1I-M).  
 
VI.2.1 MDM2 and Polycomb repressor complexes – similarities and differences 
 
Even though both Polycomb repressor complexes mediate histone modifications that are 
thought to promote facultative heterochromatin formation, the nature of the modifications 
and the enzymes responsible for them are very different. EZH2, the catalytic subunit of 
the PRC2 contains a SET domain with histone-methyltransferase activity. Next to the so-
called “writers” that add modifications to histone tails, “erasers” in the form of 
demethylases remove them, and “readers” contain domains that specifically detect and 
bind to methylated tails. Readers often act as adaptor molecules to bridge the signal on 
the histone tail to a cellular response. One such reader mechanism was recently shown to 
occur at replication forks, too. In this study, EZH2 was shown to deposit H3K27me3 marks 
at stalled replication forks as a writer to recruit the MUS81 endonuclease to sites of 
damage. This in turn allows homologous recombination-mediated repair of stalled fork to 
preserve genome stability (Rondinelli et al., 2017). According to this model, a depletion of 
MDM2 and PRC2 components in our cells would lead to impaired H3K27me3 deposition 
and recruitment of repair enzymes at stalled replication forks followed by genomic 
instability. If true, this would be visible in the form of shorter fibers and increased fork 
stalling events that cannot be rescued by repair, both of which match our data.  
 
In contrast, the PRC1 complex contains RNF2 as its catalytic core to ubiquitinate H2A at 
lysine 119. Like MDM2, RNF2 contains a RING domain with intrinsic E3 ubiquitin ligase 
activity. The finding that both MDM2 and RNF2 expression can also rescue replication 
defects caused by the depletion of each other respectively, argues for an independent but 
compensatory mechanism of the two E3 ligases (Fig.V.II4H-M). By using catalytically 
inactive RING mutants of MDM2 we identified this domain to be critical in supporting DNA 
replication (Fig.V.II.3A-G).  
 
Previous work identified a physical interaction between MDM2 and both Polycomb 
repressor complexes with a co-localisation of these complexes at transcriptional start sites 
of common target genes (Wen et al., 2014; Wienken et al., 2016). Another study identified 
an interaction of MDM2 with two other methyltransferases, SUV39H1 and EMHT1, via the 
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acidic domain of MDM2 (Chen et al., 2010). Both mediate di- and trimethylation of H3K9, 
which is a mark also associated with heterochromatin and late replicating origins (Becker 
et al., 2016; Rivera et al., 2014). It remains unclear whether MDM2 catalyses the two 
PRC-mediated chromatin marks directly, or if enhances the activity of the PRC complexes 
or both. It seems possible that it interacts with a number of histone methyltransferases, 
including EZH2, to target them to specific sites and enhance their activity through the 
stimulation of its intrinsic E3 ubiquitin ligase activity towards local H2AK119 in conjunction 
with PRC1, but further studies would be required need to clarify its exact role in this 
process.  
 
VI.2.2 MDM2 and MDMX 
 
MDMX is a homologue of MDM2 that arose from a gene duplication about 440 million 
years ago. Even though they share the same domain architecture and differ in length by 
just one amino acid, their activities differ. The RING domain that both proteins contain in 
their C-terminal half seems to be catalytically inactive as a E3 ligase in MDMX, but is 
required to form heterodimers with MDM2 (Shvarts et al., 1996; Tanimura et al., 1999). As 
with MDM2, the existence for p53-independent roles of MDMX have been postulated as a 
result of the observation that p53-mutant cancers often concomitantly lose functional 
MDMX (Bartel et al., 2005; Carrillo et al., 2014).  An alternatively spliced variant of MDMX 
lacking exon 6 produces a truncated version of the transcript that consists of a p53-
binding domain only. This isoform, also referred to as MDMX-S, lacks the RING portion of 
the protein required for MDM2 interactions and is associated with a poor prognosis even 
in the absence of wildtype p53 (Lenos et al., 2012). In addition, it was recently shown that 
the Zn-finger domain in MDMX is able to maintain genome stability by preventing 
multipolar mitosis whereas its RING domain is able to suppress proliferation in the 
absence of p53 (Matijasevic et al., 2016). Taken together, the data discussed here argues 
for a p53- and possibly even MDM2-independent role of MDMX in preventing genome 
instability. As its RING domain has been described to regulate proliferation independently 
of p53, it would be of interest to investigate whether the proliferation defect is due to 
impaired replication and whether this is dependent on a MDM2 interaction and its intrinsic 
E3 ligase activity.  
 
 
 
128 
 
VI.3 R-loops form in the absence of MDM2 
 
Apart from proteins bound to chromatin, secondary structure elements can pose as 
obstacles to a moving replication fork. One example of such a structural element 
described to have detrimental effects on replication are stable DNA:RNA hybrid structures 
called R-loops. The mechanism by which R-loops form is not completely understood but 
experimental evidence suggests that they can arise in a co-transcriptional fashion in the 
so called “thread-back model” (Fig.II.3.5). In such a scenario, the DNA and RNA strands 
that exit the RNA polymerase complex via two separate exit channels re-anneal at 
complementary sites so that the second DNA strand is displaced (Santos-Pereira and 
Aguilera, 2015; Westover, 2004).  
We observed an increase in chromatin-bound R-loops in p53- and MDM2 co-depleted 
cells. The method used to analyse this was developed and carried out by the Altmeyer 
group in Zurich and involves an inducible cell system for overexpressing catalytically 
inactive GFP-tagged RNaseH1 (Teloni et al., manuscript submitted). This enzyme is one 
of several players that can bind to remove R-loops in a cell by removing the RNA moiety 
of the hybrid structure (Wahba et al., 2011). A point mutation in its catalytic triad render its 
ribonuclease activity inactive but retains its ability to specifically bind to R-loops. A GFP-
tag on the mutant RNaseH1 allows a microscopy-based detection and quantification of the 
chromatin-bound fraction of the protein after permeabilisation of the cells. According to the 
high-throughput analysis of data generated in this cell system, replicative stress and R-
loops are present in cells lacking both p53 and MDM2 in all phases of the cell cycle 
including S-phase and could explain why we see impaired replication fork progression 
when depleting MDM2 in a p53-null background.   
 
But how exactly can the depletion of a protein involved in chromatin compaction lead to 
the re-annealing of nascent RNA to its template DNA strand and how does that affect 
DNA replication?  
 
VI.3.1 R-loops – natural intermediates and drivers of genome instability 
 
R-loops are natural intermediates in a number of physiological processes including Ig 
class switch recombination, bacterial DNA replication, mitochondrial DNA replication, as 
well as the regulation of eukaryotic transcription (Aguilera and García-Muse, 2012). 
Genome-wide analysis has revealed a preferential formation of R-loops at CpG-island 
promotor sites that have an asymmetric arrangement of guanosines and cytosines called 
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a “GC-skew”, and form stable G-quadruplex structures (Sollier and Cimprich, 2015). As R-
loops protect the template DNA from de novo methylation, these promotor regions can no 
longer be epigenetically silenced, thus gene expression at these sites is active (Ginno et 
al., 2012). At transcription termination sites, G-rich stretches downstream of the poly-A 
signal allow the formation of R-loops, associated also with low DNA methylation patterns, 
and RNA polymerase II pausing upon an encounter with the hybrid. Helicases then 
catalyse the removal of the R-loop structure and facilitate the release of the RNA molecule 
for efficient transcription termination (Santos-Pereira and Aguilera, 2015).  
 
As intermediates, R-loops have fast turnover rates in order to regulate physiological 
processes efficiently. It might be this turnover rate that causes the shift from a regulatory 
R-loop to a persistent R-loop that is a threat to genome integrity.  
 
The DNA:RNA hybrid within a R-loop is thermodynamically very stable and difficult to 
access, whereas the single stranded portion of the displaced DNA is very vulnerable to 
DNA damage. In particular, RNA editing enzymes target ssDNA and activate DNA repair 
pathways that cause the formation of double strand breaks (DSBs). One member of this 
protein family, activation-induced cytidine deaminase (AID), catalyses the conversion of 
deoxy-cytidine to deoxy-uracil which is removed by the base-excision repair (BER) 
enzyme uracil DNA glycosylase creating a DNA lesion in the form of an abasic site 
(Santos-Pereira and Aguilera, 2015; Sollier and Cimprich, 2015). Besides BER, 
nucleotide-excision repair (NER) enzymes xeroderma pigmentosum factors F and G (XPF 
and XPG) process flaps on either side of the R-loop into DSBs.  
 
As is the case in other physiological processes within a cell including DNA replication, the 
persistent presence of ssDNA causes stress signalling to be activated and needs to be 
prevented for maintaining genome integrity. The formation and persistence of R-loops is 
regulated by a number of factors could be a starting point for understanding how the loss 
of MDM2 leads to an accumulation of R-loops in p53-deficient cells.  
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VI.3.2 Defects in ribonucleoproteins cause pre-mRNA to thread back into the DNA 
duplex   
R-loop formation has been associated with the loss of several factors involved in mRNA 
metabolism (Aguilera and García-Muse, 2012; Hamperl and Cimprich, 2014). As the 
nascent RNA emerges from the RNA polymerase channel, it is coated by heterogeneous 
nuclear ribonucleoproteins (hnRNPs) to retain the pre-mRNA in the nucleus until it is fully 
post-transcriptionally modified and spliced. In addition to preventing RNA misfolding into 
secondary structures, hnRNPs also prevent re-annealing of the strand to its 
complementary DNA template. So far, MDM2 is only known to interact with hnRNP K, an 
important co-activator in p53-dependent transcription, and MDM2 can cause its 
proteasomal degradation (Enge et al., 2009; Moumen et al., 2005). In the context of our 
data, this role of MDM2 does not explain the increase in R-loop formation in the absence 
of MDM2. A loss of MDM2 would result in an accumulation rather than a loss of hnRNP K 
due to a lack of negative regulation. However, we cannot exclude that MDM2 can 
positively affect other hnRNPs, such that a loss of MDM2 concomitantly leads to a loss in 
binding proteins or recruitment of splicing factors that would allow nascent RNA to re-
anneal to its template.  
 
VI.3.3 Topoisomerases suppress R-loop formation by relaxing torsional stress 
R-loop formation is additionally suppressed by the activity of DNA topoisomerases that 
relieve torsional stress which can be generated by transcription and replication (García-
Muse and Aguilera, 2016). In transcription, the RNA polymerase moves along DNA 
strands and unwinds the double helix for access to the template sequence. The resulting 
positive and negative supercoils ahead and behind the polymerase are relaxed by 
topoisomerases I and II. A loss of topoisomerase I not only causes the helix behind the 
RNA polymerase to be underwound and more accessible to for an intruding RNA strand, 
but it also impairs ASF/SF2-dependent assembly of messenger ribonucleoprotein (mRNP) 
during transcription (Tuduri et al., 2009). Both types of topoisomerases have additionally 
been described to counteract torsional stress and sister chromatid entanglement 
generated by replicative helicases (Bermejo et al., 2007).  
 
Even though no direct interaction between MDM2 and topoisomerases has been 
described, a loss of MDM2 seems to sensitise cells towards topoisomerase II inhibition, 
whereas an MDM2 amplification protects cells from DNA damage when treated with 
inhibitors to topoisomerase II in a RING finger-dependent but p53-independent way 
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(Conradt et al., 2013; Senturk et al., 2017). Along the same lines, p53-deficient cells were 
also found to be more sensitive to topoisomerase II inhibitors, a phenotype that could be 
rescued by inhibiting transcriptional elongation (Yeo et al., 2016). As p53-deficient cells 
will also have low levels of MDM2 due to a lack of MDM2 induction by p53, it seems 
possible the results observed in this study are a not a direct effect of p53-deficiency but 
rather caused by a loss of MDM2. Until now, it remains unclear from this data whether the 
synergism between MDM2 and topoisomerase loss is attributed to the canonical and non-
canonical roles of topoisomerases in preventing R-loops or whether replication forks are 
directly affected by torsional stress in the absence of MDM2.    
 
VI.3.4 Ribonucleases and helicases catalyse the removal of R-loops  
Next to the enzymes that prevent R-loop formation in the first place, there are also a 
number of enzymes that catalyse their removal. RNase H endonucleases specifically 
degrade the RNA moiety of hybrid structures and are found in two forms in human cells – 
RNase H1 and H2.  RNase H1 is monomeric and acts to remove long DNA:RNA hybrids, 
whereas RNase H2 is a trimeric complex and removes single mis-incorporated 
ribonucleotides from DNA (Reijns et al., 2012). In addition to its roles in protecting 
mitochondrial replication and telomeres from recombination, RNaseH1 was also found to 
play a role in nuclear DNA replication and to support genome integrity (Arora et al., 2014; 
Parajuli et al., 2017; Suzuki et al., 2010). Apart from nucleases-mediated removal of 
DNA:RNA hybrids, senataxin (SETX), Aquarius (AQR), and DEAH box protein 9 (DHX9) 
helicases are thought to unwind stable hybrid structures to facilitate their removal 
(Chakraborty and Grosse, 2011; Santos-Pereira and Aguilera, 2015; Sollier et al., 2014).  
 
Ectopic expression of RNase H1 is commonly used to suppress R-loop accumulation and 
subsequent DNA damage in mammalian cells. We showed that the overexpression of 
wildtype RNase H1 restored replication fork progression that was impaired as a result of 
MDM2 and RNF2 depletion, whereas a catalytically inactive mutant version of RNase H1 
did not. However, we could not identify a direct correlation between endogenous levels of 
MDM2 and RNase H1 and suggest that rescued fork progression is rather due to the 
removal of R-loops that arise from a different mechanism. Interestingly, a recent study 
suggested that p53-deficient cells are dependent on DHX9 expression for cell cycle 
progression and survival (Lee and Pelletier, 2017).   
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The susceptibility of p53-deficient cells for two different mechanisms by which cells 
counteract R-loops suggests that topoisomerase II inhibition and DHX9 depletion mediate 
the persistence rather than formation of R-loops in the absence of a functional p53-MDM2 
axis.  
 
VI.3.5 Transcription – replication conflicts 
 
In addition to the mechanisms described above, cells also try to avoid the persistence of 
long R-loops by uncoupling the processes of DNA transcription and replication, both 
temporally as well as spatially. Replication initiation in human cells is subject to complex 
regulatory mechanisms, given that only a fraction of licensed origins is fired at one time 
and the set of origins used differs greatly between cell type and during development. With 
the development of more sensitive sequencing methods, it was discovered that replication 
initiates mainly from intergenic regions and is often co-oriented with transcription (Petryk 
et al., 2016). Replisomes move along the template much faster than transcription factories 
causing them to catch up and collide when present at the same genomic loci. These co-
directional collisions between transcription and replication seem to be much less 
detrimental in terms of replication compared to collisions that occur “head-on”. In this 
conformation, unwinding of the template from both sides creates an additive positive 
supercoil in the region between the two polymerase complexes promoting the formation of 
R-loops (Aguilera and García-Muse, 2012; García-Muse and Aguilera, 2016; Lang et al., 
2017). Experiments using a human-cell-based plasmid system even suggested that 
replisomes can resolve co-transcriptional R-loops via its MCM components when it is 
encountered co-directionally. Converging replication and transcription on the other hand, 
cause the formation of R-loops and DNA damage signalling by blocking the transcription 
machinery and confining the nascent RNA close to its template. Additional torsional stress 
created by both machineries might facilitate the re-annealing of the transcript to DNA 
(Hamperl et al., 2017).  
 
We found that inhibiting transcriptional elongation by CDK9 inhibition was sufficient to 
restore impaired replication forks after MDM2 and RNF2 depletion, likely due to fewer 
conflicts between transcription and replication. On one hand, changes in chromatin 
compaction mediated by MDM2/RNF depletion could lead to unscheduled transcription of 
target genes. On the other hand, the increase in R-loops observed after MDM2 depletion 
could additionally activate gene expression by preventing promotor methylation. In both 
cases, increased transcription raises the chances of head-on collisions with DNA 
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replication forks. CDK9 inhibition blocks the elongation step of transcription so that RNA 
polymerases remain associated with the template in an inactive state. This prevents the 
formation of co-transcriptional R-loops in the time of inhibition but whether it also 
facilitates the replication fork moving past it, is unclear. This makes it difficult to distinguish 
whether fork stalling observed in our assays is a direct consequence of transcription-
replication collisions, replication forks running into R-loops, or even both.  
 
VI.4 Targeting the p53-MDM2 axis in chemotherapy 
The tumour suppressor p53 is mutated in about 50% of all cancers, ranging from about 
10% to 96% depending on the cancer entity. Next to mutations, p53 levels in tumours can 
also be affected by elevated levels of its negative regulators MDM2/MDMX. Genes for 
both MDM2 and MDMX are amplified in a number of cancers including sarcomas and 
breast tumours. Given its canonical role of regulating p53 levels, these amplifications 
make MDM2 and MDMX potent oncogenes and present suitable therapeutic targets to 
restore p53 levels in cancers (Burgess et al., 2016). The first small-molecule inhibitor 
targeting MDM2 developed by Vassilev at al. in 2004 and was designed to bind to the N-
terminal hydrophobic cleft of MDM2, a binding site for p53 (Vassilev et al., 2004). 
Unfortunately, this inhibitor (Nutlin-3a) as well as many similar derivatives were promising 
during pre-clinical development but failed clinical trials due to poor bioavailability and high 
cytotoxicity (Ray-Coquard et al., 2012).  
 
Our results highlighted an important role of both p53 and MDM2 in supporting DNA 
replication and genome integrity. An inhibitor targeting the N-terminal p53-binding site on 
MDM2 (Nutlin-3a) was able to accumulate p53 and reduce replication fork stalling in cells, 
adding to the guardian of the genome role of p53. As we hypothesised that MDM2 acts 
downstream and independently of p53 to support DNA replication via its RING domain, it 
would be of interest to study the effects of inhibitors targeting the RING domain of MDM2. 
Inhibitors that could be tested include HLI373, thought to inhibit E3 ligase activity of 
MDM2, as well as MX69, described to lead to MDM2 degradation. For comparison, 
RG7388 an inhibitor targeting the p53-binding domain of MDM2 could also be tested in 
several cancer cell lines (Ding et al., 2013; Gu et al., 2016; Kitagaki et al., 2008).  
 
Our results highlighted that a loss of MDM2 has two different effects on DNA replication in 
p53-proficient cells. On one hand, the inability to bind to p53 results in a loss of negative 
regulation and accumulation of p53 which is accompanied by more processive DNA 
replication. Our work in p53-null cells has also highlighted that its RING domain with 
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intrinsic E3 ubiquitin ligase activity is required to support DNA replication. As MDM2 is 
known to be induced by active p53 transcription factor, an accumulation of p53 would also 
result in increased MDM2 protein levels and enhanced DNA replication. As a result of this 
complicated feedback loop, it seems essential to distinguish between a complete loss of 
MDM2, an inhibition of its p53-binding ability, and an inhibition of its C-terminal RING 
domain. This consideration should also be taken into account when targeting the p53-
MDM2 axis with small-molecule inhibitors. Treatment of tumours containing wildtype p53 
with inhibitors like Nutlin-3a or Isadanutlin (RG7388) targeting the interaction of MDM2 
and p53 causes an accumulation of both proteins and supports DNA replication in the 
cells rather than causing the anticipated genomic instability. In this context, it would be 
more suitable to target both, p53-binding and RING domains of MDM2 in order to induce 
replicative stress via the RING domain inhibition and apoptosis pathways via p53 
accumulation. For this, inhibitors targeting the RING activity of MDM2 need to be further 
developed and brought forward to clinical trials.  
 
 
VI.5 Conclusions 
In conclusion, our work has highlighted an important non-canonical pathway of the p53-
MDM2 network in tumour suppression. It adds to the role of p53 as the guardian of the 
genome by supporting DNA replication and suppressing genomic instability via its target 
gene MDM2. It supports DNA replication by preventing the formation and persistence of 
R-loops that pose as obstacles to replisomes and cause them to stall. Resulting under-
replicated DNA is a frequent cause for genomic instability found in cancers. The exact 
mechanism of how MDM2 depletion leads to R-loop formation remains subject to further 
studies. For this, understanding exactly how MDM2 mediates chromatin marks and how 
its depletion affects transcription could provide vital information on the mechanism. 
Targeting the p53-MDM2 network remains an attractive strategy in chemotherapy and 
should be further explored in terms of inhibitors targeting the RING domain of MDM2 that 
is responsible for DNA replication support and combination therapies of inhibitors 
targeting different domains of MDM2 in tumours bearing wildtype p53. 
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h hour 
H2AK119ub1 
histone 2A lysine 119 
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HR homologous recombination 
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IdU iododeoxyuridine 
iPSC induced pluripotent stem cell 
kb kilobases 
kd knockdown 
kDa kilodalton 
M molar 
Mdm2/MDM2 murine double minute 2 
MEF mouse embryonic fibroblast 
MetOH methanol 
mg milligram 
min Minute 
ml millilitre 
mM millimolar 
mRNA messenger RNA 
n sample size 
NER nucleotide excision repair 
NES nuclear export signal 
NHEJ non-homologous end joining 
NLS nuclear localisation signal 
nm nanometer 
nM nanomolar 
nM nanomolar 
NoLS nucleolar localisation signal 
NOS reactive nitrogen species 
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OE overexpression 
ORC origin recognition proteins 
p53RE p53 response element 
PBS phosphate buffered saline 
PcG Polycomb group 
PCNA Proliferating cell nuclear antigen 
PIC pre-initiation complex 
PRC polycomb repressor complex 
pre-mRNA pre-messenger RNA 
pre-RC pre-replication complex 
qRT-PCR 
quantitative real time polymerase chain 
reaction 
RING really interesting new gene 
RNA ribonucleic acid 
RNA Pol 
(RNAP) 
RNA polymerase  
RNase ribonuclease 
RNR ribonucleotide reductase 
ROS reactive oxygen species 
RPA replication protein A 
rpm Rounds per minute 
SDS sodium dodecyl sulfate 
SDS-PAGE 
SDS-polyacrylamide gel 
electrophoresis 
Ser serine 
SET Su(var)3-9, Enhancer-of-zeste and 
Trithorax 
SETX senataxin 
siRNA small interfering ribonucleic acid 
ssDNA single stranded DNA 
SUZ12 suppressor of zeste homologue 12 
TAD  trans-activation domain 
TAR transcription-associated repair 
TBP TATA-binding protein 
TBS Tris buffered saline  
TBS-T Tris buffered saline + Tween20 
TEMED tetramethylethylenediamine 
TF transcription factor 
Thr threonine 
TLS translesion synthesis 
Tris trisamine 
wt wildtype 
XPF xeroderma pigmentosum factor F 
XPG xeroderma pigmentosum factor G 
μg microgram 
μl microlitre 
μM micromolar 
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